{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:37:54Z","timestamp":1793241474862,"version":"4.5.0"},"reference-count":1551,"publisher":"Georg Thieme Verlag KG","issue":"04","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacopsychiatry"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>TDM involves measuring and interpreting drug concentrations in blood plasma or\n                    serum to optimize pharmacotherapy. In psychiatry and neurology, TDM is a\n                    well-established tool for personalized drug treatments. The AGNP-TDM task force\n                    initially published guidelines for best practice TDM in 2004, 2011, and 2017. A\n                    fundamental methodological revision has now been carried out on how to determine\n                    therapeutic reference ranges and dose-related reference ranges transparently and\n                    systematically. In the current edition, 50 experts in neuropsychopharmacology\n                    offer a complete update of both ranges for each substance following an\n                    evidence-based approach. Various types of data were considered for reference\n                    range determination, ranging from meta-analyses to drug concentrations expected\n                    under recommended doses. Therapeutic reference ranges are now listed for 160\n                    neuropsychiatric drugs, newly included for 30 drugs and revised for 88 drugs.\n                    Expected drug concentrations can be calculated based on a revised formula for\n                    162 drugs. Obligatory TDM (i.e. for dose titration) is strongly recommended for\n                    15 neuropsychiatric drugs and recommended for 39 drugs. TDM is classified as\n                    useful for 49 drugs and potentially useful for 62 drugs, indicating that it is\n                    recommended in specific clinical situations, such as suspected non-adherence,\n                    insufficient clinical response despite recommended doses, relapse during\n                    maintenance treatment, and many more. The 2026 update includes practical\n                    pharmacogenetic recommendations that are directly relevant to TDM. This work\n                    integrates a combination of strategies to guide drug treatments in clinical\n                    practice using all available tools. A consistent implementation of TDM and\n                    pharmacogenetic recommendations will enhance neuropsychopharmacotherapy, improve\n                    patient outcomes, and reduce healthcare costs.<\/jats:p>","DOI":"10.1055\/a-2860-7861","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T23:15:37Z","timestamp":1783034137000},"page":"166-295","source":"Crossref","is-referenced-by-count":19,"title":["Consensus Guidelines for Therapeutic Drug Monitoring in\n                    Neuropsychopharmacology: Update 2026 \u2013 Pharmacokinetic, pharmacogenetic and\n                    clinical aspects"],"prefix":"10.1055","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6033-0189","authenticated-orcid":false,"given":"Xenia M.","family":"Hart","sequence":"first","affiliation":[{"name":"Keio University School of Medicine, Japan","place":["Tokyo"],"department":["Department of Neuropsychiatry"]},{"name":"Medical Faculty Mannheim, University of Heidelberg, BW, Germany","place":["Mannheim"],"department":["Central Institute of Mental Health, Department of Molecular Neuroimaging"]},{"name":"University Hospital Carl Gustav Carus, Technische Universit\u00e4t Dresden, Germany","place":["Dresden"],"department":["Department of Psychiatry and Psychotherapy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7868-3903","authenticated-orcid":false,"given":"Gerhard","family":"Gr\u00fcnder","sequence":"first","affiliation":[{"name":"Medical Faculty Mannheim, University of Heidelberg, BW, Germany","place":["Mannheim"],"department":["Central Institute of Mental Health, Department of Molecular Neuroimaging"]},{"name":"partner site Mannheim \u2013 Heidelberg \u2013 Ulm, Mannheim, Germany","department":["German Center for Mental Health (DZPG)"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Unterecker","sequence":"first","affiliation":[{"name":"University Hospital of W\u00fcrzburg, Germany","place":["W\u00fcrzburg"],"department":["Department of Psychiatry, Psychosomatics and Psychotherapy"]},{"name":"Social Foundation Bamberg, Germany","place":["Bamberg"],"department":["Department of Psychiatry and Psychotherapy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3851-4117","authenticated-orcid":false,"given":"Georgios","family":"Schoretsanitis","sequence":"first","affiliation":[{"name":"Lausanne University Hospital and University of Lausanne, Switzerland","place":["Lausanne"]},{"name":"Psychiatric University Hospital Z\u00fcrich, ZH, Switzerland","place":["Z\u00fcrich"],"department":["Adult Psychiatry and Psychotherapy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2820-8738","authenticated-orcid":false,"given":"Christoph","family":"Hiemke","sequence":"additional","affiliation":[{"name":"University Medical Center Mainz, Germany","place":["Mainz"],"department":["Department of Psychiatry and Psychotherapy, Institute of Clinical Chemistry and Laboratory Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Adamovic","sequence":"additional","affiliation":[{"name":"University of G\u00f6ttingen, Faculty of Medicine, NDS, Germany","place":["G\u00f6ttingen"],"department":["Department of Psychiatry and Psychotherapy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7653-3746","authenticated-orcid":false,"given":"Friederike","family":"Amann","sequence":"additional","affiliation":[{"name":"Medical Faculty Mannheim, University of Heidelberg, BW, Germany","place":["Mannheim"],"department":["Central Institute of Mental Health, Department of Molecular Neuroimaging"]},{"name":"partner site Mannheim \u2013 Heidelberg \u2013 Ulm, Mannheim, Germany","department":["German Center for Mental Health (DZPG)"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6253-5225","authenticated-orcid":false,"given":"Pierre","family":"Baumann","sequence":"additional","affiliation":[{"name":"Lausanne University Hospital and University of Lausanne, Switzerland","place":["Lausanne"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9749-7743","authenticated-orcid":false,"given":"Niels","family":"Bergemann","sequence":"additional","affiliation":[{"name":"Trier University, Germany","place":["Trier"],"department":["Department of Biological and Clinical Psychology"]},{"name":"University Hospital Heidelberg, Germany","place":["Heidelberg"],"department":["Department of Psychiatry and Psychotherapy, Center for Psychosocial Medicine"]},{"name":"Regena Private Clinic Bad Br\u00fcckenau, Germany","place":["Bad Br\u00fcckenau"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Brandt","sequence":"additional","affiliation":[{"name":"Krankenhaus Mara gGmbh, NRW, Germany","place":["Bielefeld"],"department":["Bethel Epilepsy Centre, Department of Epileptology, Medical School OWL, Bielefeld University"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Willi","family":"Clement","sequence":"additional","affiliation":[{"name":"University of Freiburg, Germany","place":["Freiburg"],"department":["Department of Child and Adolescent Psychiatry and Psychotherapy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4841-7510","authenticated-orcid":false,"given":"Andreas","family":"Conca","sequence":"additional","affiliation":[{"name":"Bolzano Hospital, Trentino-Alto Adige, Italy","place":["Bolzano"],"department":["Psychiatry"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1008-4650","authenticated-orcid":false,"given":"J\u00fcrgen","family":"Deckert","sequence":"additional","affiliation":[{"name":"University Hospital of W\u00fcrzburg, Germany","place":["W\u00fcrzburg"],"department":["Institute of Clinical Epidemiology and Biometrics, Julius-Maximilians-University W\u00fcrzburg"]},{"name":"University Hospital of W\u00fcrzburg, Germany","place":["W\u00fcrzburg"],"department":["Department of Psychiatry, Psychosomatics and Psychotherapy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto","family":"Dietmaier","sequence":"additional","affiliation":[{"name":"Klinikum am Weissenhof, BW, Germany","place":["Weinsberg"],"department":["Center of Psychiatry"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Eckermann","sequence":"additional","affiliation":[{"name":"BKH Kaufbeuren, Germany","place":["Kaufbeuren"],"department":["Psychiatric Hospital"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0270-0954","authenticated-orcid":false,"given":"Karin","family":"Egberts","sequence":"additional","affiliation":[{"name":"University of W\u00fcrzburg, BY, Germany","place":["W\u00fcrzburg"],"department":["Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy"]},{"name":"Reinier van Arkel groep\u2019s, Netherlands","place":["Hertogenbosch"],"department":["Department of Child and Adolescent Psychiatry"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Endres","sequence":"additional","affiliation":[{"name":"Klinikum Starnberg, BY, Germany","place":["Starnberg"],"department":["Central Pharmacy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Erlacher","sequence":"additional","affiliation":[{"name":"Vitos Clinic for Forensic Psychiatry, HE, Germany","place":["Gie\u00dfen"],"department":["Forensic Psychiatry"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1925-6228","authenticated-orcid":false,"given":"Stefanie","family":"Fekete","sequence":"additional","affiliation":[{"name":"University of W\u00fcrzburg, BY, Germany","place":["W\u00fcrzburg"],"department":["Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Ferrea","sequence":"additional","affiliation":[{"name":"Psychiatric University Hospital Z\u00fcrich, ZH, Switzerland","place":["Z\u00fcrich"],"department":["Adult Psychiatry and Psychotherapy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Florio","sequence":"additional","affiliation":[{"name":"Bolzano Hospital, Trentino-Alto Adige, Italy","place":["Bolzano"],"department":["Psychiatry"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Gerlach","sequence":"additional","affiliation":[{"name":"University of W\u00fcrzburg, BY, Germany","place":["W\u00fcrzburg"],"department":["Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4430-4148","authenticated-orcid":false,"given":"Ekkehard","family":"Haen","sequence":"additional","affiliation":[{"name":"Universit\u00e4t Regensburg, Germany","place":["Regensburg"],"department":["Klinische Pharmakologie am Lehrstuhl f\u00fcr Pharmakologie und Toxikologie"]},{"name":"Institut AGATE gGmbH, Germany","place":["Pentling"],"department":["Clinical Pharmacology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8355-8584","authenticated-orcid":false,"given":"Martina","family":"Hahn","sequence":"additional","affiliation":[{"name":"Goethe-Universit\u00e4t Frankfurt am Main, Germany","place":["Frankfurt am Main"],"department":["Department of Psychiatry, Psychosomatics and Psychotherapy"]},{"name":"Varisano Hospital Frankfurt Hoechst, Germany","place":["Frankfurt am Main"],"department":["Department of Mental Health"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Havemann-Reinecke","sequence":"additional","affiliation":[{"name":"University of G\u00f6ttingen, Faculty of Medicine, NDS, Germany","place":["G\u00f6ttingen"],"department":["Department of Psychiatry and Psychotherapie"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudrun","family":"Hefner","sequence":"additional","affiliation":[{"name":"Vitos Clinic for Forensic Psychiatry, Germany","place":["Eltville"],"department":["Psychiatric Hospital"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang H.","family":"Jost","sequence":"additional","affiliation":[{"name":"Parkinson-Klinik Ortenau GmbH & Co. KG, BW, Germany","place":["Wolfach"]},{"name":"Saarland University, SL, Germany","place":["Homburg"],"department":["Department of Neurology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxim","family":"Kuzin","sequence":"additional","affiliation":[{"name":"Oberberg Specialist Clinic Rhein-Jura, Germany","place":["Bad S\u00e4ckingen"],"department":["Private Clinic for Psychiatry, Psychosomatics and Psychotherapy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Laux","sequence":"additional","affiliation":[{"name":"Institute of Psychological Medicine, Germany","place":["Soyen"],"department":["IPM"]},{"name":"MVZ Waldkraiburg of M\u00fchldorf Clinics\/Hospital, Germany","place":["Waldkraiburg"],"department":["Center of Neuropsychiatry"]},{"name":"Ludwig Maximilian University of Munich, BY, Germany","place":["Munich"],"department":["Department of Psychiatry and Psychotherapy, University Hospital"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4934-4352","authenticated-orcid":false,"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[{"name":"TUM School of Medicine and Health, Technical University of Munich, BY, Germany","place":["Munich"],"department":["Department of Psychiatry and Psychotherapy"]},{"name":"German Center for Mental Health (DZPG), partner site Munich\/Augsburg (FKZ 1EE2503B 2025-2030 and FKZ 01EE2303B 2023-2025), BY, Germany","place":["Munich"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignazio","family":"Maniscalco","sequence":"additional","affiliation":[{"name":"Bolzano Hospital, Trentino-Alto Adige, Italy","place":["Bolzano"],"department":["Psychiatry"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1498-1992","authenticated-orcid":false,"given":"Andreas","family":"Menke","sequence":"additional","affiliation":[{"name":"Ludwig Maximilian University of Munich, BY, Germany","place":["Munich"],"department":["Department of Psychiatry and Psychotherapy, University Hospital"]},{"name":"Medical Park Chiemseeblick in Bernau-Felden, BY, Germany","place":["Rosenheim"],"department":["Department of Psychosomatic Medicine and Psychotherapy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5737-7701","authenticated-orcid":false,"given":"Thomas","family":"Messer","sequence":"additional","affiliation":[{"name":"Danuviusklinik Pfaffenhofen, Germany","place":["Pfaffenhofen"],"department":["Department of Psychiatry"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2605-6160","authenticated-orcid":false,"given":"Rainald","family":"Moessner","sequence":"additional","affiliation":[{"name":"German Center for Mental Health T\u00fcbingen, BW, Germany","place":["T\u00fcbingen"],"department":["Department of Psychiatry and Psychotherapy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"University of Toronto, Canada","place":["Toronto"],"department":["Psychiatry and Pharmacology & Toxicology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"St. Joseph Hospital Berlin Weissensee, BE, Germany","place":["Berlin"],"department":["Department of Neurology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4198-5160","authenticated-orcid":false,"given":"Michael","family":"Paulzen","sequence":"additional","affiliation":[{"name":"Alexianer Hospital Aachen, Germany","place":["Aachen"]},{"name":"JARA \u2013 Translational Brain Medicine, RWTH Aachen University, NRW, Germany","place":["Aachen"],"department":["Department of Psychiatry, Psychotherapy and Psychosomatics"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Petri","sequence":"additional","affiliation":[{"name":"Wicker Kliniken Bad Wildungen, Germany","place":["Bad Wildungen"],"department":["Central Pharmacy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Pfeifer","sequence":"additional","affiliation":[{"name":"University of Bern, BE, Switzerland","place":["Bern"],"department":["University Hospital of Psychiatry and Psychotherapy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2501-5500","authenticated-orcid":false,"given":"Bruno","family":"Pfuhlmann","sequence":"additional","affiliation":[{"name":"Psychiatrische Klinik Weisser Hirsch, Germany","place":["Dresden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Riederer","sequence":"additional","affiliation":[{"name":"Julius-Maximilians-Universit\u00e4t W\u00fcrzburg, Medizinische Fakult\u00e4t, Bayern, Germany","place":["W\u00fcrzburg"],"department":["Klinik f\u00fcr Psychiatrie, Psychosomatik und Psychotherapie"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibylle C.","family":"Roll","sequence":"additional","affiliation":[{"name":"varisano Hospital Frankfurt H\u00f6chst, Germany","place":["Frankfurt"],"department":["Department of Mental Health"]},{"name":"Philipps-University Marburg, Germany","place":["Marburg"],"department":["College of Pharmacy, Department of Pharmacology and Clinical Pharmacy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4780-612X","authenticated-orcid":false,"given":"Maike","family":"Scherf-Clavel","sequence":"additional","affiliation":[{"name":"University Hospital of W\u00fcrzburg, Germany","place":["W\u00fcrzburg"],"department":["Department of Psychiatry, Psychosomatics and Psychotherapy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8895-3743","authenticated-orcid":false,"given":"Markus","family":"Schwarz","sequence":"additional","affiliation":[{"name":"Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, BY, Germany","place":["M\u00fcnchen"],"department":["LMU Klinikum, Institut f\u00fcr Laboratoriumsmedizin"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Steimer","sequence":"additional","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen, Bayern, Germany","place":["M\u00fcnchen"],"department":["Institute of Clinical Chemistry and Pathobiochemistry"]},{"name":"INSTAND e.V., society for promoting quality assurance in medical laboratories, Germany","place":["M\u00fcnchen"]},{"name":"Therapeutic Drug Monitoring and Clinical Toxicology section of the German Society for Clinical Chemistry and Laboratory Medicine, Germany","place":["M\u00fcnchen"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1566-8156","authenticated-orcid":false,"given":"Julia C.","family":"Stingl","sequence":"additional","affiliation":[{"name":"Medical Faculty Heidelberg \/ Heidelberg University Hospital, Germany","department":["Department of Clinical Pharmacology and Pharmacoepidemiology, Internal Medicine IX, Heidelberg University"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sermin","family":"Toto","sequence":"additional","affiliation":[{"name":"Medizinische Hochschule Hannover, Niedersachsen, Germany","place":["Hannover"],"department":["Department of Psychiatry, Social Psychiatry and Psychotherapy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Ulrich","sequence":"additional","affiliation":[{"name":"Aristo Pharma GmbH, Berlin, Germany","place":["Berlin"],"department":["Med.-Sci. Dptm."]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1247-1024","authenticated-orcid":false,"given":"Gerald","family":"Zernig","sequence":"additional","affiliation":[{"name":"Medical University of Innsbruck, Tyrol, Austria","place":["Innsbruck"],"department":["Department of Pharmacology"]},{"name":"Private Practice for Psychotherapy and Court-Certified Witness, Austria","place":["Hall in Tirol"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Zurek","sequence":"additional","affiliation":[{"name":"Medizinisches Labor Bremen, Bremen, Germany","place":["Bremen"],"department":["Drug Analysis"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"ref1","volume-title":"Psychotropic Drug Directory 2020\/21: The Professionals' Pocket Handbook and\n                    Aide Memoire","author":"S Bazire","year":"2020"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1176\/ps.2009.60.9.1164","article-title":"Best practices: improving quality of care for patients with first-episode\n                    psychosis","volume":"60","author":"D Addington","year":"2009","journal-title":"Psychiatr Serv"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00406-005-0579-5","article-title":"Is dose escalation of antidepressants a rational strategy after a medium-dose\n                    treatment has failed? A systematic review","volume":"255","author":"M Adli","year":"2005","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"J A Lieberman","year":"2005","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1038\/sj.npp.1301390","article-title":"Maximizing the adequacy of medication treatment in controlled trials and\n                    clinical practice: STAR(*)D measurement-based care","volume":"32","author":"M H Trivedi","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/bcpt.12278","article-title":"Development of clinical pharmacology as a medical speciality in Europe - the\n                    roles of WHO, IUPHAR and EACPT","volume":"115","author":"F Sj\u00f6qvist","year":"2014","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1056\/NEJMp1500523","article-title":"A new initiative on precision medicine","volume":"372","author":"F S Collins","year":"2015","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/13651501.2020.1809680","article-title":"Precision psychiatry in clinical practice","volume":"25","author":"R Zanardi","year":"2021","journal-title":"Int J Psychiatry Clin Pract"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1038\/s41380-025-03070-5","article-title":"Precision psychiatry roadmap: towards a biology-informed framework for mental\n                    disorders","volume":"30","author":"MJ H Kas","year":"2025","journal-title":"Mol Psychiatry"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0193-953X(18)30167-9","article-title":"Therapeutic drug monitoring. Principles and practice","volume":"16","author":"S H Preskorn","year":"1993","journal-title":"Psychiatr Clin North Am"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/01.pra.0000336757.42437.fe","article-title":"Practical application of therapeutic drug monitoring: a tale of two\n                    patients","volume":"14","author":"S H Preskorn","year":"2008","journal-title":"J Psychiatr Pract"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/00007691-200404000-00010","article-title":"Therapeutic drug monitoring of psychotropic drugs","volume":"26","author":"F Bengtsson","year":"2004","journal-title":"TDM \"nouveau\". Ther Drug Monit"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1055\/s-0031-1286291","article-title":"Therapeutic drug monitoring in child and adolescent psychiatry","volume":"44","author":"K M Egberts","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00228-007-0430-1","article-title":"Clinical utility of drug measurement and pharmacokinetics: therapeutic drug\n                    monitoring in psychiatry","volume":"64","author":"C Hiemke","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00406-007-1005-y","article-title":"Therapeutic drug monitoring in neuropsychopharmacology: does it hold its\n                    promises?","volume":"258","author":"C Hiemke","year":"2008","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/JCP.0b013e3181acc372","article-title":"ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of\n                    clozapine","volume":"29","author":"E Jaquenoud Sirot","year":"2009","journal-title":"J Clin Psychopharmacol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"735","DOI":"10.2165\/00002018-200629090-00001","article-title":"Therapeutic drug monitoring and pharmacogenetic tests as tools in\n                    pharmacovigilance","volume":"29","author":"E Jaquenoud Sirot","year":"2006","journal-title":"Drug Saf"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/03602530902722679","article-title":"Pharmacokinetics and drug metabolism in the elderly","volume":"41","author":"U Klotz","year":"2009","journal-title":"Drug Metab Rev"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/01.yic.0000091305.72168.6e","article-title":"Effects of an educational compliance enhancement programme and therapeutic drug\n                    monitoring on treatment adherence in depressed patients managed by general\n                    practitioners","volume":"18","author":"A C Akerblad","year":"2003","journal-title":"Int Clin Psychopharmacol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/FTD.0b013e3182885d9d","article-title":"Potential cost-effectiveness of therapeutic drug monitoring for depressed\n                    patients treated with citalopram","volume":"35","author":"E Ostad Haji","year":"2013","journal-title":"Ther Drug Monit"},{"key":"ref21","first-page":"23","article-title":"Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost\n                    effectiveness","volume":"52","author":"S H Preskorn","year":"1991","journal-title":"J Clin Psychiatry"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/00007691-200502000-00004","article-title":"Cost-effectiveness of therapeutic drug monitoring: a systematic\n                    review","volume":"27","author":"D J Touw","year":"2005","journal-title":"Ther Drug Monit"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.eurpsy.2006.04.005","article-title":"Cost of depression: effect of adherence and treatment response","volume":"21","author":"L von Knorring","year":"2006","journal-title":"Eur Psychiatry"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1472-8206.2010.00815.x","article-title":"French summaries of product characteristics: content in relation to therapeutic\n                    monitoring of psychotropic drugs","volume":"24","author":"M Rougemont","year":"2010","journal-title":"Fundam Clin Pharmacol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs\u2013best practice guidelines for therapeutic drug monitoring: a\n                    position paper by the subcommission on therapeutic drug monitoring, ILAE\n                    Commission on Therapeutic Strategies","volume":"49","author":"P N Patsalos","year":"2008","journal-title":"Epilepsia"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1055\/s-2003-39983","article-title":"Therapeutic drug monitoring of tricyclic antidepressants: how does it work under\n                    clinical conditions?","volume":"36","author":"M J M\u00fcller","year":"2003","journal-title":"Pharmacopsychiatry"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"19","DOI":"10.64719\/pb.4251","article-title":"Therapeutic drug monitoring of antipsychotics","volume":"35","author":"P J Perry","year":"2001","journal-title":"Psychopharmacol Bull"},{"key":"ref28","first-page":"13","article-title":"The clinical management of bipolar disorder: a review of evidence-based\n                    guidelines","author":"K R Connolly","year":"2011","journal-title":"Prim Care Companion CNS Disord"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/1471-244X-10-80","article-title":"Standards of lithium monitoring in mental health trusts in the UK","volume":"10","author":"N Collins","year":"2010","journal-title":"BMC Psychiatry"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1034\/j.1600-0447.2001.104001076.x","article-title":"Guidelines for lithium monitoring: are they ideal?","volume":"104","author":"N Gupta","year":"2001","journal-title":"Acta Psychiatr Scand"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1034\/j.1600-0447.108.s419.1.x","article-title":"Psychopharmacological treatment with lithium and antiepileptic drugs: suggested\n                    guidelines from the Danish Psychiatric Association and the Child and Adolescent\n                    Psychiatric Association in Denmark","volume":"419","author":"R W Licht","year":"2003","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1055\/s-2004-832687","article-title":"The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in\n                    psychiatry","volume":"37","author":"P Baumann","year":"2004","journal-title":"Pharmacopsychiatry"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0031-1286287","article-title":"AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update\n                    2011","volume":"44","author":"C Hiemke","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology:\n                    Update 2017","volume":"51","author":"C Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/FTD.0000000000001264","article-title":"How to Determine a Therapeutic Reference Range for a Psychotropic Drug\n                    Systematically? Recommendations of the TDM Task Force of the AGN","volume":"47","author":"X M Hart","year":"2025","journal-title":"Therapeutic Drug Monitoring"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1080\/15622975.2021.1878427","article-title":"Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring,\n                    molecular brain imaging and pharmacogenetic tests): focus on\n                    antidepressants","volume":"22","author":"C B Eap","year":"2021","journal-title":"World J Biol Psychiatry"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1080\/15622975.2024.2366235","article-title":"Optimisation of pharmacotherapy in psychiatry through therapeutic drug\n                    monitoring, molecular brain imaging and pharmacogenetic tests: Focus on\n                    antipsychotics","volume":"25","author":"X M Hart","year":"2024","journal-title":"World J Biol Psychiatry"},{"key":"ref38","first-page":"783","article-title":"Clinical monitoring guidelines for neuroleptic and antidepressant drugs. Central\n                    State Hospital, Milledgeville, Georgia","volume":"26","author":"J M Holbrook","year":"1991","journal-title":"Hosp Pharm"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2165\/00003088-200645110-00002","article-title":"Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring\n                    needed?","volume":"45","author":"S I Johannessen","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"ref40","first-page":"1073","article-title":"Standards of laboratory practice: antidepressant drug monitoring. National\n                    Academy of Clinical Biochemistry","volume":"44","author":"M W Linder","year":"1998","journal-title":"Clin Chem"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00003088-200645020-00001","article-title":"Pharmacokinetic optimisation in the treatment of Parkinson's disease : an\n                    update","volume":"45","author":"D Nyholm","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"ref42","first-page":"39","article-title":"Therapeutic monitoring of antidepressant drugs: current methodology and\n                    applications","volume":"47","author":"P J Orsulak","year":"1986","journal-title":"J Clin Psychiatry"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/00007691-198909000-00002","article-title":"Therapeutic monitoring of antidepressant drugs: guidelines updated","volume":"11","author":"P J Orsulak","year":"1989","journal-title":"Ther Drug Monit"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/00007691-197901020-00002","article-title":"Guidelines for therapeutic monitoring of tricyclic antidepressant plasma\n                    levels","volume":"1","author":"P J Orsulak","year":"1979","journal-title":"Ther Drug Monit"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/10408360701713112","article-title":"Relevant issues in the monitoring and the toxicology of antidepressants","volume":"45","author":"S M Wille","year":"2008","journal-title":"Crit Rev Clin Lab Sci"},{"key":"ref46","first-page":"133","article-title":"[Therapeutic drug monitoring to optimize psychopharmacotherapy in children and\n                    adolescents\u2013Update and guidelines for practice]","volume":"50","author":"K Egberts","year":"2021","journal-title":"Z Kinder Jugendpsychiatr Psychother"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1176\/ajp.142.2.155","article-title":"Tricyclic antidepressants\u2013blood level measurements and clinical outcome: an APA\n                    Task Force report. Task Force on the Use of Laboratory Tests in Psychiatry","volume":"142","year":"1985","journal-title":"Am J Psychiatry"},{"key":"ref49","first-page":"558","article-title":"Expanding therapeutic reference ranges using dose-related reference ranges","volume":"79","author":"E Haen","year":"2008","journal-title":"Nervenarzt"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0924-977X(02)00051-2","article-title":"Enantiomers\u2019 potential in psychopharmacology-a critical analysis with special\n                    emphasis on the antidepressant escitalopram","volume":"12","author":"P Baumann","year":"2002","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/toxsci\/kfp097","article-title":"Chiral toxicology: it's the same thing only different","volume":"110","author":"S W Smith","year":"2009","journal-title":"Toxicol Sci"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2165\/00003088-200241140-00003","article-title":"Interindividual variability of the clinical pharmacokinetics of methadone:\n                    implications for the treatment of opioid dependence","volume":"41","author":"C B Eap","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s00213-012-2699-8","article-title":"Flupentixol: relevance of stereoselective therapeutic drug monitoring","volume":"221","author":"P Baumann","year":"2012","journal-title":"Psychopharmacology (Berl)"},{"key":"ref57","first-page":"47","article-title":"Drug binding to human alpha-1-acid glycoprotein in health and disease","author":"JM H Kremer","year":"1988","journal-title":"Pharmacological Reviews"},{"key":"ref58","first-page":"287","article-title":"The pharmacokinetics of citalopram","volume":"6","author":"P Baumann","year":"1995","journal-title":"Reviews in Contemporary Pharmacotherapy"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/BF00498432","article-title":"The contribution of alpha 1-acid glycoprotein, lipoproteins, and albumin to the\n                    plasma binding of perazine, amitriptyline, and nortriptyline in healthy man","volume":"314","author":"M Brinkschulte","year":"1980","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref60","first-page":"1986","article-title":"The plasma protein binding of basic drugs","author":"P A Routledge","journal-title":"British Journal of Clinical Pharmacology"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2165\/00003088-199019020-00004","article-title":"Disease-induced variations in plasma protein levels implications for drug dosage\n                    regimens (Part I)","volume":"19","author":"R Zini","year":"1990","journal-title":"Clinical Pharmacokinetics"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1081\/DMR-100104402","article-title":"Human alpha-1-glycoprotein and its interactions with drugs","volume":"33","author":"Z H Israili","year":"2001","journal-title":"Drug Metab Rev"},{"key":"ref63","first-page":"44","article-title":"Drug binding in plasma. A summary of recent trends in the study of drug and\n                    hormone binding","volume":"26","author":"F Herv\u00e9","year":"1994","journal-title":"Clinical Pharmacokinetics"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1365-2125.1993.tb04224.x","article-title":"Evidence for differences in the binding of drugs to the two main genetic\n                    variants of human \u00d31-acid glycoprotein","volume":"36","author":"F Herv\u00e9","year":"1993","journal-title":"British Journal of Clinical Pharmacology"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/aps.2013.78","article-title":"Stereoselective binding of chiral drugs to plasma proteins","volume":"34","author":"Q Shen","year":"2013","journal-title":"Acta Pharmacologica Sinica"},{"key":"ref66","first-page":"69","volume-title":"Pharmacogenetics of drug binding to albumin and alpha1-acid glycoprotein, in\n                    Plasma binding of drugs and its consequences, F. Belpaire, et al., Editors","author":"C B Eap","year":"1990"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s40262-022-01171-w","article-title":"Clinical Pharmacokinetic Monitoring of Free Valproic A cid Levels: A Systematic\n                    Review","volume":"61","author":"K Lin","year":"2022","journal-title":"Clin Pharmacokinet"},{"issue":"01","key":"ref68","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/FTD.0000000000000705","article-title":"Future Studies on the Interaction Between Clozapine and Valproic Acid Should\n                    Aspire to Include Longitudinal Designs and Free Valproate Concentrations, and\n                    Should Consider that Inducer and\/or Inhibitory Effects May Vary With Time, the\n                    Individual, and the Auto-Induction of Valproic Acid","volume":"42","author":"J De Leon","year":"2020","journal-title":"Therapeutic Drug Monitoring"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s40262-019-00744-6","article-title":"Unbound Fraction of Clozapine Significantly Decreases with Elevated Plasma\n                    Concentrations of the Inflammatory Acute-Phase Protein Alpha-1-Acid\n                    Glycoprotein","volume":"58","author":"W H Man","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/JCP.0000000000001791","article-title":"Elevation of Alpha-1 Acid Glycoprotein During Acute Infection Increases\n                    Clozapine Levels Without Signs of Intoxication","volume":"44","author":"M Spangemacher","year":"2024","journal-title":"J Clin Psychopharmacol"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1124\/dmd.30.11.1257","article-title":"Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases\n                    (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is\n                    glucuronidated by UGT2B7 and UGT1A9","volume":"30","author":"M H Court","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00004714-200004000-00009","article-title":"Interindividual variation in bromperidol metabolism and relationship to\n                    therapeutic effects","volume":"20","author":"T Someya","year":"2000","journal-title":"J Clin Psychopharmacol"},{"key":"ref74","first-page":"830","article-title":"N+-glucuronidation, a common pathway in human metabolism of drugs with a\n                    tertiary amine grou","volume":"26","author":"E M Hawes","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/clpt.2012.46","article-title":"UGT1A4*3 encodes significantly increased glucuronidation of olanzapine in\n                    patients on maintenance treatment and in recombinant systems","volume":"92","author":"T Haslemo","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/clpt.1992.155","article-title":"Enantioselective amitriptyline metabolism in patients phenotyped for two\n                    cytochrome P450 isozymes","volume":"52","author":"U Breyer-Pfaff","year":"1992","journal-title":"Clin Pharmacol Ther"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/00004714-200110000-00008","article-title":"Drug glucuronidation in clinical psychopharmacology","volume":"21","author":"H L Liston","year":"2001","journal-title":"J Clin Psychopharmacol"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1017\/S1461145703003249","article-title":"Glucuronidation enzymes, genes and psychiatry","volume":"6","author":"J de Leon","year":"2003","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1124\/dmd.109.030981","article-title":"Role of human UGT2B10 in N-glucuronidation of tricyclic antidepressants,\n                    amitriptyline, imipramine, clomipramine, and trimipramine","volume":"38","author":"D Zhou","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"ref80","first-page":"11","article-title":"The Functionality of UDP-Glucuronosyltransferase Genetic Variants and their\n                    Association with Drug Responses and Human Diseases","author":"Y Jarrar","year":"2021","journal-title":"J Pers Med"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1124\/pr.115.011411","article-title":"Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions","volume":"68","author":"J T Backman","year":"2016","journal-title":"Pharmacol Rev"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression,\n                    enzyme activities, and impact of genetic variation","volume":"138","author":"U M Zanger","year":"2013","journal-title":"Pharmacol Ther"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"689","DOI":"10.2165\/11318030-000000000-00000","article-title":"Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part\n                    I","volume":"48","author":"S F Zhou","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2165\/11318070-000000000-00000","article-title":"Polymorphism of human cytochrome P450 2D6 and its clinical significance: part\n                    II","volume":"48","author":"S F Zhou","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/03602530902843483","article-title":"Polymorphism of human cytochrome P450 enzymes and its clinical impact","volume":"41","author":"S F Zhou","year":"2009","journal-title":"Drug Metab Rev"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2165\/00003088-199835050-00001","article-title":"Clinical pharmacokinetics of acamprosate","volume":"35","author":"S Saivin","year":"1998","journal-title":"Clin Pharmacokinet"},{"key":"ref87","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0928-0987(00)00146-9","article-title":"Prediction of interindividual variation in drug plasma levels in vivo from\n                    individual enzyme kinetic data and physiologically based pharmacokinetic\n                    modeling","volume":"12","author":"J J Bogaards","year":"2000","journal-title":"Eur J Pharm Sci"},{"key":"ref88","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.bcp.2016.03.020","article-title":"Characterizing novel metabolic pathways of melatonin receptor agonist\n                    agomelatine using metabolomic approaches","volume":"109","author":"X Liu","year":"2016","journal-title":"Biochem Pharmacol"},{"key":"ref89","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00228-006-0230-z","article-title":"Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine\n                    by ketoconazole as racemate and four different enantiomers","volume":"63","author":"A Allqvist","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"ref90","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.clpt.2006.02.008","article-title":"Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of\n                    alprazolam in healthy subjects","volume":"79","author":"J Y Park","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/00003088-198814010-00003","article-title":"Clinical pharmacokinetics of amantadine hydrochloride","volume":"14","author":"F Y Aoki","year":"1988","journal-title":"Clin Pharmacokinet"},{"key":"ref92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hup.320","article-title":"A review of the pharmacokinetics, tolerability and pharmacodynamics of\n                    amisulpride in healthy volunteers","volume":"17","author":"P Rosenzweig","year":"2002","journal-title":"Hum Psychopharmacol"},{"key":"ref93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00007691-199202000-00001","article-title":"Dextromethorphan and mephenytoin phenotyping of patients treated with\n                    thioridazine or amitriptyline","volume":"14","author":"P Baumann","year":"1992","journal-title":"Ther Drug Monit"},{"key":"ref94","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1081\/DMR-200033482","article-title":"The metabolic fate of amitriptyline, nortriptyline and amitriptylinoxide in\n                    man","volume":"36","author":"U Breyer-Pfaff","year":"2004","journal-title":"Drug Metab Rev"},{"key":"ref95","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00414-007-0184-4","article-title":"Correlation of inter-individual variations of amitriptyline metabolism examined\n                    in hairs with CYP2C19 and CYP2D6 polymorphisms","volume":"122","author":"D Thieme","year":"2008","journal-title":"Int J Legal Med"},{"key":"ref96","first-page":"2016","article-title":"Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6\n                    and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update","author":"J K Hicks","journal-title":"Clin Pharmacol Ther"},{"key":"ref97","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cbi.2008.02.001","article-title":"Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite\n                    nortriptyline to arene oxide intermediates in human liver microsomes and\n                    recombinant P450s","volume":"173","author":"B Wen","year":"2008","journal-title":"Chem Biol Interact"},{"key":"ref98","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0893-133X(99)00095-0","article-title":"Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in\n                    mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene\n                    disruption","volume":"22","author":"M Uhr","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"ref99","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S0006-3223(03)00074-X","article-title":"Differential enhancement of antidepressant penetration into the brain in mice\n                    with abcb1ab (mdr1ab) P-glycoprotein gene disruption","volume":"54","author":"M Uhr","year":"2003","journal-title":"Biol Psychiatry"},{"key":"ref100","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.dmpk.2014.12.001","article-title":"A comprehensive review of UDP-glucuronosyltransferase and esterases for drug\n                    development","volume":"30","author":"S Oda","year":"2015","journal-title":"Drug Metab Pharmacokinet"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/clpt.2013.2","article-title":"Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and\n                    CYP2C19 genotypes and dosing of tricyclic antidepressants","volume":"93","author":"J K Hicks","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"ref102","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/cpt.597","article-title":"Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6\n                    and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update","volume":"102","author":"J K Hicks","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"ref103","first-page":"129","article-title":"[Comparative study of the pharmacokinetics of amitriptyline oxide and\n                    trimipramine after single administration in healthy male probands and patients\n                    with renal failure]","volume":"88","author":"J Degen","year":"1993","journal-title":"Med Klin (Munich)"},{"key":"ref104","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1080\/004982599238344","article-title":"Involvement of CYP2D6 in the in vitro metabolism of amphetamine, two\n                    N-alkylamphetamines and their 4-methoxylated derivatives","volume":"29","author":"M V Bach","year":"1999","journal-title":"Xenobiotica"},{"key":"ref105","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00228-007-0373-6","article-title":"Impact of the CYP2D6 genotype on steady-state serum concentrations of\n                    aripiprazole and dehydroaripiprazole","volume":"63","author":"M Hendset","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"ref106","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/FTD.0b013e3181956726","article-title":"Influence of comedication on serum concentrations of aripiprazole and\n                    dehydroaripiprazole","volume":"31","author":"R B Waade","year":"2009","journal-title":"Ther Drug Monit"},{"key":"ref107","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.neuropharm.2010.06.010","article-title":"Pharmacokinetics of acute and sub-chronic aripiprazole in P-glycoprotein\n                    deficient mice","volume":"59","author":"K M Kirschbaum","year":"2010","journal-title":"Neuropharmacology"},{"key":"ref108","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/bdd.1801","article-title":"Effects of aripiprazole and its active metabolite dehydroaripiprazole on the\n                    activities of drug efflux transporters expressed both in the intestine and at\n                    the blood-brain barrier","volume":"33","author":"Y Nagasaka","year":"2012","journal-title":"Biopharm Drug Dispos"},{"key":"ref109","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2165\/11200860-000000000-00000","article-title":"Asenapine","volume":"23","author":"J Weber","year":"2009","journal-title":"CNS Drugs"},{"key":"ref110","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1517\/17425255.2014.908185","article-title":"Asenapine review, part I: chemistry, receptor affinity profile, pharmacokinetics\n                    and metabolism","volume":"10","author":"L Citrome","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/01.chi.0000246056.83791.b6","article-title":"CYP2D6 and clinical response to atomoxetine in children and adolescents with\n                    ADHD","volume":"46","author":"D Michelson","year":"2007","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"ref112","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/JCP.0b013e3182a608a2","article-title":"Effects of CYP2C19 genetic polymorphisms on atomoxetine pharmacokinetics","volume":"34","author":"C I Choi","year":"2014","journal-title":"J Clin Psychopharmacol"},{"key":"ref113","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ejphar.2007.09.035","article-title":"Interactions of attention-deficit\/hyperactivity disorder therapeutic agents with\n                    the efflux transporter P-glycoprotein","volume":"578","author":"H J Zhu","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"ref114","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/cpt.1409","article-title":"Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome\n                    P450 (CYP)2D6 Genotype and Atomoxetine Therapy","volume":"106","author":"J T Brown","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"ref115","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/BF02247478","article-title":"Pharmacokinetics and bioavailability of benperidol in schizophrenic patients\n                    after intravenous and two different kinds of oral application","volume":"116","author":"W Seiler","year":"1994","journal-title":"Psychopharmacology (Berl)"},{"key":"ref116","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1468-1331.1999.tb00015.x","article-title":"The effect of tolcapone on the pharmacokinetics of benserazide","volume":"6","author":"K M Jorga","year":"1999","journal-title":"Eur J Neurol"},{"key":"ref117","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1271\/bbb.80820","article-title":"Kinetic characterization of the oxidation of carbidopa and benserazide by\n                    tyrosinase and peroxidase","volume":"73","author":"J L Munoz-Munoz","year":"2009","journal-title":"Biosci Biotechnol Biochem"},{"key":"ref118","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.bbagen.2018.04.007","article-title":"Interference of carbidopa and other catechols with reactions catalyzed by\n                    peroxidases","volume":"1862","author":"B G\u0105sowska-Bajger","year":"2018","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"ref119","first-page":"610","article-title":"[Metabolism of antiparkinson drugs. An example of competitive\n                    hydroxylation]","volume":"29","author":"B Stock","year":"1979","journal-title":"Arzneimittelforschung"},{"key":"ref120","first-page":"32","article-title":"Use of Brexanolone for Postpartum Depression","volume":"16","author":"J R Scarff","year":"2019","journal-title":"Innov Clin Neurosci"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1007\/s40265-015-0462-2","article-title":"Brexpiprazole: First Global Approval","volume":"75","author":"S L Greig","year":"2015","journal-title":"Drugs"},{"key":"ref122","doi-asserted-by":"crossref","first-page":"106327","DOI":"10.1016\/j.eplepsyres.2020.106327","article-title":"A review of the drug-drug interactions of the antiepileptic drug\n                    brivaracetam","volume":"163","author":"B D Moseley","year":"2020","journal-title":"Epilepsy Res"},{"key":"ref123","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1517\/17425255.2013.759209","article-title":"Understanding the pharmacokinetics of anxiolytic drugs","volume":"9","author":"A C Altamura","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref124","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/clpt.1987.72","article-title":"Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives,\n                    cimetidine, and propranolol","volume":"41","author":"H R Ochs","year":"1987","journal-title":"Clin Pharmacol Ther"},{"key":"ref125","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/j.1432-1033.1994.tb19072.x","article-title":"High affinity of ergopeptides for cytochromes P450 3A. Importance of their\n                    peptide moiety for P450 recognition and hydroxylation of bromocriptine","volume":"223","author":"M A Peyronneau","year":"1994","journal-title":"Eur J Biochem"},{"key":"ref126","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s002130051048","article-title":"Effects of itraconazole on the steady-state plasma concentrations of bromperidol\n                    and reduced bromperidol in schizophrenic patients","volume":"145","author":"H Furukori","year":"1999","journal-title":"Psychopharmacology (Berl)"},{"key":"ref127","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00007691-199706000-00003","article-title":"Increased plasma concentrations of bromperidol and its reduced metabolite with\n                    levomepromazine, but not with thioridazine","volume":"19","author":"A Suzuki","year":"1997","journal-title":"Ther Drug Monit"},{"key":"ref128","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1016\/S0024-3205(00)00874-2","article-title":"CYP3A is responsible for N-dealkylation of haloperidol and bromperidol and\n                    oxidation of their reduced forms by human liver microsomes","volume":"67","author":"T Tateishi","year":"2000","journal-title":"Life Sci"},{"key":"ref129","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.pnpbp.2005.06.019","article-title":"Association between multidrug resistance 1 (MDR1) gene polymorphisms and\n                    therapeutic response to bromperidol in schizophrenic patients: a preliminary\n                    study","volume":"30","author":"N Yasui-Furukori","year":"2006","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref130","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1365-2125.2005.02380.x","article-title":"Inhibition of the metabolism of brotizolam by erythromycin in humans: In vivo\n                    evidence for the involvement of CYP3A4 in brotizolam metabolism","volume":"60","author":"T Tokairin","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s00228-006-0147-6","article-title":"Effect of psychotropic medication on the in vitro metabolism of buprenorphine in\n                    human cDNA-expressed cytochrome P450 enzymes","volume":"62","author":"S Bomsien","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"ref132","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1742-7843.2009.00432.x","article-title":"The in vivo response of novel buprenorphine metabolites, M1 and M3, to\n                    antiretroviral inducers and inhibitors of buprenorphine metabolism","volume":"105","author":"D E Moody","year":"2009","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref133","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/cpt.2149","article-title":"Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1,\n                    and COMT Genotypes and Select Opioid Therapy","volume":"110","author":"K R Crews","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"ref134","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00008571-200404000-00002","article-title":"Pharmacogenetic determinants of interindividual variability in bupropion\n                    hydroxylation by cytochrome P450 2B6 in human liver microsomes","volume":"14","author":"L M Hesse","year":"2004","journal-title":"Pharmacogenetics"},{"key":"ref135","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1124\/dmd.115.063107","article-title":"Metabolism of bupropion by carbonyl reductases in liver and intestine","volume":"43","author":"J N Connarn","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"ref136","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2165\/00003088-199936040-00003","article-title":"Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic\n                    drug","volume":"36","author":"I Mahmood","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"ref137","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2165\/00003088-200342070-00003","article-title":"Clinical pharmacokinetics of cabergoline","volume":"42","author":"P Del Dotto","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"ref138","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1530\/EJE-12-0198","article-title":"Polymorphisms of the drug transporter gene ABCB1 predict side effects of\n                    treatment with cabergoline in patients with PRL adenomas","volume":"167","author":"A P Athanasoulia","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"ref139","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1089\/omi.2013.0140","article-title":"High CYP2A6 enzyme activity as measured by a caffeine test and unique\n                    distribution of CYP2A6 variant alleles in Ethiopian population","volume":"18","author":"E Aklillu","year":"2014","journal-title":"OMICS"},{"key":"ref140","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/00008571-199604000-00003","article-title":"Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in\n                    man by in vivo versus in vitro correlations","volume":"6","author":"U Fuhr","year":"1996","journal-title":"Pharmacogenetics"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2174\/138920009788499003","article-title":"Caffeine metabolic ratios for the in vivo evaluation of CYP1A2,\n                    N-acetyltransferase 2, xanthine oxidase and CYP2A6 enzymatic activities","volume":"10","author":"N M Hakooz","year":"2009","journal-title":"Curr Drug Metab"},{"key":"ref142","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/2193-1801-2-236","article-title":"A Phase I, open-label, randomized, crossover study in three parallel groups to\n                    evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the\n                    pharmacokinetics of THC\/CBD oromucosal spray in healthy volunteers","volume":"2","author":"C Stott","year":"2013","journal-title":"Springerplus"},{"key":"ref143","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1111\/epi.16674","article-title":"Clinical implications of trials investigating drug-drug interactions between\n                    cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs","volume":"61","author":"P N Patsalos","year":"2020","journal-title":"Epilepsia"},{"key":"ref144","doi-asserted-by":"crossref","first-page":"1282831","DOI":"10.3389\/fphar.2024.1282831","article-title":"Systematic review of drug-drug interactions of delta-9-tetrahydrocannabinol,\n                    cannabidiol, and Cannabis","volume":"15","author":"R Nachnani","year":"2024","journal-title":"Front Pharmacol"},{"key":"ref145","first-page":"11","article-title":"Clinical Relevance of Drug Interactions with Cannabis: A Systematic Review","author":"V Lopera","year":"2022","journal-title":"J Clin Med"},{"key":"ref146","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1016\/0006-2952(94)90071-X","article-title":"Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide\n                    formation","volume":"47","author":"B M Kerr","year":"1994","journal-title":"Biochem Pharmacol"},{"key":"ref147","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1365-2710.2009.01057.x","article-title":"Effect of CYP3A5*3 genotype on serum carbamazepine concentrations at\n                    steady-state in Korean epileptic patients","volume":"34","author":"P W Park","year":"2009","journal-title":"J Clin Pharm Ther"},{"key":"ref148","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/FTD.0000000000000306","article-title":"The Impact of Pharmacokinetic Interactions With Eslicarbazepine Acetate Versus\n                    Oxcarbazepine and Carbamazepine in Clinical Practice","volume":"38","author":"C Johannessen Landmark","year":"2016","journal-title":"Ther Drug Monit"},{"key":"ref149","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.2174\/138161211797440212","article-title":"Do ATP-binding cassette transporters cause pharmacoresistance in epilepsy?\n                    Problems and approaches in determining which antiepileptic drugs are\n                    affected","volume":"17","author":"W Loscher","year":"2011","journal-title":"Curr Pharm Des"},{"key":"ref150","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1097\/FPC.0b013e3283498131","article-title":"Impact of ABCC2 genotype on antiepileptic drug response in Caucasian patients\n                    with childhood epilepsy","volume":"21","author":"M Ufer","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.eplepsyres.2015.09.001","article-title":"Effects of CYP3A4\/5 and ABCB1 genetic polymorphisms on carbamazepine metabolism\n                    and transport in Chinese patients with epilepsy treated with carbamazepine in\n                    monotherapy and bitherapy","volume":"117","author":"P Wang","year":"2015","journal-title":"Epilepsy Res"},{"key":"ref152","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/cpt.1004","article-title":"Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype\n                    and Use of Carbamazepine and Oxcarbazepine: 2017 Update","volume":"103","author":"E J Phillips","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"ref153","first-page":"S1","article-title":"Pharmacokinetics of continuous-release carbidopa\/levodopa","volume":"17","author":"J I Sage","year":"1994","journal-title":"Clin Neuropharmacol"},{"key":"ref154","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1021\/jm00236a004","article-title":"Further studies on the metabolism of carbidopa,\n                    (minus)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid\n                    monohydrate, in the human, Rhesus monkey, dog, and rat","volume":"18","author":"S Vickers","year":"1975","journal-title":"J Med Chem"},{"key":"ref155","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2147\/DDDT.S95100","article-title":"Clinical pharmacology study of cariprazine (MP-214) in patients with\n                    schizophrenia (12-week treatment)","volume":"10","author":"T Nakamura","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"ref156","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2147\/TCRM.S35137","article-title":"A new generation of antipsychotics: pharmacology and clinical utility of\n                    cariprazine in schizophrenia","volume":"9","author":"S Caccia","year":"2013","journal-title":"Ther Clin Risk Manag"},{"key":"ref157","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s40263-021-00819-8","article-title":"Pharmacology of Cenobamate: Mechanism of Action, Pharmacokinetics, Drug-Drug\n                    Interactions and Tolerability","volume":"35","author":"R Roberti","year":"2021","journal-title":"CNS Drugs"},{"key":"ref158","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.tox.2007.12.018","article-title":"Kinetics of chloral hydrate and its metabolites in male human volunteers","volume":"245","author":"J L Merdink","year":"2008","journal-title":"Toxicology"},{"key":"ref159","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/jat\/bkw059","article-title":"Postmortem Brain and Blood Reference Concentrations of Alprazolam, Bromazepam,\n                    Chlordiazepoxide, Diazepam, and their Metabolites and a Review of the\n                    Literature","volume":"40","author":"L Skov","year":"2016","journal-title":"J Anal Toxicol"},{"key":"ref160","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.bcp.2010.06.045","article-title":"Main contribution of the cytochrome P450 isoenzyme 1A2 (CYP1A2) to\n                    N-demethylation and 5-sulfoxidation of the phenothiazine neuroleptic\n                    chlorpromazine in human liver--A comparison with other phenothiazines","volume":"80","author":"J Wojcikowski","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00213-006-0437-9","article-title":"Evaluation of antipsychotic drugs as inhibitors of multidrug resistance\n                    transporter P-glycoprotein","volume":"187","author":"J S Wang","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"key":"ref162","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1093\/jat\/bky038","article-title":"Segmental Analysis of Chlorprothixene and Desmethylchlorprothixene in Postmortem\n                    Hair","volume":"42","author":"K N G\u00fcnther","year":"2018","journal-title":"J Anal Toxicol"},{"key":"ref163","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0924-977X(01)00101-8","article-title":"Review of pharmacokinetic and pharmacodynamic interaction studies with\n                    citalopram","volume":"11","author":"K Brosen","year":"2001","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref164","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ejphar.2009.10.007","article-title":"Evaluation of the influence of sex and CYP2C19 and CYP2D6 polymorphisms in the\n                    disposition of citalopram","volume":"626","author":"S Fudio","year":"2010","journal-title":"Eur J Pharmacol"},{"key":"ref165","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/01.jcp.0000227355.54074.14","article-title":"Phenotype-genotype relationship and clinical effects of citalopram in Chinese\n                    patients","volume":"26","author":"O Q Yin","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"ref166","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/cpt.2903","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6,\n                    CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor\n                    Antidepressants","volume":"114","author":"C A Bousman","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"ref167","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/FTD.0b013e31827ada88","article-title":"Clobazam therapeutic drug monitoring: a comprehensive review of the literature\n                    with proposals to improve future studies","volume":"35","author":"J de Leon","year":"2013","journal-title":"Ther Drug Monit"},{"key":"ref168","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/epi.13060","article-title":"Drug-drug interaction between clobazam and cannabidiol in children with\n                    refractory epilepsy","volume":"56","author":"A L Geffrey","year":"2015","journal-title":"Epilepsia"},{"key":"ref169","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s00228-003-0598-y","article-title":"Pharmacokinetics and sedative effects in healthy subjects and subjects with\n                    impaired liver function after continuous infusion of clomethiazole","volume":"59","author":"C Centerholt","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"key":"ref170","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/sj.bjp.0707253","article-title":"Tricyclic antidepressant pharmacology and therapeutic drug interactions\n                    updated","volume":"151","author":"P K Gillman","year":"2007","journal-title":"Br J Pharmacol"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1472-8206.1993.tb00219.x","article-title":"Identification of the human and animal hepatic cytochromes P450 involved in\n                    clonazepam metabolism","volume":"7","author":"E J Seree","year":"1993","journal-title":"Fundam Clin Pharmacol"},{"key":"ref172","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1520\/JFS11562J","article-title":"Identification of some interferences in the analysis of clorazepate","volume":"28","author":"E M Suzuki","year":"1983","journal-title":"J Forensic Sci"},{"key":"ref173","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1177\/00912700122010717","article-title":"Contributions of five human cytochrome P450 isoforms to the N-demethylation of\n                    clozapine in vitro at low and high concentrations","volume":"41","author":"O V Olesen","year":"2001","journal-title":"J Clin Pharmacol"},{"key":"ref174","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/00008571-200303000-00006","article-title":"The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on\n                    clozapine clearance and dose requirement","volume":"13","author":"J van der Weide","year":"2003","journal-title":"Pharmacogenetics"},{"key":"ref175","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1742-7843.2008.00298.x","article-title":"Antipsychotic drugs inhibit the function of breast cancer resistance\n                    protein","volume":"103","author":"J S Wang","year":"2008","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref176","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/01.ftd.0000211812.27558.6e","article-title":"Toxicokinetics of drugs of abuse: current knowledge of the isoenzymes involved\n                    in the human metabolism of tetrahydrocannabinol, cocaine, heroin, morphine, and\n                    codeine","volume":"28","author":"H H Maurer","year":"2006","journal-title":"Ther Drug Monit"},{"key":"ref177","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.toxlet.2014.10.026","article-title":"Contribution of human esterases to the metabolism of selected drugs of\n                    abuse","volume":"232","author":"M R Meyer","year":"2015","journal-title":"Toxicol Lett"},{"key":"ref178","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ejps.2007.09.003","article-title":"Characterization of human cytochrome P450 enzymes involved in the metabolism of\n                    cyamemazine","volume":"32","author":"C Arbus","year":"2007","journal-title":"Eur J Pharm Sci"},{"key":"ref179","first-page":"687","article-title":"Effects of 22 novel CYP2D6 variants found in Chinese population on the\n                    metabolism of dapoxetine","volume":"10","author":"R A Xu","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"ref180","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/bcp.15029","article-title":"Effect of gastric pH and of a moderate CYP3A4 inducer on the pharmacokinetics of\n                    daridorexant, a dual orexin receptor antagonist","volume":"88","author":"M Gehin","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/psp4.12877","article-title":"Population pharmacokinetic modeling of daridorexant, a novel dual orexin\n                    receptor antagonist","volume":"12","author":"A Krause","year":"2023","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"ref182","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1080\/17425255.2020.1817380","article-title":"Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for\n                    the treatment of insomnia disorders","volume":"16","author":"C Muehlan","year":"2020","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref183","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s40262-021-01028-8","article-title":"Effect of Liver Cirrhosis on the Pharmacokinetics, Metabolism, and Tolerability\n                    of Daridorexant, A Novel Dual Orexin Receptor Antagonist","volume":"60","author":"B Berger","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"ref184","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.clinthera.2013.03.013","article-title":"An open-label, single-dose, parallel-group study of the effects of chronic\n                    hepatic impairment on the safety and pharmacokinetics of desvenlafaxine","volume":"35","author":"S Baird-Bellaire","year":"2013","journal-title":"Clin Ther"},{"key":"ref185","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1358\/dot.2008.44.7.1227147","article-title":"Desvenlafaxine succinate for major depressive disorder","volume":"44","author":"B A Sproule","year":"2008","journal-title":"Drugs Today (Barc)"},{"key":"ref186","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2147\/NDT.S157708","article-title":"Drug-drug interactions involving antidepressants: focus on desvenlafaxine","volume":"14","author":"Y Low","year":"2018","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref187","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1111\/j.2042-7158.1998.tb06914.x","article-title":"Multiple human cytochromes contribute to biotransformation of dextromethorphan\n                    in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A","volume":"50","author":"L L von Moltke","year":"1998","journal-title":"J Pharm Pharmacol"},{"key":"ref188","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/(SICI)1099-081X(199704)18:3<227::AID-BDD18>3.0.CO;2-L","article-title":"Metabolism of dextromethorphan in vitro: involvement of cytochromes P450 2D6 and\n                    3A3\/4, with a possible role of 2E1","volume":"18","author":"J Schmider","year":"1997","journal-title":"Biopharm Drug Dispos"},{"key":"ref189","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0009-9236(96)90056-9","article-title":"The influence of CYP2D6 polymorphism and quinidine on the disposition and\n                    antitussive effect of dextromethorphan in humans","volume":"60","author":"D A Capon","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"ref190","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/(SICI)1099-081X(199910)20:7<341::AID-BDD195>3.0.CO;2-F","article-title":"Enzymes in addition to CYP3A4 and 3A5 mediate N-demethylation of\n                    dextromethorphan in human liver microsomes","volume":"20","author":"Y Wang","year":"1999","journal-title":"Biopharm Drug Dispos"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1365-2710.2007.00829.x","article-title":"Effects of genetic polymorphism of cytochrome P450 enzymes on the\n                    pharmacokinetics of benzodiazepines","volume":"32","author":"T Fukasawa","year":"2007","journal-title":"J Clin Pharm Ther"},{"key":"ref192","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1365-2125.1996.tb00010.x","article-title":"The elimination of diazepam in Chinese subjects is dependent on the mephenytoin\n                    oxidation phenotype","volume":"42","author":"J Wan","year":"1996","journal-title":"Br J Clin Pharmacol"},{"key":"ref193","doi-asserted-by":"crossref","first-page":"432","DOI":"10.31083\/ph.2012.1742","article-title":"Blood-brain barrier in vitro models as tools in drug discovery: assessment of\n                    the transport ranking of antihistaminic drugs","volume":"67","author":"W Neuhaus","year":"2012","journal-title":"Pharmazie"},{"key":"ref194","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1080\/00498250010002261","article-title":"In vitro identification of the cytochrome P450 isoform responsible for the\n                    metabolism of alpha-dihydroergocryptine","volume":"30","author":"M Althaus","year":"2000","journal-title":"Xenobiotica"},{"key":"ref195","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1067\/mcp.2001.117286","article-title":"Erythromycin increases plasma concentrations of alpha-dihydroergocryptine in\n                    humans","volume":"70","author":"C de Mey","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"ref196","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1124\/dmd.106.012088","article-title":"Identification of human cytochrome p450 isozymes involved in diphenhydramine\n                    N-demethylation","volume":"35","author":"T Akutsu","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"ref197","first-page":"1212","article-title":"Identification of the human P-450 enzymes responsible for the sulfoxidation and\n                    thiono-oxidation of diethyldithiocarbamate methyl ester: role of P-450 enzymes\n                    in disulfiram bioactivation","volume":"22","author":"A Madan","year":"1998","journal-title":"Alcohol Clin Exp Res"},{"key":"ref198","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00228-006-0168-1","article-title":"Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and\n                    clinical outcome of donepezil in Alzheimer's disease patients","volume":"62","author":"F Varsaldi","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"ref199","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/bcp.12325","article-title":"Population pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A,\n                    ABCB1, POR and NR1I2 genotypes on donepezil clearance","volume":"78","author":"M Noetzli","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"ref200","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/jps.2600750612","article-title":"Pharmacokinetics of dothiepin in humans: a single dose dose-proportionality\n                    study","volume":"75","author":"D K Yu","year":"1986","journal-title":"J Pharm Sci"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1023\/A:1016478708902","article-title":"The N-demethylation of the doxepin isomers is mainly catalyzed by the\n                    polymorphic CYP2C19","volume":"19","author":"S Hartter","year":"2002","journal-title":"Pharm Res"},{"key":"ref202","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/sj.mp.4001494","article-title":"Pharmacogenetics of antidepressants and antipsychotics: the contribution of\n                    allelic variations to the phenotype of drug response","volume":"9","author":"J Kirchheiner","year":"2004","journal-title":"Mol Psychiatry"},{"key":"ref203","doi-asserted-by":"crossref","first-page":"993","DOI":"10.3109\/00498258709044198","article-title":"Identification in in vivo acetylation pathway for N-dealkylated metabolites of\n                    doxylamine in humans","volume":"17","author":"D A Ganes","year":"1987","journal-title":"Xenobiotica"},{"key":"ref204","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.bcp.2005.07.007","article-title":"CYP2C-catalyzed delta9-tetrahydrocannabinol metabolism: kinetics,\n                    pharmacogenetics and interaction with phenytoin","volume":"70","author":"T M Bland","year":"2005","journal-title":"Biochem Pharmacol"},{"key":"ref205","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1124\/dmd.109.026898","article-title":"Characterization of human hepatic and extrahepatic UDP-glucuronosyltransferase\n                    enzymes involved in the metabolism of classic cannabinoids","volume":"37","author":"A Mazur","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"ref206","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/clpt.2008.213","article-title":"Interindividual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol\n                    as related to genetic polymorphisms in CYP2C9","volume":"85","author":"C Sachse-Seeboth","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"ref207","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2165\/00003088-200847030-00005","article-title":"In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with\n                    duloxetine","volume":"47","author":"E D Lobo","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"ref208","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/hup.1152","article-title":"In vitro and in vivo evaluation of the effects of duloxetine on P-gp\n                    function","volume":"25","author":"Z Ruike","year":"2010","journal-title":"Hum Psychopharmacol"},{"key":"ref209","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0090-9556(24)15088-X","article-title":"The specificity of glucuronidation of entacapone and tolcapone by recombinant\n                    human UDP-glucuronosyltransferases","volume":"28","author":"P Lautala","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"ref210","doi-asserted-by":"crossref","first-page":"537","DOI":"10.2217\/pgs.09.168","article-title":"Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the\n                    antidepressant escitalopram and treatment response","volume":"11","author":"M H Tsai","year":"2010","journal-title":"Pharmacogenomics"},{"key":"ref211","first-page":"1102","article-title":"Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating\n                    biotransformation, inhibitory effects, and comparison to R-citalopram","volume":"29","author":"L L von Moltke","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"ref212","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.neuropharm.2015.12.009","article-title":"P-glycoprotein differentially affects escitalopram, levomilnacipran, vilazodone\n                    and vortioxetine transport at the mouse blood-brain barrier in vivo","volume":"103","author":"C Bundgaard","year":"2016","journal-title":"Neuropharmacology"},{"key":"ref213","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.apsb.2016.07.016","article-title":"Insights into CYP2B6-mediated drug-drug interactions","volume":"6","author":"W D Hedrich","year":"2016","journal-title":"Acta Pharm Sin B"},{"key":"ref214","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jpsychires.2021.11.036","article-title":"Pharmacogenomics of ketamine: A systematic review","volume":"145","author":"S Meshkat","year":"2021","journal-title":"J Psychiatr Res"},{"key":"ref215","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s40262-020-00953-4","article-title":"Population Pharmacokinetics of Esketamine Nasal Spray and its Metabolite\n                    Noresketamine in Healthy Subjects and Patients with Treatment-Resistant\n                    Depression","volume":"60","author":"C Perez-Ruixo","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"ref216","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/j.1528-1167.2012.03519.x","article-title":"Pharmacokinetics and drug interactions of eslicarbazepine acetate","volume":"53","author":"M Bialer","year":"2012","journal-title":"Epilepsia"},{"key":"ref217","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1080\/00498250500111612","article-title":"Identification of human cytochrome P450 enzymes involved in the formation of\n                    4-hydroxyestazolam from estazolam","volume":"35","author":"M Miura","year":"2005","journal-title":"Xenobiotica"},{"key":"ref218","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/00007691-200206000-00008","article-title":"No effect of itraconazole on the single oral dose pharmacokinetics and\n                    pharmacodynamics of estazolam","volume":"24","author":"Y Otsuji","year":"2002","journal-title":"Ther Drug Monit"},{"key":"ref219","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.clinthera.2006.04.014","article-title":"Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of\n                    transient and chronic insomnia","volume":"28","author":"J Najib","year":"2006","journal-title":"Clin Ther"},{"key":"ref220","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s40262-014-0190-x","article-title":"Pharmacokinetic and pharmacodynamic drug interactions with ethanol\n                    (alcohol)","volume":"53","author":"L N Chan","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/17425255.2020.1724956","article-title":"Therapeutic drug monitoring of antiepileptic drugs: current status and future\n                    prospects","volume":"16","author":"C Johannessen Landmark","year":"2020","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref222","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1046\/j.1365-2125.1997.00642.x","article-title":"Single and multiple dose pharmacokinetics of felbamate in the elderly","volume":"44","author":"A Richens","year":"1997","journal-title":"Br J Clin Pharmacol"},{"key":"ref223","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1080\/004982599238056","article-title":"Flunitrazepam oxidative metabolism in human liver microsomes: involvement of\n                    CYP2C19 and CYP3A4","volume":"29","author":"J K Coller","year":"1999","journal-title":"Xenobiotica"},{"key":"ref224","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/00004714-200304000-00009","article-title":"The role of cytochrome P450 2C19 activity in flunitrazepam metabolism in\n                    vivo","volume":"23","author":"I Gafni","year":"2003","journal-title":"J Clin Psychopharmacol"},{"key":"ref225","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1006\/bbrc.1993.1761","article-title":"Involvement of CYP2D6 in oxidative metabolism of cinnarizine and flunarizine in\n                    human liver microsomes","volume":"193","author":"S Narimatsu","year":"1993","journal-title":"Biochem Biophys Res Commun"},{"key":"ref226","first-page":"85","article-title":"Effects of CYP2C19 genotype and CYP2C9 on fluoxetine N-demethylation in human\n                    liver microsomes","volume":"22","author":"Z Q Liu","year":"2001","journal-title":"Acta Pharmacol Sin"},{"key":"ref227","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1742-7843.2005.pto_194.x","article-title":"Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state\n                    plasma concentrations of the enantiomers of fluoxetine and norfluoxetine","volume":"97","author":"M G Scordo","year":"2005","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref228","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/00007691-198204000-00005","article-title":"Active metabolites of neuroleptic drugs: possible contribution to therapeutic\n                    and toxic effects","volume":"4","author":"S G Dahl","year":"1982","journal-title":"Ther Drug Monit"},{"key":"ref229","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1002\/jps.2600591220","article-title":"Metabolism of flurazepam, a benzodiazepine, in man and dog","volume":"59","author":"M A Schwartz","year":"1970","journal-title":"J Pharm Sci"},{"key":"ref230","doi-asserted-by":"crossref","first-page":"310","DOI":"10.2174\/15748847113089990051","article-title":"The pharmacokinetics of long-acting antipsychotic medications","volume":"9","author":"S Spanarello","year":"2014","journal-title":"Curr Clin Pharmacol"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1248\/bpb.33.285","article-title":"Effects of cigarette smoking and cytochrome P450 2D6 genotype on fluvoxamine\n                    concentration in plasma of Japanese patients","volume":"33","author":"Y Katoh","year":"2010","journal-title":"Biol Pharm Bull"},{"key":"ref232","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/00498250600718464","article-title":"Identification of human cytochrome P450 enzymes involved in the major metabolic\n                    pathway of fluvoxamine","volume":"37","author":"M Miura","year":"2007","journal-title":"Xenobiotica"},{"key":"ref233","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1124\/dmd.104.001230","article-title":"The impact of P-glycoprotein on the disposition of drugs targeted for\n                    indications of the central nervous system: evaluation using the MDR1A\/1B\n                    knockout mouse model","volume":"33","author":"A Doran","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"ref234","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/11536200-000000000-00000","article-title":"A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and\n                    gabapentin","volume":"49","author":"H N Bockbrader","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"ref235","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/00008571-199912000-00001","article-title":"The O-demethylation of the antidementia drug galanthamine is catalysed by\n                    cytochrome P450 2D6","volume":"9","author":"R Bachus","year":"1999","journal-title":"Pharmacogenetics"},{"key":"ref236","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/bcp.12863","article-title":"Pharmacokinetics and pharmacodynamics of gamma-hydroxybutyrate in healthy\n                    subjects","volume":"81","author":"M E Liechti","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"ref237","doi-asserted-by":"crossref","first-page":"25S","DOI":"10.1111\/j.1365-2125.1980.tb04901.x","article-title":"Pharmacokinetics and metabolism of guanfacine in man: a review","volume":"10","author":"J R Kiechel","year":"1980","journal-title":"Br J Clin Pharmacol"},{"key":"ref238","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1080\/03602530802431439","article-title":"The aldo-keto reductase superfamily and its role in drug metabolism and\n                    detoxification","volume":"40","author":"O A Barski","year":"2008","journal-title":"Drug Metab Rev"},{"key":"ref239","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1067\/mcp.2002.127494","article-title":"The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the\n                    outcome of haloperidol treatment","volume":"72","author":"J Brockmoller","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"ref240","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2165\/00003088-200241020-00006","article-title":"Population pharmacokinetics of haloperidol using routine clinical\n                    pharmacokinetic data in Japanese patients","volume":"41","author":"E Yukawa","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1124\/dmd.111.042150","article-title":"Human UDP-glucuronosyltransferase isoforms involved in haloperidol\n                    glucuronidation and quantitative estimation of their contribution","volume":"40","author":"Y Kato","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"ref242","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2165\/00003088-199937060-00001","article-title":"Pharmacokinetics of haloperidol: an update","volume":"37","author":"S Kudo","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"ref243","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1208\/s12248-020-00536-y","article-title":"The role of alcohol dehydrogenase in drug metabolism: beyond ethanol\n                    oxidation","volume":"23","author":"L Di","year":"2021","journal-title":"aaps j"},{"key":"ref244","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2147\/DDDT.S6443","article-title":"New atypical antipsychotics for schizophrenia: iloperidone","volume":"4","author":"S Caccia","year":"2010","journal-title":"Drug Des Devel Ther"},{"key":"ref245","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1365-2125.1995.tb04473.x","article-title":"Imipramine metabolism in relation to the sparteine and mephenytoin oxidation\n                    polymorphisms--a population study","volume":"39","author":"H Madsen","year":"1995","journal-title":"Br J Clin Pharmacol"},{"key":"ref246","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s40262-013-0080-7","article-title":"Impact of impaired renal function on the pharmacokinetics of the antiepileptic\n                    drug lacosamide","volume":"52","author":"W Cawello","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"ref247","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1021\/tx9003243","article-title":"Bioactivation of lamotrigine in vivo in rat and in vitro in human liver\n                    microsomes, hepatocytes, and epidermal keratinocytes: characterization of\n                    thioether conjugates by liquid chromatography\/mass spectrometry and high field\n                    nuclear magnetic resonance spectroscopy","volume":"23","author":"H Chen","year":"2010","journal-title":"Chem Res Toxicol"},{"key":"ref248","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/FTD.0000000000000271","article-title":"Effects of UGT2B7 genetic polymorphisms on serum concentrations of valproic acid\n                    in chinese children with epilepsy comedicated with lamotrigine","volume":"38","author":"Q Wang","year":"2016","journal-title":"Ther Drug Monit"},{"key":"ref249","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/cpdd.915","article-title":"Evaluation of the CYP3A and CYP2B6 drug-drug interaction potential of\n                    lemborexant","volume":"10","author":"I Landry","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"key":"ref250","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S0090-9556(24)15285-3","article-title":"In vitro evaluation of potential drug interactions with levetiracetam, a new\n                    antiepileptic agent","volume":"27","author":"J M Nicolas","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"ref251","first-page":"646","article-title":"Bioequivalence and absolute bioavailability of oblong and coated levomepromazine\n                    tablets in CYP2D6 phenotyped subjects","volume":"33","author":"M Bagli","year":"1995","journal-title":"Int J Clin Pharmacol Ther"},{"key":"ref252","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.bcp.2014.05.005","article-title":"The cytochrome P450-catalyzed metabolism of levomepromazine: a phenothiazine\n                    neuroleptic with a wide spectrum of clinical application","volume":"90","author":"J Wojcikowski","year":"2014","journal-title":"Biochem Pharmacol"},{"key":"ref253","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1177\/1060028014535074","article-title":"Levomilnacipran: A New Serotonin-Norepinephrine Reuptake Inhibitor for the\n                    Treatment of Major Depressive Disorder","volume":"48","author":"E C Palmer","year":"2014","journal-title":"Ann Pharmacother"},{"key":"ref254","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.clpt.2006.09.012","article-title":"ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone\n                    plasma levels and response to treatment","volume":"80","author":"S Crettol","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"ref255","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.neuroscience.2010.04.065","article-title":"Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of\n                    levosulpiride in healthy subjects","volume":"169","author":"H Y Cho","year":"2010","journal-title":"Neuroscience"},{"key":"ref256","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1124\/dmd.106.011973","article-title":"An evaluation of the cytochrome p450 inhibition potential of lisdexamfetamine in\n                    human liver microsomes","volume":"35","author":"S Krishnan","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"ref257","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0926-6917(95)00016-X","article-title":"Stable expression of human cytochrome P450 3A4 in V79 cells and its application\n                    for metabolic profiling of ergot derivatives","volume":"293","author":"R Rauschenbach","year":"1995","journal-title":"Eur J Pharmacol"},{"key":"ref258","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2165\/00023210-200923040-00005","article-title":"Lithium: updated human knowledge using an evidence-based approach. Part II:\n                    Clinical pharmacology and therapeutic monitoring","volume":"23","author":"E M Grandjean","year":"2009","journal-title":"CNS Drugs"},{"key":"ref259","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2165\/00002512-200016030-00002","article-title":"Differential pharmacokinetics of lithium in elderly patients","volume":"16","author":"B A Sproule","year":"2000","journal-title":"Drugs Aging"},{"key":"ref260","doi-asserted-by":"crossref","first-page":"466","DOI":"10.5414\/CPP44466","article-title":"Lorazepam concentrations, pharmacokinetics and pharmacodynamics in a cohort of\n                    mechanically ventilated ICU patients","volume":"44","author":"M de Wit","year":"2006","journal-title":"Int J Clin Pharmacol Ther"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/BF00427897","article-title":"Comparative pharmacokinetics and pharmacodynamics of lorazepam, alprazolam and\n                    diazepam","volume":"86","author":"E H Ellinwood","year":"1985","journal-title":"Psychopharmacology (Berl)"},{"key":"ref262","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/bdd.768","article-title":"In vitro identification of the human cytochrome p450 enzymes involved in the\n                    oxidative metabolism of loxapine","volume":"32","author":"J P Luo","year":"2011","journal-title":"Biopharm Drug Dispos"},{"key":"ref263","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s40265-020-01271-6","article-title":"Lumateperone: First Approval","volume":"80","author":"H A Blair","year":"2020","journal-title":"Drugs"},{"key":"ref264","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1515\/dmdi-2014-0005","article-title":"Lurasidone drug-drug interaction studies: a comprehensive review","volume":"29","author":"Y Y Chiu","year":"2014","journal-title":"Drug Metabol Drug Interact"},{"key":"ref265","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1034\/j.1600-0773.2002.900306.x","article-title":"Cytochrome P450 enzymes contributing to demethylation of maprotiline in man","volume":"90","author":"L Brachtendorf","year":"2002","journal-title":"Pharmacol Toxicol"},{"key":"ref266","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.euroneuro.2017.01.008","article-title":"Pharmacogenetics of ecstasy: CYP1A2, CYP2C19, and CYP2B6 polymorphisms moderate\n                    pharmacokinetics of MDMA in healthy subjects","volume":"27","author":"P Vizeli","year":"2017","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref267","first-page":"649","article-title":"Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine\n                    disposition in humans: use of paroxetine as a metabolic inhibitor probe","volume":"44","author":"M Segura","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"ref268","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2133\/dmpk.DMPK-12-RG-032","article-title":"Changes in CYP1A2 activity in humans after 3,4-methylenedioxymethamphetamine\n                    (MDMA, ecstasy) administration using caffeine as a probe drug","volume":"27","author":"S Yubero-Lahoz","year":"2012","journal-title":"Drug Metab Pharmacokinet"},{"key":"ref269","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/bja\/51.6.493","article-title":"Plasma concentrations of medazepam and its metabolites after oral\n                    administration","volume":"51","author":"D M Hailey","year":"1979","journal-title":"Br J Anaesth"},{"key":"ref270","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/00004714-200104000-00008","article-title":"Differential effects of fluvoxamine and other antidepressants on the\n                    biotransformation of melatonin","volume":"21","author":"S Hartter","year":"2001","journal-title":"J Clin Psychopharmacol"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/BF00545974","article-title":"Pharmacokinetics of parenteral and oral melperone in man","volume":"23","author":"L Borgstrom","year":"1982","journal-title":"Eur J Clin Pharmacol"},{"key":"ref272","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2165\/11634390-000000000-00000","article-title":"The role of memantine in the treatment of psychiatric disorders other than the\n                    dementias: a review of current preclinical and clinical evidence","volume":"26","author":"G Sani","year":"2012","journal-title":"CNS Drugs"},{"key":"ref273","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1111\/j.1532-5415.2010.03048.x","article-title":"Once-daily memantine: pharmacokinetic and clinical considerations","volume":"58","author":"I H Gomolin","year":"2010","journal-title":"J Am Geriatr Soc"},{"key":"ref274","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.euroneuro.2007.06.003","article-title":"A review on the impact of P-glycoprotein on the penetration of drugs into the\n                    brain. Focus on psychotropic drugs","volume":"18","author":"K Linnet","year":"2008","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref275","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/ALN.0b013e3181642938","article-title":"Role of CYP2B6 in stereoselective human methadone metabolism","volume":"108","author":"R A Totah","year":"2008","journal-title":"Anesthesiology"},{"key":"ref276","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0376-8716(02)00320-4","article-title":"Cytochrome P4503A4 metabolic activity, methadone blood concentrations, and\n                    methadone doses","volume":"69","author":"M Shinderman","year":"2003","journal-title":"Drug Alcohol Depend"},{"key":"ref277","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.neuropharm.2009.08.014","article-title":"Carboxylesterase 1 gene polymorphism and methylphenidate response in ADHD","volume":"57","author":"Z Nemoda","year":"2009","journal-title":"Neuropharmacology"},{"key":"ref278","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0022-3565(25)20103-3","article-title":"Identification of human cytochrome P450 isoforms involved in the stereoselective\n                    metabolism of mianserin enantiomers","volume":"278","author":"E Koyama","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"ref279","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1124\/dmd.110.032094","article-title":"Selection of alternative CYP3A4 probe substrates for clinical drug interaction\n                    studies using in vitro data and in vivo simulation","volume":"38","author":"R S Foti","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"ref280","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1124\/dmd.109.028274","article-title":"In vitro inhibition and induction of human liver cytochrome p450 enzymes by\n                    milnacipran","volume":"37","author":"B L Paris","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/BF03189351","article-title":"Pharmacokinetics of milnacipran in liver impairment","volume":"23","author":"C Puozzo","year":"1998","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"ref282","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1124\/dmd.112.045120","article-title":"Excretion and metabolism of milnacipran in humans after oral administration of\n                    milnacipran hydrochloride","volume":"40","author":"F Li","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"ref283","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2165\/0003088-200948010-00005","article-title":"Steady-state concentrations of mirtazapine, N-desmethylmirtazapine,\n                    8-hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6\n                    genotype, age and smoking behaviour","volume":"48","author":"A B Lind","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"ref284","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/S0026-895X(24)12045-7","article-title":"Metabolism of the antidepressant mirtazapine in vitro: contribution of\n                    cytochromes P-450 1A2, 2D6, and 3A4","volume":"28","author":"E Stormer","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"ref285","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/0009-9236(95)90230-9","article-title":"Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and\n                    CYP1A2: a panel study","volume":"57","author":"L F Gram","year":"1995","journal-title":"Clin Pharmacol Ther"},{"key":"ref286","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2165\/00003088-200342020-00002","article-title":"Clinical pharmacokinetic profile of modafinil","volume":"42","author":"P Robertson","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"ref287","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1177\/009127009903900312","article-title":"Open-label, single-dose pharmacokinetic study of modafinil tablets: influence of\n                    age and gender in normal subjects","volume":"39","author":"Y N Wong","year":"1999","journal-title":"J Clin Pharmacol"},{"key":"ref288","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1177\/00912709922007534","article-title":"A double-blind, placebo-controlled, ascending-dose evaluation of the\n                    pharmacokinetics and tolerability of modafinil tablets in healthy male\n                    volunteers","volume":"39","author":"Y N Wong","year":"1999","journal-title":"J Clin Pharmacol"},{"key":"ref289","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11011-011-9274-6","article-title":"Morphine metabolism, transport and brain disposition","volume":"27","author":"S De Gregori","year":"2012","journal-title":"Metab Brain Dis"},{"key":"ref290","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.clpt.2003.08.011","article-title":"Role of P-glycoprotein in the intestinal absorption and clinical effects of\n                    morphine","volume":"74","author":"E D Kharasch","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3747\/co.23.3487","article-title":"A user's guide to cannabinoid therapies in oncology","volume":"23","author":"V Maida","year":"2016","journal-title":"Curr Oncol"},{"key":"ref292","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2165\/00003495-198530050-00002","article-title":"Nabilone. A preliminary review of its pharmacological properties and therapeutic\n                    use","volume":"30","author":"A Ward","year":"1985","journal-title":"Drugs"},{"key":"ref293","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/j.1552-4604.1987.tb02191.x","article-title":"Nalmefene: safety and kinetics after single and multiple oral doses of a new\n                    opioid antagonist","volume":"27","author":"R Dixon","year":"1987","journal-title":"J Clin Pharmacol"},{"key":"ref294","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1211\/0022357045020","article-title":"Carbonyl reduction of naltrexone and dolasetron by oxidoreductases isolated from\n                    human liver cytosol","volume":"56","author":"U Breyer-Pfaff","year":"2004","journal-title":"J Pharm Pharmacol"},{"key":"ref295","doi-asserted-by":"crossref","first-page":"e0126113","DOI":"10.1371\/journal.pone.0126113","article-title":"Drug Metabolizing Enzyme and Transporter Gene Variation, Nicotine Metabolism,\n                    Prospective Abstinence, and Cigarette Consumption","volume":"10","author":"A W Bergen","year":"2015","journal-title":"PLoS One"},{"key":"ref296","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1046\/j.1365-2710.1998.00175.x","article-title":"Pharmacokinetic interactions between acute alcohol ingestion and single doses of\n                    benzodiazepines, and tricyclic and tetracyclic antidepressants -- an update","volume":"23","author":"E Tanaka","year":"1998","journal-title":"J Clin Pharm Ther"},{"key":"ref297","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.3109\/00498259609050260","article-title":"Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome\n                    P450s: role of CYP2B6, 2C19 and the 3A subfamily","volume":"26","author":"S Ono","year":"1996","journal-title":"Xenobiotica"},{"key":"ref299","doi-asserted-by":"crossref","first-page":"869","DOI":"10.2165\/00003088-200140110-00005","article-title":"Quantitative pharmacogenetics of nortriptyline: a novel approach","volume":"40","author":"E E Kvist","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"ref300","first-page":"740","article-title":"Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by\n                    cDNA-expressed human cytochrome P-450 isozymes","volume":"25","author":"O V Olesen","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/00912709922008173","article-title":"Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high\n                    affinity) and CYP3A4 (low affinity): implications for interactions with\n                    enzyme-inducing drugs","volume":"39","author":"K Venkatakrishnan","year":"1999","journal-title":"J Clin Pharmacol"},{"key":"ref302","first-page":"177","article-title":"Olanzapine. Pharmacokinetic and pharmacodynamic profile","volume":"37","author":"J T Callaghan","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"ref303","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/FPC.0b013e328348c76b","article-title":"Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y\n                    variants","volume":"21","author":"K K Erickson-Ridout","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"ref304","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1055\/s-0043-100762","article-title":"[Update Opipramol]","volume":"85","author":"M Gahr","year":"2017","journal-title":"Fortschr Neurol Psychiatr"},{"key":"ref305","doi-asserted-by":"crossref","first-page":"256","DOI":"10.18433\/J37S4K","article-title":"First Analysis of the Association Between CYP3A4\/5, ABCB1 Genetic Polymorphisms\n                    and Oxcarbazepine Metabolism and Transport in Chinese Epileptic Patients with\n                    Oxcarbazepine Monotherapy and Bitherapy","volume":"18","author":"P Wang","year":"2015","journal-title":"J Pharm Pharm Sci"},{"key":"ref306","first-page":"87","article-title":"Metabolism of oxycodone in human hepatocytes from different age groups and\n                    prediction of hepatic plasma clearance","volume":"2","author":"T Korjamo","year":"2011","journal-title":"Front Pharmacol"},{"key":"ref307","doi-asserted-by":"crossref","first-page":"e60239","DOI":"10.1371\/journal.pone.0060239","article-title":"CYP2D6 genotype dependent oxycodone metabolism in postoperative patients","volume":"8","author":"U M Stamer","year":"2013","journal-title":"PLoS One"},{"key":"ref308","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/FPC.0000000000000351","article-title":"PharmGKB summary: oxycodone pathway, pharmacokinetics","volume":"28","author":"R Huddart","year":"2018","journal-title":"Pharmacogenet Genomics"},{"key":"ref309","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0033-3182(10)70664-2","article-title":"The pharmacokinetics of paliperidone versus risperidone","volume":"51","author":"J de Leon","year":"2010","journal-title":"Psychosomatics"},{"key":"ref310","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1097\/FTD.0b013e3181858ca9","article-title":"ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone\n                    and risperidone active moiety","volume":"30","author":"A Gunes","year":"2008","journal-title":"Ther Drug Monit"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1124\/dmd.107.018275","article-title":"Absorption, metabolism, and excretion of paliperidone, a new monoaminergic\n                    antagonist, in humans","volume":"36","author":"M Vermeir","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"ref312","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/cpdd.122","article-title":"Effect of carbamazepine on the pharmacokinetics of paliperidone extended-release\n                    tablets at steady-state","volume":"3","author":"V Kerbusch-Herben","year":"2014","journal-title":"Clin Pharmacol Drug Dev"},{"key":"ref313","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1365-2125.2006.02629.x","article-title":"Paroxetine: population pharmacokinetic analysis in late-life depression using\n                    sparse concentration sampling","volume":"61","author":"Y Feng","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"ref314","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1124\/dmd.109.030551","article-title":"Identification of cytochrome P450 isoforms involved in the metabolism of\n                    paroxetine and estimation of their importance for human paroxetine metabolism\n                    using a population-based simulator","volume":"38","author":"J Jornil","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"ref315","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2165\/11318050-000000000-00000","article-title":"Effect of cytochrome P450 2D6 genotype on maternal paroxetine plasma\n                    concentrations during pregnancy","volume":"48","author":"F F Ververs","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"ref316","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/epi.12865","article-title":"The clinical pharmacology profile of the new antiepileptic drug perampanel: A\n                    novel noncompetitive AMPA receptor antagonist","volume":"56","author":"P N Patsalos","year":"2015","journal-title":"Epilepsia"},{"key":"ref317","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s002130000489","article-title":"Cytochrome P-450 enzymes and FMO3 contribute to the disposition of the\n                    antipsychotic drug perazine in vitro","volume":"151","author":"E Stormer","year":"2000","journal-title":"Psychopharmacology (Berl)"},{"key":"ref318","first-page":"1211","article-title":"Assessment of potential interactions between dopamine receptor agonists and\n                    various human cytochrome P450 enzymes using a simple in vitro inhibition\n                    screen","volume":"25","author":"M A Wynalda","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"ref319","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1097\/FPC.0b013e3282f01aa3","article-title":"CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time\n                    course of prolactin response to perphenazine","volume":"17","author":"E Aklillu","year":"2007","journal-title":"Pharmacogenet Genomics"},{"key":"ref320","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1046\/j.1365-2125.2000.00298.x","article-title":"Identification of the human cytochrome P450 isoforms mediating in vitro\n                    N-dealkylation of perphenazine","volume":"50","author":"O V Olesen","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/cpt.2008","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9\n                    and HLA-B Genotypes and Phenytoin Dosing: 2020 Update","volume":"109","author":"J H Karnes","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"ref322","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1212\/WNL.63.10_suppl_4.S3","article-title":"Pharmacogenetics and enzyme induction\/inhibition properties of antiepileptic\n                    drugs","volume":"63","author":"G D Anderson","year":"2004","journal-title":"Neurology"},{"key":"ref323","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/clpt.1981.66","article-title":"Mechanism of valproate-phenobarbital interaction in epileptic patients","volume":"29","author":"I M Kapetanovi\u0107","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"ref324","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1684\/epd.2014.0714","article-title":"Interactions between antiepileptic drugs, and between antiepileptic drugs and\n                    other drugs","volume":"16","author":"G Zaccara","year":"2014","journal-title":"Epileptic Disord"},{"key":"ref325","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0022-3565(24)37449-X","article-title":"Identification and characterization of human cytochrome P450 isoforms\n                    interacting with pimozide","volume":"285","author":"Z Desta","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"ref326","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.4088\/JCP.11m07572","article-title":"CYP2D6 genotype information to guide pimozide treatment in adult and pediatric\n                    patients: basis for the U.S. Food and Drug Administration's new dosing\n                    recommendations","volume":"73","author":"H L Rogers","year":"2012","journal-title":"J Clin Psychiatry"},{"key":"ref327","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2165\/00003088-200241040-00003","article-title":"Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the\n                    treatment of Parkinson's disease","volume":"41","author":"D Deleu","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"ref328","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.sleep.2017.01.002","article-title":"The European Medicines Agency review of pitolisant for treatment of narcolepsy:\n                    summary of the scientific assessment by the Committee for Medicinal Products for\n                    Human Use","volume":"33","author":"M Kollb-Sielecka","year":"2017","journal-title":"Sleep Med"},{"key":"ref329","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1007\/s40265-016-0620-1","article-title":"Pitolisant: First Global Approval","volume":"76","author":"Y Y Syed","year":"2016","journal-title":"Drugs"},{"key":"ref330","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0022-510X(98)00307-4","article-title":"Pramipexole--a new dopamine agonist for the treatment of Parkinson's\n                    disease","volume":"163","author":"J P Bennett","year":"1999","journal-title":"J Neurol Sci"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/S0026-895X(25)09711-1","article-title":"Metabolism of prazepam by rat liver microsomes: stereoselective formation and\n                    N-dealkylation of 3-hydroxyprazepam","volume":"36","author":"X L Lu","year":"1989","journal-title":"Mol Pharmacol"},{"key":"ref332","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/sj.bjp.0705195","article-title":"Contribution of human cytochrome p-450 isoforms to the metabolism of the\n                    simplest phenothiazine neuroleptic promazine","volume":"138","author":"J Wojcikowski","year":"2003","journal-title":"Br J Pharmacol"},{"key":"ref333","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/00008571-199610000-00009","article-title":"CYP2D6 is the principal cytochrome P450 responsible for metabolism of the\n                    histamine H1 antagonist promethazine in human liver microsomes","volume":"6","author":"K Nakamura","year":"1996","journal-title":"Pharmacogenetics"},{"key":"ref334","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/YIC.0000000000000277","article-title":"Reintroduction of quazepam: an update on comparative hypnotic and adverse\n                    effects","volume":"34","author":"N H Moniri","year":"2019","journal-title":"Int Clin Psychopharmacol"},{"key":"ref335","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1124\/dmd.108.023291","article-title":"Metabolism of quetiapine by CYP3A4 and CYP3A5 in presence or absence of\n                    cytochrome B5","volume":"37","author":"G V Bakken","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"ref336","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1124\/dmd.110.034009","article-title":"Metabolism of ramelteon in human liver microsomes and correlation with the\n                    effect of fluvoxamine on ramelteon pharmacokinetics","volume":"38","author":"R S Obach","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"ref337","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.amjopharm.2006.12.001","article-title":"Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for\n                    Parkinson's disease","volume":"4","author":"D R Guay","year":"2006","journal-title":"Am J Geriatr Pharmacother"},{"key":"ref338","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1053\/cp.1999.v66.a101207","article-title":"Ketoconazole inhibits the clearance of the enantiomers of the antidepressant\n                    reboxetine in humans","volume":"66","author":"B D Herman","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"ref339","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/S0090-9556(24)14936-7","article-title":"Cytochrome P-450-mediated metabolism of the individual enantiomers of the\n                    antidepressant agent reboxetine in human liver microsomes","volume":"27","author":"L C Wienkers","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"ref340","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2174\/15748847113089990053","article-title":"Clinical pharmacokinetics of retigabine\/ezogabine","volume":"8","author":"D J Tompson","year":"2013","journal-title":"Curr Clin Pharmacol"},{"key":"ref341","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1177\/0091270009347867","article-title":"Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics\n                    of risperidone and its active moiety","volume":"50","author":"Q Xiang","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"ref342","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1211\/0022357043969","article-title":"Identification of P-glycoprotein substrates and inhibitors among psychoactive\n                    compounds--implications for pharmacokinetics of selected substrates","volume":"56","author":"A A El Ela","year":"2004","journal-title":"J Pharm Pharmacol"},{"key":"ref343","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2165\/00003088-200039040-00001","article-title":"Clinical pharmacokinetics of ropinirole","volume":"39","author":"C M Kaye","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"ref344","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1124\/dmd.109.027383","article-title":"Absorption, disposition, metabolic fate, and elimination of the dopamine agonist\n                    rotigotine in man: administration by intravenous infusion or transdermal\n                    delivery","volume":"37","author":"W Cawello","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"ref345","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/jcph.658","article-title":"Identification of the Human SULT Enzymes Involved in the Metabolism of\n                    Rotigotine","volume":"56","author":"C Jia","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"ref346","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s40265-015-0377-y","article-title":"An update on pharmacological, pharmacokinetic properties and drug-drug\n                    interactions of rotigotine transdermal system in Parkinson's disease and\n                    restless legs syndrome","volume":"75","author":"J P Elshoff","year":"2015","journal-title":"Drugs"},{"key":"ref347","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/cpdd.78","article-title":"No influence of the CYP2C19-selective inhibitor omeprazole on the\n                    pharmacokinetics of the dopamine receptor agonist rotigotine","volume":"3","author":"J P Elshoff","year":"2014","journal-title":"Clin Pharmacol Drug Dev"},{"key":"ref348","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1528-1167.2008.01665.x","article-title":"Rufinamide: clinical pharmacokinetics and concentration-response relationships\n                    in patients with epilepsy","volume":"49","author":"E Perucca","year":"2008","journal-title":"Epilepsia"},{"key":"ref349","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s40262-016-0449-5","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Safinamide","volume":"56","author":"T M\u00fcller","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"ref350","doi-asserted-by":"crossref","first-page":"78","DOI":"10.2133\/dmpk.22.78","article-title":"P450 phenotyping of the metabolism of selegiline to desmethylselegiline and\n                    methamphetamine","volume":"22","author":"S A Benetton","year":"2007","journal-title":"Drug Metab Pharmacokinet"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s002280050278","article-title":"Pharmacokinetics of sertindole and dehydrosertindole in volunteers with normal\n                    or impaired renal function","volume":"52","author":"S L Wong","year":"1997","journal-title":"Eur J Clin Pharmacol"},{"key":"ref352","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1124\/dmd.104.002428","article-title":"Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine\n                    oxidases, and glucuronyl transferases in human: an in vitro study","volume":"33","author":"R S Obach","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"ref353","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1067\/mcp.2001.116513","article-title":"Pharmacokinetics of sertraline in relation to genetic polymorphism of\n                    CYP2C19","volume":"70","author":"J H Wang","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"ref354","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40263-019-00689-1","article-title":"Recently Approved and Upcoming Treatments for Narcolepsy","volume":"34","author":"M J Thorpy","year":"2020","journal-title":"CNS Drugs"},{"key":"ref355","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2147\/NSS.S245020","article-title":"Profile of Solriamfetol in the Management of Excessive Daytime Sleepiness\n                    Associated with Narcolepsy or Obstructive Sleep Apnea: Focus on Patient\n                    Selection and Perspectives","volume":"13","author":"V C Abad","year":"2021","journal-title":"Nat Sci Sleep"},{"key":"ref356","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s40262-017-0592-7","article-title":"Population Pharmacokinetics of Stiripentol in Paediatric Patients with Dravet\n                    Syndrome Treated with Stiripentol, Valproate and Clobazam Combination\n                    Therapy","volume":"57","author":"S Peign\u00e9","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"ref357","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s40261-019-00764-x","article-title":"Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant:\n                    Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects","volume":"39","author":"R E Wrishko","year":"2019","journal-title":"Clin Drug Investig"},{"key":"ref358","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/PRA.0000000000000690","article-title":"Comparative Pharmacology of the 3 Marketed Dual Orexin Antagonists-Daridorexant,\n                    Lemborexant, and Suvorexant-Part 2. Principal Drug Metabolizing Enzyme,\n                    Drug-Drug Interactions, and Effects of Liver and Renal Impairment on\n                    Metabolism","volume":"29","author":"S H Preskorn","year":"2023","journal-title":"J Psychiatr Pract"},{"key":"ref359","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/jcph.507","article-title":"Clinical assessment of drug-drug interactions of tasimelteon, a novel dual\n                    melatonin receptor agonist","volume":"55","author":"B W Ogilvie","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"ref360","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.pharmthera.2004.10.013","article-title":"UDP-glucuronosyltransferases and clinical drug-drug interactions","volume":"106","author":"T K Kiang","year":"2005","journal-title":"Pharmacol Ther"},{"key":"ref361","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3109\/03602532.2013.849268","article-title":"Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug\n                    metabolizing enzymes: a systematic review","volume":"46","author":"S M Stout","year":"2014","journal-title":"Drug Metab Rev"},{"key":"ref362","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/sj.clpt.6100195","article-title":"Factors affecting drug concentrations and QT interval during thioridazine\n                    therapy","volume":"82","author":"R H Thanacoody","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"ref363","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.cbi.2009.05.014","article-title":"Metabolic activation of the phenothiazine antipsychotics chlorpromazine and\n                    thioridazine to electrophilic iminoquinone species in human liver microsomes and\n                    recombinant P450s","volume":"181","author":"B Wen","year":"2009","journal-title":"Chem Biol Interact"},{"key":"ref364","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2165\/00003088-199631010-00003","article-title":"The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on\n                    topiramate, zonisamide and tiagabine","volume":"31","author":"E Perucca","year":"1996","journal-title":"Clin Pharmacokinet"},{"key":"ref365","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S0090-9556(25)08654-4","article-title":"The metabolic pathways of tianeptine, a new antidepressant, in healthy\n                    volunteers","volume":"18","author":"L Grislain","year":"1990","journal-title":"Drug Metab Dispos"},{"key":"ref366","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00210-017-1448-2","article-title":"Pharmacokinetic study of tianeptine and its active metabolite MC5 in rats\n                    following different routes of administration using a novel liquid chromatography\n                    tandem mass spectrometry analytical method","volume":"391","author":"M Szafarz","year":"2018","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref367","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/BF02455992","article-title":"Single oral dose pharmacokinetics of tiapride in patients with Huntington's\n                    disease","volume":"32","author":"T Norman","year":"1987","journal-title":"Eur J Clin Pharmacol"},{"key":"ref368","doi-asserted-by":"crossref","first-page":"e91775","DOI":"10.1371\/journal.pone.0091775","article-title":"The effects of LPM570065, a novel triple reuptake inhibitor, on extracellular\n                    serotonin, dopamine and norepinephrine levels in rats","volume":"9","author":"R Zhang","year":"2014","journal-title":"PLoS One"},{"key":"ref369","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1023\/A:1006901900106","article-title":"Metabolism of monoamine oxidase inhibitors","volume":"19","author":"G B Baker","year":"1999","journal-title":"Cell Mol Neurobiol"},{"key":"ref370","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1177\/0091270003251864","article-title":"Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse\n                    effects of trazodone","volume":"43","author":"D J Greenblatt","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"ref371","first-page":"572","article-title":"Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human\n                    sources","volume":"26","author":"S Rotzinger","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"ref372","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.clpt.2004.07.009","article-title":"Age and gender effects on the pharmacokinetics and pharmacodynamics of\n                    triazolam, a cytochrome P450 3A substrate","volume":"76","author":"D J Greenblatt","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"ref373","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/00007691-200004000-00012","article-title":"Steady state plasma levels of the enantiomers of trimipramine and of its\n                    metabolites in CYP2D6-, CYP2C19- and CYP3A4\/5-phenotyped patients","volume":"22","author":"C B Eap","year":"2000","journal-title":"Ther Drug Monit"},{"key":"ref374","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.clineuro.2010.01.002","article-title":"The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on\n                    the plasma concentrations of valproic acid in epileptic patients","volume":"112","author":"L Tan","year":"2010","journal-title":"Clin Neurol Neurosurg"},{"key":"ref375","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0893-133X(98)00113-4","article-title":"O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by\n                    microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI\n                    antidepressants","volume":"20","author":"S M Fogelman","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"ref376","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/FTD.0b013e3181fcf94d","article-title":"Effect of cytochrome P450 enzyme polymorphisms on pharmacokinetics of\n                    venlafaxine","volume":"33","author":"D E McAlpine","year":"2011","journal-title":"Ther Drug Monit"},{"key":"ref377","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/tpj.2014.50","article-title":"Influence of CYP2D6 and CYP2C19 genotypes on venlafaxine metabolic ratios and\n                    stereoselective metabolism in forensic autopsy cases","volume":"15","author":"L Karlsson","year":"2015","journal-title":"Pharmacogenomics J"},{"key":"ref378","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/00007691-200306000-00016","article-title":"Therapeutic drug monitoring of the newer antiepileptic drugs","volume":"25","author":"S I Johannessen","year":"2003","journal-title":"Ther Drug Monit"},{"key":"ref379","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.clinthera.2014.08.003","article-title":"Influence of CYP3A4 induction\/inhibition on the pharmacokinetics of vilazodone\n                    in healthy subjects","volume":"36","author":"R Boinpally","year":"2014","journal-title":"Clin Ther"},{"key":"ref380","first-page":"AA21004","volume-title":"Identification of the cytochrome P450 and other enzymes involved in the in vitro\n                    oxidative metabolism of a novel antidepressant","author":"M G Hvenegaard","year":"2012"},{"key":"ref382","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/004982598239452","article-title":"Metabolism of Zaleplon by human hepatic microsomal cytochrome P450 isoforms","volume":"28","author":"A B Renwick","year":"1998","journal-title":"Xenobiotica"},{"key":"ref383","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/01.jcp.0000084028.22282.f2","article-title":"Ziprasidone metabolism, aldehyde oxidase, and clinical implications","volume":"23","author":"C Beedham","year":"2003","journal-title":"J Clin Psychopharmacol"},{"key":"ref384","doi-asserted-by":"crossref","first-page":"35S","DOI":"10.1046\/j.1365-2125.2000.00151.x","article-title":"Identification of the major human liver cytochrome P450 isoform(s) responsible\n                    for the formation of the primary metabolites of ziprasidone and prediction of\n                    possible drug interactions","volume":"49","author":"C Prakash","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"ref385","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1046\/j.1365-2125.1999.00953.x","article-title":"Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and\n                    in vivo correlations","volume":"48","author":"L L Von Moltke","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"ref386","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1528-1167.2007.00983.x","article-title":"Pharmacokinetics and drug interactions with zonisamide","volume":"48","author":"G Sills","year":"2007","journal-title":"Epilepsia"},{"key":"ref387","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S0090-9556(24)15027-1","article-title":"Cytochrome P-450 3A4 and 2C8 are involved in zopiclone metabolism","volume":"27","author":"L Becquemont","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"ref388","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s00228-006-0155-6","article-title":"The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of\n                    zopiclone","volume":"62","author":"A Tornio","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"ref389","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/004982599238623","article-title":"Identification of cytochrome P450 enzymes involved in the metabolism of\n                    zotepine, an antipsychotic drug, in human liver microsomes","volume":"29","author":"T Shiraga","year":"1999","journal-title":"Xenobiotica"},{"key":"ref390","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00213-002-1059-5","article-title":"Maintenance therapy with zuclopenthixol decanoate: associations between plasma\n                    concentrations, neurological side effects and CYP2D6 genotype","volume":"162","author":"P Jaanson","year":"2002","journal-title":"Psychopharmacology (Berl)"},{"key":"ref392","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ctrv.2017.03.001","article-title":"The role of drug-drug interactions in prostate cancer treatment: Focus on\n                    abiraterone acetate\/prednisone and enzalutamide","volume":"55","author":"M Del Re","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"ref393","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1124\/dmd.115.065623","article-title":"P450-Based Drug-Drug Interactions of Amiodarone and its Metabolites: Diversity\n                    of Inhibitory Mechanisms","volume":"43","author":"M G McDonald","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"ref394","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2165\/00003088-200645020-00002","article-title":"Fosamprenavir : clinical pharmacokinetics and drug interactions of the\n                    amprenavir prodrug","volume":"45","author":"M B Wire","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"ref395","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0009-9236(03)00123-1","article-title":"Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a\n                    probe","volume":"74","author":"A K Majumdar","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"ref396","doi-asserted-by":"crossref","first-page":"3524","DOI":"10.1128\/AAC.00025-09","article-title":"Cytochrome P450 3A inhibition by atazanavir and ritonavir, but not demography or\n                    drug formulation, influences saquinavir population pharmacokinetics in human\n                    immunodeficiency virus type 1-infected adults","volume":"53","author":"N von Hentig","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"ref397","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/01.jcp.0000162805.46453.e3","article-title":"Inhibition of CYP2D6 activity by bupropion","volume":"25","author":"M Kotlyar","year":"2005","journal-title":"J Clin Psychopharmacol"},{"key":"ref398","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s40262-016-0461-9","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Cabozantinib","volume":"56","author":"S A Lacy","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"ref399","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/cpt.2973","article-title":"Evaluation of Cytochrome P450-Mediated Cannabinoid-Drug Interactions in Healthy\n                    Adult Participants","volume":"114","author":"S Bansal","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"ref400","first-page":"4028492","article-title":"High on Cannabis and Calcineurin Inhibitors: A Word of Warning in an Era of\n                    Legalized Marijuana","volume":"2016","author":"N Hauser","year":"2016","journal-title":"Case Rep Transplant"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/cpdd.1262","article-title":"Pharmacokinetic Drug-Drug Interaction With Coadministration of Cannabidiol and\n                    Everolimus in a Phase 1 Healthy Volunteer Trial","volume":"12","author":"L Wray","year":"2023","journal-title":"Clin Pharmacol Drug Dev"},{"key":"ref402","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1177\/0018578720985438","article-title":"Potential Drug Interactions Between Cannabinoids and Its Derivatives and Oral\n                    Anticoagulants","volume":"57","author":"M Paduch","year":"2022","journal-title":"Hosp Pharm"},{"key":"ref403","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0009-9236(03)00120-6","article-title":"Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in\n                    humans","volume":"74","author":"U Werner","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"ref404","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/cts.13204","article-title":"Effect of cenobamate on the single-dose pharmacokinetics of multiple cytochrome\n                    P450 probes using a cocktail approach in healthy subjects","volume":"15","author":"S A Greene","year":"2022","journal-title":"Clin Transl Sci"},{"key":"ref405","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0009-9236(99)70129-3","article-title":"Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6,\n                    and CYP3A by H2-receptor antagonists","volume":"65","author":"C Martinez","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"ref406","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1365-2125.1995.tb04453.x","article-title":"The effect of ciprofloxacin on theophylline pharmacokinetics in healthy\n                    subjects","volume":"39","author":"K T Batty","year":"1995","journal-title":"Br J Clin Pharmacol"},{"key":"ref407","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1365-2125.2007.02970.x","article-title":"Interaction between midazolam and clarithromycin in the elderly","volume":"65","author":"S K Quinney","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"ref408","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/j.1875-9114.2012.01028.x","article-title":"Pharmacokinetic drug interactions between clobazam and drugs metabolized by\n                    cytochrome P450 isoenzymes","volume":"32","author":"M Walzer","year":"2012","journal-title":"Pharmacotherapy"},{"key":"ref409","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.toxlet.2014.08.004","article-title":"Development of an in vitro cytochrome P450 cocktail inhibition assay for\n                    assessing the inhibition risk of drugs of abuse","volume":"230","author":"J Dinger","year":"2014","journal-title":"Toxicol Lett"},{"key":"ref410","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1124\/jpet.103.056127","article-title":"Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and\n                    ticlopidine","volume":"308","author":"T Richter","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/clpt.2014.141","article-title":"Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of\n                    CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactions","volume":"96","author":"A Tornio","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"ref412","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/clpt.2011.295","article-title":"A screening study of drug-drug interactions in cerivastatin users: an adverse\n                    effect of clopidogrel","volume":"91","author":"J S Floyd","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"ref413","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/jac\/dkw032","article-title":"Cobicistat versus ritonavir boosting and differences in the drug-drug\n                    interaction profiles with co-medications","volume":"71","author":"C Marzolini","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"ref414","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/bcp.12668","article-title":"Ritonavir is the best alternative to ketoconazole as an index inhibitor of\n                    cytochrome P450-3A in drug-drug interaction studies","volume":"80","author":"D J Greenblatt","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"ref415","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1002\/phar.1237","article-title":"Cobicistat: a new boost for the treatment of human immunodeficiency virus\n                    infection","volume":"33","author":"B M Shah","year":"2013","journal-title":"Pharmacotherapy"},{"key":"ref416","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/j.clinthera.2015.07.022","article-title":"Cobicistat: Review of a Pharmacokinetic Enhancer for HIV Infection","volume":"37","author":"E M Sherman","year":"2015","journal-title":"Clin Ther"},{"key":"ref417","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1124\/dmd.30.6.631","article-title":"Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9,\n                    respectively","volume":"30","author":"X Wen","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"ref418","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1124\/dmd.112.049114","article-title":"Prediction of crizotinib-midazolam interaction using the Simcyp population-based\n                    simulator: comparison of CYP3A time-dependent inhibition between human liver\n                    microsomes versus hepatocytes","volume":"41","author":"J Mao","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"ref419","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1111\/bcp.13092","article-title":"Edoxaban drug-drug interactions with ketoconazole, erythromycin, and\n                    cyclosporine","volume":"82","author":"D A Parasrampuria","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"ref420","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/1756287217708951","article-title":"Assessment of inhibitory effects on major human cytochrome P450 enzymes by\n                    spasmolytics used in the treatment of overactive bladder syndrome","volume":"9","author":"D Dahlinger","year":"2017","journal-title":"Ther Adv Urol"},{"key":"ref421","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0022-3565(24)36788-6","article-title":"Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4\n                    activity by oxidized diltiazem metabolites","volume":"282","author":"D Sutton","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"ref422","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0090-9556(24)15310-X","article-title":"Lack of single-dose disulfiram effects on cytochrome P-450 2C9, 2C19, 2D6, and\n                    3A4 activities: evidence for specificity toward P-450 2E1","volume":"27","author":"E D Kharasch","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"ref423","first-page":"491","article-title":"Doxepin inhibits CYP2D6 activity in vivo","volume":"56","author":"M Szewczuk-Bogus\u0142awska","year":"2004","journal-title":"Pol J Pharmacol"},{"key":"ref424","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jad.2017.11.046","article-title":"Antidepressant polypharmacy and the potential of pharmacokinetic interactions:\n                    Doxepin but not mirtazapine causes clinically relevant changes in venlafaxine\n                    metabolism","volume":"227","author":"M Paulzen","year":"2018","journal-title":"J Affect Disord"},{"key":"ref425","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1177\/1074248410367792","article-title":"Clinical pharmacology of dronedarone: implications for the therapy of atrial\n                    fibrillation","volume":"15","author":"P Dorian","year":"2010","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"ref426","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1002\/cpt.1360","article-title":"Clinical aspects of transporter-mediated drug-drug interactions","volume":"105","author":"A Gessner","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"ref427","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1067\/mcp.2003.28","article-title":"Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy\n                    volunteers","volume":"73","author":"M H Skinner","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"ref428","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1177\/0091270007302562","article-title":"Effect of the treatment period with erythromycin on cytochrome P450 3A activity\n                    in humans","volume":"47","author":"T Okudaira","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"ref429","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1124\/dmd.111.041293","article-title":"The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is\n                    a metabolism-dependent inhibitor of CYP2C19: implications for coadministration\n                    with clopidogrel","volume":"39","author":"B W Ogilvie","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"ref430","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1034\/j.1600-0773.2003.t01-1-930202_93_2.x","article-title":"A screening study on the liability of eight different female sex steroids to\n                    inhibit CYP2C9, 2C19 and 3A4 activities in human liver microsomes","volume":"93","author":"K Laine","year":"2003","journal-title":"Pharmacol Toxicol"},{"key":"ref431","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1124\/mol.110.065540","article-title":"Regulation of CYP2C19 expression by estrogen receptor \u03b1: implications for\n                    estrogen-dependent inhibition of drug metabolism","volume":"78","author":"J Mwinyi","year":"2010","journal-title":"Mol Pharmacol"},{"key":"ref432","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/j.1365-2125.2011.03903.x","article-title":"Perpetrators of pharmacokinetic drug-drug interactions arising from altered\n                    cytochrome P450 activity: a criteria-based assessment","volume":"71","author":"T M Polasek","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"ref433","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1365-2125.2010.03880.x","article-title":"The effect of ethinylestradiol-containing contraceptives on the serum\n                    concentration of olanzapine and N-desmethyl olanzapine","volume":"71","author":"T Haslemo","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"ref434","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0009-9236(95)90244-9","article-title":"Effects of felbamate on the pharmacokinetics of phenobarbital","volume":"58","author":"P Reidenberg","year":"1995","journal-title":"Clin Pharmacol Ther"},{"key":"ref435","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/00004714-199808000-00015","article-title":"Appetite suppressant drugs as inhibitors of human cytochromes P450: in vitro\n                    inhibition of P450-2D6 by D- and L-fenfluramine, but not phentermine","volume":"18","author":"L L von Moltke","year":"1998","journal-title":"J Clin Psychopharmacol"},{"key":"ref436","first-page":"P450","article-title":"Drug interactions between nine antifungal agents and drugs metabolized by human\n                    cytochromes","volume":"15","author":"T Niwa","year":"2014","journal-title":"Curr Drug Metab"},{"key":"ref437","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1111\/bcp.13517","article-title":"Pharmacokinetic\/pharmacodynamic drug-drug interactions of avatrombopag when\n                    coadministered with dual or selective CYP2C9 and CYP3A interacting drugs","volume":"84","author":"M Nomoto","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"ref438","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/bdd.291","article-title":"Influence of fluconazole on the pharmacokinetics of omeprazole in healthy\n                    volunteers","volume":"23","author":"B C Kang","year":"2002","journal-title":"Biopharm Drug Dispos"},{"key":"ref439","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s002280050163","article-title":"Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram,\n                    fluoxetine, fluvoxamine and paroxetine","volume":"51","author":"U Jeppesen","year":"1996","journal-title":"Eur J Clin Pharmacol"},{"key":"ref440","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s13318-016-0351-4","article-title":"Interaction of Citrus Juices with Cyclosporine: Systematic Review and\n                    Meta-Analysis","volume":"41","author":"K Sridharan","year":"2016","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"ref441","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1124\/jpet.119.256966","article-title":"Translation of In Vitro Transport Inhibition Studies to Clinical Drug-Drug\n                    Interactions for Glecaprevir and Pibrentasvir","volume":"370","author":"M P Kosloski","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"ref442","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s40262-019-00774-0","article-title":"Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A\n                    2019 Update","volume":"58","author":"E J Smolders","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"ref443","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40262-015-0304-0","article-title":"Clinical Pharmacokinetic and Pharmacodynamic Profile of Idelalisib","volume":"55","author":"S Ramanathan","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"ref444","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s00228-016-2038-9","article-title":"A clinically relevant pharmacokinetic interaction between cyclosporine and\n                    imatinib","volume":"72","author":"F Atiq","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"ref445","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1111\/j.1476-5381.2011.01732.x","article-title":"Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability\n                    to interact with CYP3A4 substrates","volume":"165","author":"A M Filppula","year":"2012","journal-title":"Br J Pharmacol"},{"key":"ref446","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00228-010-0972-5","article-title":"Effects of multiple-dose pegylated interferon alfa-2b on the activity of\n                    drug-metabolizing enzymes in persons with chronic hepatitis C","volume":"67","author":"S K Gupta","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"key":"ref447","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3109\/00498254.2011.560971","article-title":"Effect of interferon-\u03b12b on the expression of various drug-metabolizing enzymes\n                    and transporters in co-cultures of freshly prepared human primary\n                    hepatocytes","volume":"41","author":"C Chen","year":"2011","journal-title":"Xenobiotica"},{"key":"ref448","first-page":"2480","article-title":"Differential effect of IFNalpha-2b on the cytochrome P450 enzyme system: a\n                    potential basis of IFN toxicity and its modulation by other drugs","volume":"8","author":"M Islam","year":"2002","journal-title":"Clin Cancer Res"},{"key":"ref449","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1254\/jphs.FP0040296","article-title":"Inhibitory effect of antituberculosis drugs on human cytochrome P450-mediated\n                    activities","volume":"96","author":"Y Nishimura","year":"2004","journal-title":"J Pharmacol Sci"},{"key":"ref450","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1177\/0091270010365885","article-title":"Itraconazole, a P-glycoprotein and CYP3A4 inhibitor, markedly raises the plasma\n                    concentrations and enhances the renin-inhibiting effect of aliskiren","volume":"51","author":"T Tapaninen","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"ref451","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1128\/AAC.42.7.1738","article-title":"P-glycoprotein-mediated transport of itraconazole across the blood-brain\n                    barrier","volume":"42","author":"T Miyama","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"ref452","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/bdd.2157","article-title":"CYP3A but not P-gp plays a relevant role in the in vivo intestinal and hepatic\n                    clearance of the delta-specific phosphoinositide-3 kinase inhibitor\n                    leniolisib","volume":"39","author":"S De Buck","year":"2018","journal-title":"Biopharm Drug Dispos"},{"key":"ref453","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/chir.10294","article-title":"Enantioselectivity of inhibition of cytochrome P450 3A4 (CYP3A4) by\n                    ketoconazole: Testosterone and methadone as substrates","volume":"16","author":"S Dilmaghanian","year":"2004","journal-title":"Chirality"},{"key":"ref454","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/cpt.1120","article-title":"PBPK Modeling Strategy for Predicting Complex Drug Interactions of Letermovir as\n                    a Perpetrator in Support of Product Labeling","volume":"105","author":"Y H Wang","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"ref455","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1002\/jcph.1423","article-title":"Pharmacokinetic Drug-Drug Interactions Between Letermovir and the\n                    Immunosuppressants Cyclosporine, Tacrolimus, Sirolimus, and Mycophenolate\n                    Mofetil","volume":"59","author":"J B McCrea","year":"2019","journal-title":"J Clin Pharmacol"},{"key":"ref456","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s00228-009-0640-9","article-title":"O-demethylation of codeine to morphine inhibited by low-dose\n                    levomepromazine","volume":"65","author":"M Vevelstad","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"ref457","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/JCP.0b013e318184ff6e","article-title":"The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition\n                    in humans","volume":"28","author":"B O'Math\u00fana","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"ref458","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2165\/11584550-000000000-00000","article-title":"Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced\n                    cytochrome P450 2D6 inhibition in humans","volume":"50","author":"S Yubero-Lahoz","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"ref459","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1007\/s00702-015-1403-7","article-title":"Melperone but not bisoprolol or metoprolol is a clinically relevant inhibitor of\n                    CYP2D6: evidence from a therapeutic drug monitoring survey","volume":"122","author":"G Hefner","year":"2015","journal-title":"J Neural Transm (Vienna)"},{"key":"ref460","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1046\/j.1365-2125.1996.33311.x","article-title":"Inhibition of caffeine metabolism by 5-methoxypsoralen in patients with\n                    psoriasis","volume":"41","author":"E K Bendriss","year":"1996","journal-title":"Br J Clin Pharmacol"},{"key":"ref461","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1046\/j.1365-2133.2001.04233.x","article-title":"Liver cytochrome P450 CYP1A2 is markedly inhibited by systemic but not by bath\n                    PUVA in dermatological patients","volume":"144","author":"I Tantcheva-Po\u00f3r","year":"2001","journal-title":"Br J Dermatol"},{"key":"ref462","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3109\/00498254.2013.835885","article-title":"Metoclopramide is metabolized by CYP2D6 and is a reversible inhibitor, but not\n                    inactivator, of CYP2D6","volume":"44","author":"M R Livezey","year":"2014","journal-title":"Xenobiotica"},{"key":"ref463","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2165\/00003088-200039020-00004","article-title":"Clinically significant pharmacokinetic interactions between dietary caffeine and\n                    medications","volume":"39","author":"J A Carrillo","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"ref464","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S0022-3565(24)38211-4","article-title":"Inhibition of human liver cytochrome P-450 1A2 by the class IB antiarrhythmics\n                    mexiletine, lidocaine, and tocainide","volume":"289","author":"X Wei","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"ref465","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1177\/0091270009341961","article-title":"Effects of mexiletine, a CYP1A2 inhibitor, on tizanidine pharmacokinetics and\n                    pharmacodynamics","volume":"50","author":"K Momo","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"ref466","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00228-008-0556-9","article-title":"Oral voriconazole and miconazole oral gel produce comparable effects on the\n                    pharmacokinetics and pharmacodynamics of etoricoxib","volume":"65","author":"V V Hynninen","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"ref467","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.vascn.2008.05.131","article-title":"Development of an in vitro drug-drug interaction assay to simultaneously monitor\n                    five cytochrome P450 isoforms and performance assessment using drug library\n                    compounds","volume":"58","author":"M Zientek","year":"2008","journal-title":"J Pharmacol Toxicol Methods"},{"key":"ref468","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.dmpk.2016.08.002","article-title":"Pharmacokinetic drug interaction study between overactive bladder drugs\n                    mirabegron and tolterodine in Japanese healthy postmenopausal females","volume":"31","author":"Y Nomura","year":"2016","journal-title":"Drug Metab Pharmacokinet"},{"key":"ref469","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0924-977X(96)00023-5","article-title":"The role of cytochrome P450 2D6 in the metabolism of moclobemide","volume":"6","author":"S Hartter","year":"1996","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref470","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1046\/j.1365-2125.2002.01366.x","article-title":"Omeprazole hydroxylation is inhibited by a single dose of moclobemide in\n                    homozygotic EM genotype for CYP2C19","volume":"53","author":"J Y Cho","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"ref471","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13318-011-0024-2","article-title":"Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a\n                    re-evaluation of P450 isoform selectivity","volume":"36","author":"S C Khojasteh","year":"2011","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"ref472","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1177\/0091270004270642","article-title":"Examination of 209 drugs for inhibition of cytochrome P450 2C8","volume":"45","author":"R L Walsky","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"ref473","first-page":"466","article-title":"Grapefruit juice and potential drug interactions","volume":"18","author":"J T Hare","year":"2003","journal-title":"Consult Pharm"},{"key":"ref474","first-page":"432","article-title":"[Grapefruit juice and drugs: a hazardous combination?]","volume":"57","author":"F Lohezic-Le Devehat","year":"2002","journal-title":"Therapie"},{"key":"ref475","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.3109\/03639045.2013.819885","article-title":"Enhanced oral bioavailability of felodipine by naringenin in Wistar rats and\n                    inhibition of P-glycoprotein in everted rat gut sacs in vitro","volume":"40","author":"M Surya Sandeep","year":"2014","journal-title":"Drug Dev Ind Pharm"},{"key":"ref476","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/chir.21005","article-title":"Enantiomers of naringenin as pleiotropic, stereoselective inhibitors of\n                    cytochrome P450 isoforms","volume":"23","author":"W J Lu","year":"2011","journal-title":"Chirality"},{"key":"ref477","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1124\/dmd.110.037523","article-title":"Complex drug interactions of HIV protease inhibitors 1: inactivation, induction,\n                    and inhibition of cytochrome P450 3A by ritonavir or nelfinavir","volume":"39","author":"B J Kirby","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"ref478","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/jgs.15195","article-title":"Meta-analysis of Interventions to Reduce Adverse Drug Reactions in Older\n                    Adults","volume":"66","author":"S L Gray","year":"2018","journal-title":"J Am Geriatr Soc"},{"key":"ref479","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/00912700122009728","article-title":"Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse\n                    transcriptase inhibitors","volume":"41","author":"L L von Moltke","year":"2001","journal-title":"J Clin Pharmacol"},{"key":"ref480","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1128\/AAC.36.5.942","article-title":"Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2\n                    activity in vivo and in vitro","volume":"36","author":"U Fuhr","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"ref481","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/clpt.2010.107","article-title":"Clinically significant CYP2C inhibition by noscapine but not by glucosamine","volume":"88","author":"S Rosenborg","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"ref482","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1365-2125.2009.03572.x","article-title":"Time-dependent inhibition (TDI) of CYP3A4 and CYP2C9 by noscapine potentially\n                    explains clinical noscapine-warfarin interaction","volume":"69","author":"Z Z Fang","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"ref483","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00228-010-0821-6","article-title":"Influence of CYP2C19 on the relationship between pharmacokinetics and\n                    intragastric pH of omeprazole administered by successive intravenous infusions\n                    in Chinese healthy volunteers","volume":"66","author":"Y Wang","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"ref484","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S1734-1140(09)70141-0","article-title":"Perazine at therapeutic drug concentrations inhibits human cytochrome P450\n                    isoenzyme 1A2 (CYP1A2) and caffeine metabolism--an in vitro study","volume":"61","author":"J Wojcikowski","year":"2009","journal-title":"Pharmacol Rep"},{"key":"ref485","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s00213-013-3007-y","article-title":"Elevated clozapine serum levels in combination with perazine","volume":"226","author":"M Fischer","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"key":"ref486","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1111\/bcp.13255","article-title":"Cytochrome P450-mediated interaction between perazine and risperidone:\n                    implications for antipsychotic polypharmacy","volume":"83","author":"M Paulzen","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"ref487","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/bcpt.13373","article-title":"The effect of perazine on the CYP2D6 and CYP2C19 phenotypes as measured by the\n                    dextromethorphan and mephenytoin tests in psychiatric patients","volume":"126","author":"P Baumann","year":"2020","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref488","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.clinthera.2009.02.022","article-title":"Effects of oral posaconazole on the pharmacokinetic properties of oral and\n                    intravenous midazolam: a phase I, randomized, open-label, crossover study in\n                    healthy volunteers","volume":"31","author":"G Krishna","year":"2009","journal-title":"Clin Ther"},{"key":"ref489","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1097\/01.ftd.0000249945.64978.33","article-title":"Inhibitory effects of propafenone on the pharmacokinetics of caffeine in\n                    humans","volume":"28","author":"V Michaud","year":"2006","journal-title":"Ther Drug Monit"},{"key":"ref490","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1067\/mcp.2000.110561","article-title":"In vivo modulation of CYP enzymes by quinidine and rifampin","volume":"68","author":"R A Branch","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"ref491","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0022-3565(25)38622-2","article-title":"Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor\n                    antidepressants, and by quinidine and ketoconazole: a model system to predict\n                    drug interactions in vivo","volume":"268","author":"L L von Moltke","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"ref492","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1067\/mcp.2000.109156","article-title":"Increased drug delivery to the brain by P-glycoprotein inhibition","volume":"68","author":"A J Sadeque","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"ref493","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/cpt.1950","article-title":"Ribociclib Drug-Drug Interactions: Clinical Evaluations and\n                    Physiologically-Based Pharmacokinetic Modeling to Guide Drug Labeling","volume":"108","author":"T S Samant","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"ref494","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2165\/00003088-199936040-00004","article-title":"Pharmacokinetics and potential interactions amongst antiretroviral agents used\n                    to treat patients with HIV infection","volume":"36","author":"M Barry","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"ref495","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/j.1552-4604.1998.tb04398.x","article-title":"Protease inhibitors as inhibitors of human cytochromes P450: high risk\n                    associated with ritonavir","volume":"38","author":"L L von Moltke","year":"1998","journal-title":"J Clin Pharmacol"},{"key":"ref496","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s002280050147","article-title":"Effect of stiripentol on carbamazepine plasma concentration and metabolism in\n                    epileptic children","volume":"50","author":"A Tran","year":"1996","journal-title":"Eur J Clin Pharmacol"},{"key":"ref497","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1046\/j.0306-5251.2003.01919.x","article-title":"Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in\n                    human","volume":"56","author":"N Cazali","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"ref498","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s40263-017-0432-1","article-title":"Stiripentol in the Management of Epilepsy","volume":"31","author":"K C Nickels","year":"2017","journal-title":"CNS Drugs"},{"key":"ref499","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s40262-013-0087-0","article-title":"Drug interactions with the newer antiepileptic drugs (AEDs)--part 1:\n                    pharmacokinetic and pharmacodynamic interactions between AEDs","volume":"52","author":"P N Patsalos","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"ref500","doi-asserted-by":"crossref","first-page":"106459","DOI":"10.1016\/j.yebeh.2019.106459","article-title":"Drug-drug interactions and pharmacodynamics of concomitant clobazam and\n                    cannabidiol or stiripentol in refractory seizures","volume":"99","author":"P Klein","year":"2019","journal-title":"Epilepsy Behav"},{"key":"ref501","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/FTD.0000000000000128","article-title":"Individualized phenytoin therapy for Japanese pediatric patients with epilepsy\n                    based on CYP2C9 and CYP2C19 genotypes","volume":"37","author":"Y Yamamoto","year":"2015","journal-title":"Ther Drug Monit"},{"key":"ref502","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.yebeh.2014.03.018","article-title":"Interaction between sulthiame and clobazam: sulthiame inhibits the metabolism of\n                    clobazam, possibly via an action on CYP2C19","volume":"34","author":"Y Yamamoto","year":"2014","journal-title":"Epilepsy Behav"},{"key":"ref503","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0009-9236(99)70065-2","article-title":"Investigation of terbinafine as a CYP2D6 inhibitor in vivo","volume":"65","author":"S M Abdel-Rahman","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"ref504","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.clpt.2005.02.010","article-title":"Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as\n                    measured by bupropion hydroxylation","volume":"77","author":"M Turpeinen","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"ref505","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/psp4.12346","article-title":"Semimechanistic Population Pharmacokinetic Model to Predict the Drug-Drug\n                    Interaction Between S-ketamine and Ticlopidine in Healthy Human Volunteers","volume":"7","author":"M W Ashraf","year":"2018","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"ref506","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/JCP.0b013e31820469ea","article-title":"Advances pertaining to the pharmacology and interactions of irreversible\n                    nonselective monoamine oxidase inhibitors","volume":"31","author":"P K Gillman","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"ref507","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1742-7843.2007.00061.x","article-title":"Inhibitory effect of valproic acid on cytochrome P450 2C9 activity in epilepsy\n                    patients","volume":"100","author":"A Gunes","year":"2007","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref508","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1055\/s-0034-1371866","article-title":"Can valproic acid be an inducer of clozapine metabolism?","volume":"47","author":"F J Diaz","year":"2014","journal-title":"Pharmacopsychiatry"},{"key":"ref509","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/j.1552-4604.1997.tb04322.x","article-title":"Effect of valproate on the pharmacokinetics and pharmacodynamics of\n                    lorazepam","volume":"37","author":"E E Samara","year":"1997","journal-title":"J Clin Pharmacol"},{"key":"ref510","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/bdd.2328","article-title":"Changes in uridine 5'-diphospho-glucuronosyltransferase 1A6 expression by\n                    histone deacetylase inhibitor valproic acid","volume":"43","author":"Y Sakakibara","year":"2022","journal-title":"Biopharm Drug Dispos"},{"key":"ref511","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s40262-017-0523-7","article-title":"D. Heinzmann, and J.F. Grippo, Clinical Pharmacokinetics of Vemurafenib","volume":"56","author":"W Zhang","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"ref512","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.clpt.2005.11.001","article-title":"The effect of short- and long-term administration of verapamil on the\n                    disposition of cytochrome P450 3A and P-glycoprotein substrates","volume":"79","author":"G L Lemma","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"ref513","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1365-2710.2009.01070.x","article-title":"Effects of voriconazole on tacrolimus metabolism in a kidney transplant\n                    recipient","volume":"35","author":"D Capone","year":"2010","journal-title":"J Clin Pharm Ther"},{"key":"ref514","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2165\/00003088-199500292-00011","article-title":"Effect of zileuton on theophylline pharmacokinetics","volume":"29","author":"G R Granneman","year":"1995","journal-title":"Clin Pharmacokinet"},{"key":"ref515","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s40262-020-00882-2","article-title":"Pharmacokinetic Drug-Drug Interaction of Apalutamide, Part 1: Clinical Studies\n                    in Healthy Men and Patients with Castration-Resistant Prostate Cancer","volume":"59","author":"I Duran","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"ref516","doi-asserted-by":"crossref","first-page":"328","DOI":"10.5414\/CP202048","article-title":"Influence of St. John's wort on the steady-state pharmacokinetics and\n                    metabolism of bosentan","volume":"52","author":"C Markert","year":"2014","journal-title":"Int J Clin Pharmacol Ther"},{"key":"ref517","doi-asserted-by":"crossref","first-page":"198","DOI":"10.2165\/00003088-199631030-00004","article-title":"Clinically significant pharmacokinetic drug interactions with carbamazepine. An\n                    update","volume":"31","author":"E Spina","year":"1996","journal-title":"Clin Pharmacokinet"},{"key":"ref518","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2165\/00003088-200847100-00004","article-title":"General framework for the prediction of oral drug interactions caused by CYP3A4\n                    induction from in vivo information","volume":"47","author":"Y Ohno","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"ref519","first-page":"97","article-title":"The effects of antiepileptic inducers in neuropsychopharmacology, a neglected\n                    issue. Part I: A summary of the current state for clinicians","volume":"8","author":"J de Leon","year":"2015","journal-title":"Rev Psiquiatr Salud Ment"},{"key":"ref520","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/jcpt.12286","article-title":"Multiple inductive effects of carbamazepine on combined therapy with\n                    paliperidone and amlodipine","volume":"40","author":"Y Akamine","year":"2015","journal-title":"J Clin Pharm Ther"},{"key":"ref521","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.clpt.2004.04.011","article-title":"Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance\n                    protein MRP2 and influences disposition of talinolol in humans","volume":"76","author":"T Giessmann","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"ref522","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00228-006-0104-4","article-title":"The influence of co-treatment with carbamazepine, amiodarone and statins on\n                    warfarin metabolism and maintenance dose","volume":"62","author":"D Herman","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"ref523","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1592\/phco.26.11.1650","article-title":"P, Effect of carbamazepine initiation and discontinuation on antithrombotic\n                    control in a patient receiving warfarin: case report and review of the\n                    literature","volume":"26","author":"R H Parrish","year":"2006","journal-title":"Pharmacotherapy"},{"key":"ref524","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/jcpt.12135","article-title":"Case report: dose adjustment of warfarin using genetic information and plasma\n                    concentration monitoring","volume":"39","author":"T Aomori","year":"2014","journal-title":"J Clin Pharm Ther"},{"key":"ref525","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s40262-018-0703-0","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Dabrafenib","volume":"58","author":"A Puszkiel","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"ref526","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1093\/jac\/dkab412","article-title":"Dexamethasone is a dose-dependent perpetrator of drug-drug interactions:\n                    implications for use in people living with HIV","volume":"77","author":"T G Jacobs","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"ref527","doi-asserted-by":"crossref","first-page":"160","DOI":"10.4103\/joacp.JOACP_461_20","article-title":"Common anti-COVID-19 drugs and their anticipated interaction with anesthetic\n                    agents","volume":"37","author":"S B Shah","year":"2021","journal-title":"J Anaesthesiol Clin Pharmacol"},{"key":"ref528","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1097\/00007890-200211270-00014","article-title":"Lowered blood concentration of tacrolimus and its recovery with changes in\n                    expression of CYP3A and P-glycoprotein after high-dose steroid therapy","volume":"74","author":"T Shimada","year":"2002","journal-title":"Transplantation"},{"key":"ref529","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jphs.2019.04.007","article-title":"Dexamethasone changes the pharmacokinetics of amitriptyline and reduces its\n                    accumulation in rat brain: The roles of P-gp and cyp3a2","volume":"140","author":"J Wen","year":"2019","journal-title":"J Pharmacol Sci"},{"key":"ref530","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/QAI.0b013e318183a425","article-title":"Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy\n                    subjects","volume":"49","author":"S M Robertson","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref531","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/bcp.13425","article-title":"Drug-drug interaction potential in men treated with enzalutamide: Mind the\n                    ga","volume":"84","author":"G E Benoist","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"ref532","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1081\/DMR-200033441","article-title":"The discovery of the microsomal ethanol oxidizing system and its physiologic and\n                    pathologic role","volume":"36","author":"C S Lieber","year":"2004","journal-title":"Drug Metab Rev"},{"key":"ref533","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00414-007-0181-7","article-title":"Ultra-rapid rate of ethanol elimination from blood in drunken drivers with\n                    extremely high blood-alcohol concentrations","volume":"122","author":"A W Jones","year":"2008","journal-title":"Int J Legal Med"},{"key":"ref534","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/00000441-199905000-00007","article-title":"Isoniazid drug and food interactions","volume":"317","author":"T H Self","year":"1999","journal-title":"Am J Med Sci"},{"key":"ref535","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/clpt.1993.125","article-title":"Inhibition and induction of cytochrome P4502E1-catalyzed oxidation by isoniazid\n                    in humans","volume":"54","author":"R Zand","year":"1993","journal-title":"Clin Pharmacol Ther"},{"key":"ref536","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/j.1528-1157.2000.tb00218.x","article-title":"Methsuximide lowers lamotrigine blood levels: A pharmacokinetic antiepileptic\n                    drug interaction","volume":"41","author":"F M Besag","year":"2000","journal-title":"Epilepsia"},{"key":"ref537","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00007691-199904000-00007","article-title":"Influence of oxcarbazepine and methsuximide on lamotrigine concentrations in\n                    epileptic patients with and without valproic acid comedication: results of a\n                    retrospective study","volume":"21","author":"T W May","year":"1999","journal-title":"Ther Drug Monit"},{"key":"ref538","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/sj.clpt.6100138","article-title":"Selective induction of human hepatic cytochromes P450 2B6 and 3A4 by\n                    metamizole","volume":"82","author":"T Saussele","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"ref539","doi-asserted-by":"crossref","first-page":"4608","DOI":"10.1111\/bcp.14874","article-title":"Effect of deglucuronidation on the results of the Basel phenotyping\n                    cocktail","volume":"87","author":"F Bachmann","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"ref540","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/j.1365-2125.2012.04304.x","article-title":"Rapid clinical induction of bupropion hydroxylation by metamizole in healthy\n                    Chinese men","volume":"74","author":"W J Qin","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"ref541","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/cpt.2141","article-title":"Metamizole is a Moderate Cytochrome P450 Inducer Via the Constitutive Androstane\n                    Receptor and a Weak Inhibitor of CYP1A2","volume":"109","author":"F Bachmann","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"ref542","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1111\/bcp.16168","article-title":"Discovering interactions in polypharmacy: Impact of metamizole on the metabolism\n                    of quetiapine","volume":"90","author":"F Watermeyer","year":"2024","journal-title":"Br J Clin Pharmacol"},{"key":"ref543","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S0090-9556(24)15146-X","article-title":"In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by\n                    modafinil","volume":"28","author":"P Robertson","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"ref544","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1530\/EJE-10-0956","article-title":"Mitotane has a strong and a durable inducing effect on CYP3A4 activity","volume":"164","author":"N P van Erp","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"ref545","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1528-1167.2007.00924.x","article-title":"A comparative pharmacokinetic study in healthy volunteers of the effect of\n                    carbamazepine and oxcarbazepine on cyp3a4","volume":"48","author":"A H Andreasen","year":"2007","journal-title":"Epilepsia"},{"key":"ref546","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/00004714-199906000-00022","article-title":"Oxybutynin enhances the metabolism of clomipramine and dextrorphan possibly by\n                    induction of a cytochrome P450 isoenzyme","volume":"19","author":"M Grozinger","year":"1999","journal-title":"J Clin Psychopharmacol"},{"key":"ref547","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1124\/dmd.31.4.421","article-title":"Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression\n                    in cultured human hepatocytes","volume":"31","author":"A Madan","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"ref548","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1528-1157.1996.tb00021.x","article-title":"Concentrations and effects of oral midazolam are greatly reduced in patients\n                    treated with carbamazepine or phenytoin","volume":"37","author":"J T Backman","year":"1996","journal-title":"Epilepsia"},{"key":"ref549","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1365-2125.2005.02529.x","article-title":"Clinically relevant drug interactions with antiepileptic drugs","volume":"61","author":"E Perucca","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"ref550","doi-asserted-by":"crossref","first-page":"156","DOI":"10.31083\/ph.2008.7660","article-title":"Rifabutin autoinduction is caused by involvement of cytochrome P450 and\n                    cholinesterase","volume":"63","author":"L Zhaoxu","year":"2008","journal-title":"Pharmazie"},{"key":"ref551","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/clpt.2013.167","article-title":"Chronological effects of rifampicin discontinuation on cytochrome P450 activity\n                    in healthy Japanese volunteers, using the cocktail method","volume":"94","author":"N Inui","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"ref552","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1177\/0091270004273492","article-title":"Effect of the MDR1 C3435T variant and P-glycoprotein induction on dicloxacillin\n                    pharmacokinetics","volume":"45","author":"W S Putnam","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"ref553","doi-asserted-by":"crossref","first-page":"e00386","DOI":"10.1002\/prp2.386","article-title":"Rifampin modulation of xeno- and endobiotic conjugating enzyme mRNA expression\n                    and associated microRNAs in human hepatocytes","volume":"6","author":"B T Gufford","year":"2018","journal-title":"Pharmacol Res Perspect"},{"key":"ref554","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1093\/jac\/dku504","article-title":"Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a\n                    new anti-TB drug","volume":"70","author":"E M Svensson","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"ref555","doi-asserted-by":"crossref","first-page":"6366","DOI":"10.1128\/AAC.01124-13","article-title":"Induction of influx and efflux transporters and cytochrome P450 3A4 in primary\n                    human hepatocytes by rifampin, rifabutin, and rifapentine","volume":"57","author":"B Williamson","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"ref556","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1345\/aph.1K615","article-title":"Induction effects of ritonavir: implications for drug interactions","volume":"42","author":"M M Foisy","year":"2008","journal-title":"Ann Pharmacother"},{"key":"ref557","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/01.qai.0000219774.20174.64","article-title":"Lopinavir\/ritonavir induces the hepatic activity of cytochrome P450 enzymes\n                    CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of\n                    CYP3A as measured by a phenotyping drug cocktail in healthy volunteers","volume":"42","author":"R F Yeh","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref558","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/BF00196109","article-title":"Smoking and body weight influence the clearance of chlorpromazine","volume":"46","author":"M Chetty","year":"1994","journal-title":"Eur J Clin Pharmacol"},{"key":"ref559","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1002\/jps.2600681106","article-title":"Factors affecting theophylline clearances: age, tobacco, marijuana, cirrhosis,\n                    congestive heart failure, obesity, oral contraceptives, benzodiazepines,\n                    barbiturates, and ethanol","volume":"68","author":"W J Jusko","year":"1979","journal-title":"J Pharm Sci"},{"key":"ref560","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/cpt1978244406","article-title":"Enhanced biotransformation of theophylline in marihuana and tobacco smokers","volume":"24","author":"W J Jusko","year":"1978","journal-title":"Clin Pharmacol Ther"},{"key":"ref561","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.clpt.2004.04.003","article-title":"Time response of cytochrome P450 1A2 activity on cessation of heavy smoking","volume":"76","author":"M S Faber","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"ref562","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1742-7843.2005.pto_973160.x","article-title":"Assessment of CYP1A2 activity in clinical practice: why, how, and when?","volume":"97","author":"M S Faber","year":"2005","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref563","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1055\/s-2006-931585","article-title":"Hypericum perforatum: which constituents may induce intestinal MDR1 and CYP3A4\n                    mRNA expression?","volume":"72","author":"H Gutmann","year":"2006","journal-title":"Planta Med"},{"key":"ref564","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1177\/0091270004265642","article-title":"The influence of St John's Wort on CYP2C19 activity with respect to\n                    genotype","volume":"44","author":"L S Wang","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"ref565","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1742-7843.2009.00412.x","article-title":"Trade herbal products and induction of CYP2C19 and CYP2E1 in cultured human\n                    hepatocytes","volume":"105","author":"B H Hellum","year":"2009","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref566","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1046\/j.1528-1157.2003.64402.x","article-title":"Topiramate and lamotrigine pharmacokinetics during repetitive monotherapy and\n                    combination therapy in epilepsy patients","volume":"44","author":"D R Doose","year":"2003","journal-title":"Epilepsia"},{"key":"ref567","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1528-1157.1997.tb01123.x","article-title":"Effect of topiramate on the pharmacokinetics of an oral contraceptive containing\n                    norethindrone and ethinyl estradiol in patients with epilepsy","volume":"38","author":"W E Rosenfeld","year":"1997","journal-title":"Epilepsia"},{"key":"ref568","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1345\/aph.1L497","article-title":"Warfarin-antiretroviral interactions","volume":"43","author":"M D Liedtke","year":"2009","journal-title":"Ann Pharmacother"},{"key":"ref569","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/0897190018758541","article-title":"Inductive Effect of a Ritonavir-Containing Hepatitis C Treatment Regimen on\n                    Warfarin in a Patient-A Case Report","volume":"32","author":"A C Rosene","year":"2019","journal-title":"J Pharm Pract"},{"key":"ref571","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/epd2.20093","article-title":"The pharmacological treatment of epilepsy in adults","volume":"25","author":"T Tomson","year":"2023","journal-title":"Epileptic Disord"},{"key":"ref572","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-198409010-00001","article-title":"First-pass elimination. Basic concepts and clinical consequences","volume":"9","author":"S M Pond","year":"1984","journal-title":"Clin Pharmacokinet"},{"key":"ref573","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/clpt.1982.219","article-title":"Nortriptyline formation after single oral and intramuscular doses of\n                    amitriptyline","volume":"32","author":"B Mellstr\u00f6m","year":"1982","journal-title":"Clin Pharmacol Ther"},{"key":"ref574","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/978-3-030-88773-5_7","volume-title":"Pharmacokinetic Concepts in Brain Drug Delivery, in Drug Delivery to the Brain:\n                    Physiological Concepts, Methodologies and","author":"M Hammarlund-Udenaes","year":"2022"},{"key":"ref575","doi-asserted-by":"crossref","first-page":"6233","DOI":"10.1021\/jm901036q","article-title":"Structure-brain exposure relationships in rat and human using a novel data set\n                    of unbound drug concentrations in brain interstitial and cerebrospinal\n                    fluids","volume":"52","author":"M Frid\u00e9n","year":"2009","journal-title":"J Med Chem"},{"key":"ref576","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1124\/jpet.111.180398","article-title":"Quantitative evaluation of the impact of active efflux by p-glycoprotein and\n                    breast cancer resistance protein at the blood-brain barrier on the\n                    predictability of the unbound concentrations of drugs in the brain using\n                    cerebrospinal fluid concentration as a surrogate","volume":"339","author":"H Kodaira","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"ref577","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0022-3956(03)00022-0","article-title":"abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine\n                    into the brain of mice","volume":"37","author":"M Uhr","year":"2003","journal-title":"J Psychiatr Res"},{"key":"ref578","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s40262-015-0267-1","article-title":"Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug\n                    Disposition and Potential Clinical Implications: Update of the Literature","volume":"54","author":"S Wolking","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"ref579","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.2217\/pgs.16.18","article-title":"ABCB1 genotyping in the treatment of depression","volume":"17","author":"T M Br\u00fcckl","year":"2016","journal-title":"Pharmacogenomics"},{"key":"ref580","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/cpt.2854","article-title":"ABCB1 Gene Variants and Antidepressant Treatment Outcomes: A Systematic Review\n                    and Meta-Analysis Including Results from the CAN-BIND-1 Study","volume":"114","author":"L Magarbeh","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"ref581","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1001\/archpsyc.1992.01820070032005","article-title":"Positron emission tomographic analysis of central D1 and D2 dopamine receptor\n                    occupancy in patients treated with classical neuroleptics and clozapine.\n                    Relation to extrapyramidal side effects","volume":"49","author":"L Farde","year":"1992","journal-title":"Arch Gen Psychiatry"},{"key":"ref582","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-0031-1286282","article-title":"Therapeutic plasma concentrations of antidepressants and antipsychotics: lessons\n                    from PET imaging","volume":"44","author":"G Gr\u00fcnder","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"ref583","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrd2806","article-title":"The 'atypicality' of antipsychotics: a concept re-examined and\n                    re-defined","volume":"8","author":"G Gr\u00fcnder","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"ref584","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.schres.2015.02.020","article-title":"Dopamine D\u2082\/\u2083 receptor availability in the striatum of antipsychotic-free older\n                    patients with schizophrenia-A [\u00b9\u00b9C]-raclopride PET study","volume":"164","author":"S Nakajima","year":"2015","journal-title":"Schizophrenia research"},{"key":"ref585","first-page":"212","article-title":"Dopamine D2\/3 Receptor Occupancy Following Dose Reduction Is Predictable With\n                    Minimal Plasma Antipsychotic Concentrations: An Open-Label Clinical Trial","volume":"42","author":"S Nakajima","year":"2016","journal-title":"Schizophr Bull"},{"key":"ref586","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.jagp.2013.01.045","article-title":"Therapeutic window for striatal dopamine D(2\/3) receptor occupancy in older\n                    patients with schizophrenia: a pilot PET study","volume":"22","author":"H Uchida","year":"2014","journal-title":"Am J Geriatr Psychiatry"},{"key":"ref587","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/FTD.0000000000001131","article-title":"Update Lessons from Positron Emission Tomography Imaging Part I: A Systematic\n                    Critical Review on Therapeutic Plasma Concentrations of Antipsychotics","volume":"46","author":"X M Hart","year":"2024","journal-title":"Ther Drug Monit"},{"key":"ref588","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/jcbfm.2011.180","article-title":"Predicting brain occupancy from plasma levels using PET: superiority of\n                    combining pharmacokinetics with pharmacodynamics while modeling the\n                    relationshi","volume":"32","author":"E Kim","year":"2012","journal-title":"J Cereb Blood Flow Metab"},{"key":"ref589","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1001\/archpsyc.60.10.974","article-title":"Mechanism of new antipsychotic medications: occupancy is not just\n                    antagonism","volume":"60","author":"G Grunder","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"ref590","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/00007691-200404000-00012","article-title":"Therapeutic monitoring of new antipsychotic drugs","volume":"26","author":"C Hiemke","year":"2004","journal-title":"Ther Drug Monit"},{"key":"ref591","first-page":"81","article-title":"Positron emission tomography studies on D2 dopamine receptor occupancy and\n                    plasma antipsychotic drug levels in man","volume":"10","author":"S Nyberg","year":"1995","journal-title":"Int Clin Psychopharmacol"},{"key":"ref592","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1742-7843.2011.00810.x","article-title":"Occupancy of the serotonin transporter after administration of Lu AA21004 and\n                    its relation to plasma concentration in healthy subjects","volume":"110","author":"J Areberg","year":"2012","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref593","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.neuroimage.2013.10.002","article-title":"Regional differences in SERT occupancy after acute and prolonged SSRI intake\n                    investigated by brain PET","volume":"88","author":"P Baldinger","year":"2014","journal-title":"Neuroimage"},{"key":"ref594","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1139\/jpn.0709","article-title":"Imaging the serotonin transporter during major depressive disorder and\n                    antidepressant treatment","volume":"32","author":"J H Meyer","year":"2007","journal-title":"J Psychiatry Neurosci"},{"key":"ref595","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1176\/appi.ajp.161.5.826","article-title":"Serotonin transporter occupancy of five selective serotonin reuptake inhibitors\n                    at different doses: an [11C]DASB positron emission tomography study","volume":"161","author":"J H Meyer","year":"2004","journal-title":"Am J Psychiatry"},{"key":"ref596","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1017\/S1461145712001009","article-title":"Occupancy of serotonin and norepinephrine transporter by milnacipran in patients\n                    with major depressive disorder: a positron emission tomography study with\n                    [(11)C]DASB and (S,S)-[(18)F]FMeNER-D(2)","volume":"16","author":"T Nogami","year":"2013","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref597","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S2215-0366(15)00232-1","article-title":"The serotonin transporter in psychiatric disorders: insights from PET\n                    imaging","volume":"2","author":"M Spies","year":"2015","journal-title":"Lancet Psychiatry"},{"key":"ref598","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.tips.2022.09.011","article-title":"Pharmacogenomics in treatment of depression and psychosis: an update","volume":"43","author":"M Jukic","year":"2022","journal-title":"Trends Pharmacol Sci"},{"key":"ref599","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/gim.2016.87","article-title":"Standardizing terms for clinical pharmacogenetic test results: consensus terms\n                    from the Clinical Pharmacogenetics Implementation Consortium (CPIC)","volume":"19","author":"K E Caudle","year":"2017","journal-title":"Genet Med"},{"key":"ref600","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s002280100284","article-title":"Duplication of CYP2D6 predicts high clearance of desipramine but high clearance\n                    does not predict duplication of CYP2D6","volume":"57","author":"T K Bergmann","year":"2001","journal-title":"Eur J Clin Pharmacol"},{"key":"ref601","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0140-6736(22)01841-4","article-title":"A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an\n                    open-label, multicentre, controlled, cluster-randomised crossover implementation\n                    study","volume":"401","author":"J J Swen","year":"2023","journal-title":"Lancet"},{"key":"ref602","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1124\/pr.110.003459","article-title":"Prodrugs--from serendipity to rational design","volume":"63","author":"K M Huttunen","year":"2011","journal-title":"Pharmacol Rev"},{"key":"ref603","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4155\/fmc.12.197","article-title":"Cytochrome P450-activated prodrugs","volume":"5","author":"P R Ortiz de Montellano","year":"2013","journal-title":"Future Med Chem"},{"key":"ref604","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1124\/jpet.111.189597","article-title":"Estimation of drug-metabolizing capacity by cytochrome P450 genotyping and\n                    expression","volume":"341","author":"M Temesv\u00e1ri","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"ref605","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/clpt.2014.83","article-title":"Geneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using\n                    dried blood spots","volume":"96","author":"M Bosilkovska","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"ref606","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1248\/bpb.32.717","article-title":"A simplified method to determine five cytochrome p450 probe drugs by HPLC in a\n                    single run","volume":"32","author":"Y Liu","year":"2009","journal-title":"Biol Pharm Bull"},{"key":"ref607","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/00007691-199910000-00016","article-title":"Could discontinuing smoking be hazardous for patients administered clozapine\n                    medication?","volume":"21","author":"E Skogh","year":"1999","journal-title":"A case report. Ther Drug Monit"},{"key":"ref608","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/00004850-200205000-00008","article-title":"Tobacco and cannabis smoking cessation can lead to intoxication with clozapine\n                    or olanzapine","volume":"17","author":"D F Zullino","year":"2002","journal-title":"Int Clin Psychopharmacol"},{"key":"ref609","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/BF03189732","article-title":"Metabolic ratios of four probes of CYP2D6 in Turkish subjects: a cross-over\n                    study","volume":"21","author":"A Bozkurt","year":"1996","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"ref610","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/sj.clpt.6100406","article-title":"The CYP2D6 activity score: translating genotype information into a qualitative\n                    measure of phenotype","volume":"83","author":"A Gaedigk","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"ref611","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/cpt.258","article-title":"Heritability of metoprolol and torsemide pharmacokinetics","volume":"98","author":"J Matthaei","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"ref612","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/s41397-022-00288-2","article-title":"The genetic landscape of major drug metabolizing cytochrome P450 genes-an\n                    updated analysis of population-scale sequencing data","volume":"22","author":"Y Zhou","year":"2022","journal-title":"Pharmacogenomics J"},{"key":"ref613","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1373\/clinchem.2003.030825","article-title":"Allele-specific change of concentration and functional gene dose for the\n                    prediction of steady-state serum concentrations of amitriptyline and\n                    nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers","volume":"50","author":"W Steimer","year":"2004","journal-title":"Clin Chem"},{"key":"ref617","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s11096-023-01588-8","article-title":"Effect of CYP2D6 pharmacogenetic phenotype and phenoconversion on serum\n                    concentrations of antidepressants and antipsychotics: a retrospective cohort\n                    study","volume":"45","author":"M Scherf-Clavel","year":"2023","journal-title":"Int J Clin Pharm"},{"key":"ref618","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3109\/03602530903209288","article-title":"Interindividual variability in hepatic drug glucuronidation: studies into the\n                    role of age, sex, enzyme inducers, and genetic polymorphism using the human\n                    liver bank as a model system","volume":"42","author":"M H Court","year":"2010","journal-title":"Drug Metab Rev"},{"key":"ref619","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.pharmthera.2013.09.002","article-title":"Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A\n                    quantitative systematic review","volume":"141","author":"J C Stingl","year":"2014","journal-title":"Pharmacol Ther"},{"key":"ref621","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.pnpbp.2010.11.031","article-title":"Genome-wide association studies of antidepressant outcome: a brief review","volume":"35","author":"G Laje","year":"2011","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref622","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(16)00143-4","article-title":"Genetic variants associated with response to lithium treatment in bipolar\n                    disorder: a genome-wide association study","volume":"387","author":"L Hou","year":"2016","journal-title":"Lancet"},{"key":"ref623","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1017\/S1092852913000278","article-title":"Pharmacogenetics of mood disorders: what clinicians need to know","volume":"18","author":"G Laje","year":"2013","journal-title":"CNS Spectr"},{"key":"ref624","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.2217\/pgs.10.127","article-title":"Pharmacogenetics of lithium response in bipolar disorder","volume":"11","author":"M J McCarthy","year":"2010","journal-title":"Pharmacogenomics"},{"key":"ref625","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000314708","article-title":"The International Consortium on Lithium Genetics (ConLiGen): an initiative by\n                    the NIMH and IGSLI to study the genetic basis of response to lithium\n                    treatment","volume":"62","author":"T G Schulze","year":"2010","journal-title":"Neuropsychobiology"},{"key":"ref626","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1080\/14622416.2025.2470605","article-title":"Pharmacogenomics and response to lithium in bipolar disorder","volume":"25","author":"P Paribello","year":"2024","journal-title":"Pharmacogenomics"},{"key":"ref627","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1369-1600.2012.00442.x","article-title":"Association of \u00b5-opioid receptor (OPRM1) gene polymorphism with response to\n                    naltrexone in alcohol dependence: a systematic review and meta-analysis","volume":"17","author":"A J Chamorro","year":"2012","journal-title":"Addict Biol"},{"key":"ref628","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1177\/070674371405900203","article-title":"Pharmacogenetics of antipsychotics","volume":"59","author":"E J Brandl","year":"2014","journal-title":"Can J Psychiatry"},{"key":"ref629","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.euroneuro.2015.12.035","article-title":"Pharmacogenetics of clozapine response and induced weight gain: A comprehensive\n                    review and meta-analysis","volume":"26","author":"F Gressier","year":"2016","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref630","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/tpj.2008.6","article-title":"Further evidence for association of the RGS2 gene with antipsychotic-induced\n                    parkinsonism: protective role of a functional polymorphism in the\n                    3'-untranslated region","volume":"9","author":"L Greenbaum","year":"2009","journal-title":"Pharmacogenomics J"},{"key":"ref631","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/FPC.0b013e32800ffbb4","article-title":"Association of the RGS2 gene with extrapyramidal symptoms induced by treatment\n                    with antipsychotic medication","volume":"17","author":"L Greenbaum","year":"2007","journal-title":"Pharmacogenet Genomics"},{"key":"ref632","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/YPG.0b013e3283328dcd","article-title":"Association study of serotonergic gene variants with antipsychotic-induced\n                    adverse reactions","volume":"19","author":"I Al-Janabi","year":"2009","journal-title":"Psychiatr Genet"},{"key":"ref633","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.pnpbp.2009.01.010","article-title":"Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in Russian\n                    psychiatric inpatients from Siberia","volume":"33","author":"A F Al Hadithy","year":"2009","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref634","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s002130000521","article-title":"Association between the serotonin 2C receptor gene and tardive dyskinesia in\n                    chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to\n                    susceptibility","volume":"152","author":"R H Segman","year":"2000","journal-title":"Psychopharmacology (Berl)"},{"key":"ref635","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1017\/S1461145705005389","article-title":"Combined analysis of 635 patients confirms an age-related association of the\n                    serotonin 2A receptor gene with tardive dyskinesia and specificity for the\n                    non-orofacial subtype","volume":"8","author":"B Lerer","year":"2005","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref636","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/sj.mp.4000842","article-title":"Association between the serotonin 2A receptor gene and tardive dyskinesia in\n                    chronic schizophrenia","volume":"6","author":"R H Segman","year":"2001","journal-title":"Mol Psychiatry"},{"key":"ref637","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/FPC.0b013e328311a917","article-title":"Functional serotonin 1A receptor variant influences treatment response to\n                    atypical antipsychotics in schizophrenia","volume":"19","author":"R M\u00f6ssner","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"ref638","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/ijnp\/pyv125","article-title":"HTR1A Polymorphisms and Clinical Efficacy of Antipsychotic Drug Treatment in\n                    Schizophrenia: A Meta-Analysis","volume":"19","author":"Y Takekita","year":"2016","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref639","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.eplepsyres.2017.05.015","article-title":"Association between the HLA-B alleles and carbamazepine-induced SJS\/TEN: A\n                    meta-analysis","volume":"135","author":"Q Wang","year":"2017","journal-title":"Epilepsy Res"},{"key":"ref640","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.4088\/JCP.v68n1011","article-title":"Quetiapine and drug interactions: evidence from a routine therapeutic drug\n                    monitoring service","volume":"68","author":"I Castberg","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"ref641","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/JCP.0000000000000433","article-title":"Pharmacokinetic Interaction Between Valproic Acid, Meropenem, and\n                    Risperidone","volume":"36","author":"M Paulzen","year":"2016","journal-title":"J Clin Psychopharmacol"},{"key":"ref642","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/00007691-200004000-00001","article-title":"Is therapeutic drug monitoring a case for optimizing clinical outcome and\n                    avoiding interactions of the selective serotonin reuptake inhibitors?","volume":"22","author":"B B Rasmussen","year":"2000","journal-title":"Ther Drug Monit"},{"key":"ref643","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/JCP.0000000000000601","article-title":"Pharmacokinetic Drug-Drug Interactions of Mood Stabilizers and Risperidone in\n                    Patients Under Combined Treatment","volume":"36","author":"G Schoretsanitis","year":"2016","journal-title":"J Clin Psychopharmacol"},{"key":"ref644","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.schres.2016.12.016","article-title":"Effect of smoking on risperidone pharmacokinetics - A multifactorial approach to\n                    better predict the influence on drug metabolism","volume":"185","author":"G Schoretsanitis","year":"2017","journal-title":"Schizophr Res"},{"key":"ref645","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1055\/s-0034-1390477","article-title":"Influence of concomitant medications on the total clearance and the risk for\n                    supra-therapeutic plasma concentrations of Citalopram. A population-based cohort\n                    study","volume":"47","author":"K Wenzel-Seifert","year":"2014","journal-title":"Pharmacopsychiatry"},{"key":"ref646","first-page":"14","article-title":"The Influence of Pharmacogenetics on the Clinical Relevance of Pharmacokinetic\n                    Drug-Drug Interactions: Drug-Gene, Drug-Gene-Gene and Drug-Drug-Gene\n                    Interactions","author":"M Hahn","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref647","first-page":"12","article-title":"Mechanisms of CYP450 Inhibition: Understanding Drug-Drug Interactions Due to\n                    Mechanism-Based Inhibition in Clinical Practice","author":"M Deodhar","year":"2020","journal-title":"Pharmaceutics"},{"key":"ref648","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4062\/biomolther.2021.102","article-title":"Inhibition of Cytochrome P450 Enzymes by Drugs-Molecular Basis and Practical\n                    Applications","volume":"30","author":"F P Guengerich","year":"2022","journal-title":"Biomol Ther (Seoul)"},{"key":"ref649","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1007\/s00204-020-02936-7","article-title":"Inhibition and induction of CYP enzymes in humans: an update","volume":"94","author":"J Hakkola","year":"2020","journal-title":"Arch Toxicol"},{"key":"ref650","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1124\/dmd.31.3.289","article-title":"Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine:\n                    comparison with fluoxetine and quinidine","volume":"31","author":"K M Bertelsen","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"ref652","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/0006-3223(85)90063-0","article-title":"Effects of smoking on fluphenazine clearance in psychiatric inpatients","volume":"20","author":"L Ereshefsky","year":"1985","journal-title":"Biol Psychiatry"},{"key":"ref653","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.ftd.0000164609.14808.93","article-title":"Increased clozapine plasma concentrations and side effects induced by smoking\n                    cessation in 2 CYP1A2 genotyped patients","volume":"27","author":"G Bondolfi","year":"2005","journal-title":"Ther Drug Monit"},{"key":"ref654","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1055\/s-2008-1073173","article-title":"The influence of smoking on the serum level of duloxetine","volume":"41","author":"M Fric","year":"2008","journal-title":"Pharmacopsychiatry"},{"key":"ref655","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/JCP.0000000000001080","article-title":"Smoking Is Associated With Lower Dose-Corrected Serum Concentrations of\n                    Escitalopram","volume":"39","author":"M Scherf-Clavel","year":"2019","journal-title":"Journal of clinical psychopharmacology"},{"key":"ref656","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0924-977X(03)00042-7","article-title":"Toxic rise of clozapine plasma concentrations in relation to inflammation","volume":"13","author":"M J Haack","year":"2003","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref657","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1517\/17425255.2014.952630","article-title":"Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their\n                    impact on drug bioavailability and clinical relevance","volume":"10","author":"O Bruhn","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref658","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/mp.2009.92","article-title":"Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2:\n                    association with major depression and antidepressant response in\n                    Mexican-Americans","volume":"14","author":"C Dong","year":"2009","journal-title":"Mol Psychiatry"},{"key":"ref659","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/j.1472-8206.2004.00291.x","article-title":"Functional interaction of intestinal CYP3A4 and P-glycoprotein","volume":"18","author":"K T Kivist\u00f6","year":"2004","journal-title":"Fundam Clin Pharmacol"},{"key":"ref660","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/FTD.0b013e31826517c6","article-title":"Association between lamotrigine concentrations and ABCB1 polymorphisms in\n                    patients with epilepsy","volume":"34","author":"M Lovri\u0107","year":"2012","journal-title":"Ther Drug Monit"},{"key":"ref661","doi-asserted-by":"crossref","first-page":"145907","DOI":"10.1016\/j.gene.2021.145907","article-title":"ABCB1 c.3435C>T and EPHX1 c.416A>G polymorphisms influence plasma\n                    carbamazepine concentration, metabolism, and pharmacoresistance in epileptic\n                    patients","volume":"805","author":"M L Zhang","year":"2021","journal-title":"Gene"},{"key":"ref662","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1097\/01.ftd.0000246761.82377.a6","article-title":"The relationship between P-glycoprotein (PGP) polymorphisms and response to\n                    olanzapine treatment in schizophrenia","volume":"28","author":"Y C Lin","year":"2006","journal-title":"Ther Drug Monit"},{"key":"ref663","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/bcpt.12938","article-title":"Effect of Polymorphisms on the Pharmacokinetics, Pharmacodynamics and Safety of\n                    Sertraline in Healthy Volunteers","volume":"122","author":"M Saiz-Rodr\u00edguez","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref664","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/cpt.2244","article-title":"Exploring the Use of Serum-Derived Small Extracellular Vesicles as Liquid Biopsy\n                    to Study the Induction of Hepatic Cytochromes P450 and Organic Anion\n                    Transporting Polypeptides","volume":"110","author":"A D Rodrigues","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"ref666","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/hep4.1210","article-title":"Abundance of Cytochromes in Hepatic Extracellular Vesicles Is Altered by Drugs\n                    Related With Drug-Induced Liver Injury","volume":"2","author":"L Palomo","year":"2018","journal-title":"Hepatol Commun"},{"key":"ref667","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1176\/ajp.149.5.587","article-title":"Gender differences in pharmacokinetics and pharmacodynamics of psychotropic\n                    medication","volume":"149","author":"K A Yonkers","year":"1992","journal-title":"Am J Psychiatry"},{"key":"ref668","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/7854_2010_118","article-title":"The impact of gender on antidepressants","volume":"8","author":"J J Sramek","year":"2011","journal-title":"Curr Top Behav Neurosci"},{"key":"ref669","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/00003088-200948030-00001","article-title":"Sex differences in pharmacokinetics and pharmacodynamics","volume":"48","author":"O P Soldin","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"ref670","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00702-014-1317-9","article-title":"Steady-state serum concentrations of venlafaxine in patients with late-life\n                    depression. Impact of age, sex and BMI","volume":"122","author":"H P Sigurdsson","year":"2015","journal-title":"J Neural Transm (Vienna)"},{"key":"ref671","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1017\/S1092852912001010","article-title":"Pharmacokinetics and pharmacodynamics of psychotropic drugs: effect of sex","volume":"18","author":"D Marazziti","year":"2013","journal-title":"CNS Spectr"},{"key":"ref672","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/01.yic.0000188213.46667.f1","article-title":"Influence of age, gender, body weight and valproate comedication on quetiapine\n                    plasma concentrations","volume":"21","author":"W Aichhorn","year":"2006","journal-title":"Int Clin Psychopharmacol"},{"key":"ref673","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1177\/0269881105053306","article-title":"Influence of age and gender on risperidone plasma concentrations","volume":"19","author":"W Aichhorn","year":"2005","journal-title":"J Psychopharmacol"},{"key":"ref674","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2165\/00002018-200629070-00004","article-title":"Second-generation antipsychotics: is there evidence for sex differences in\n                    pharmacokinetic and adverse effect profiles?","volume":"29","author":"W Aichhorn","year":"2006","journal-title":"Drug Saf"},{"key":"ref675","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s40262-014-0145-2","article-title":"Sex differences in the pharmacokinetics of antidepressants: influence of female\n                    sex hormones and oral contraceptives","volume":"53","author":"V A Damoiseaux","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"ref676","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1517\/17425255.2011.544250","article-title":"Sex differences in pharmacokinetics of antidepressants","volume":"7","author":"N Kokras","year":"2011","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref677","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1046\/j.1365-2710.1999.00246.x","article-title":"Gender-related differences in pharmacokinetics and their clinical\n                    significance","volume":"24","author":"E Tanaka","year":"1999","journal-title":"J Clin Pharm Ther"},{"key":"ref678","first-page":"1","article-title":"The impact of pregnancy on the pharmacokinetics of antidepressants: A\n                    systematic critical review and meta-analysis","author":"G Schoretsanitis","year":"2020","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref679","first-page":"1516","article-title":"[Gender differences in psychopharmacology]","volume":"49","author":"V Regitz-Zagrosek","year":"2008","journal-title":"Internist (Berl)"},{"key":"ref680","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/JCP.0000000000000087","article-title":"Pharmacotherapy for mood disorders in pregnancy: a review of pharmacokinetic\n                    changes and clinical recommendations for therapeutic drug monitoring","volume":"34","author":"K M Deligiannidis","year":"2014","journal-title":"J Clin Psychopharmacol"},{"key":"ref682","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","article-title":"Age-related changes in pharmacokinetics and pharmacodynamics: basic principles\n                    and practical applications","volume":"57","author":"A A Mangoni","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"ref683","doi-asserted-by":"crossref","first-page":"104779","DOI":"10.1016\/j.ebiom.2023.104779","article-title":"Pro-arrhythmic effect of escitalopram and citalopram at serum concentrations\n                    commonly observed in older patients - a study based on a cohort of 19,742\n                    patients","volume":"95","author":"P Faraj","year":"2023","journal-title":"EBioMedicine"},{"key":"ref684","volume-title":"Applied Clinical Pharmacokinetics. 3rd ed.","author":"L A Bauer","year":"2014"},{"key":"ref685","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1097\/FTD.0b013e318237b0fa","article-title":"No influence of body weight on serum levels of antidepressants","volume":"33","author":"S Unterecker","year":"2011","journal-title":"Ther Drug Monit"},{"key":"ref686","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1055\/s-0031-1286285","article-title":"Therapeutic drug monitoring in pharmacovigilance and pharmacotherapy safety","volume":"44","author":"E Haen","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"ref687","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/bcp.12706","article-title":"The law of mass action and the pharmacological concentration-effect curve:\n                    resolving the paradox of apparently non-dose-related adverse drug reactions","volume":"81","author":"J K Aronson","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"ref688","doi-asserted-by":"crossref","first-page":"853","DOI":"10.2165\/00003088-200241110-00004","article-title":"Comprehensive survey of the relationship between serum concentration and\n                    therapeutic effect of amitriptyline in depression","volume":"41","author":"S Ulrich","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"ref689","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2165\/00003088-199834030-00005","article-title":"The relationship between serum concentration and therapeutic effect of\n                    haloperidol in patients with acute schizophrenia","volume":"34","author":"S Ulrich","year":"1998","journal-title":"Clin Pharmacokinet"},{"key":"ref690","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.4088\/JCP.09r05060gre","article-title":"A systematic review of aripiprazole--dose, plasma concentration, receptor\n                    occupancy, and response: implications for therapeutic drug monitoring","volume":"71","author":"A Sparshatt","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"ref691","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/00004714-200102000-00004","article-title":"Olanzapine plasma concentrations and clinical response: acute phase results of\n                    the North American Olanzapine Trial","volume":"21","author":"P J Perry","year":"2001","journal-title":"J Clin Psychopharmacol"},{"key":"ref692","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.schres.2013.04.002","article-title":"Plasma levels of second-generation antipsychotics and clinical response in acute\n                    psychosis: a review of the literature","volume":"147","author":"L V Lopez","year":"2013","journal-title":"Schizophr Res"},{"key":"ref693","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00213-011-2319-z","article-title":"\"There is no dose-response relationship in psychopharmacotherapy\" vs\n                    \"pharmacotherapy in psychiatry is based on ligand-receptor\n                    interaction\": a unifying hypothesis and the need for plasma concentration\n                    based clinical trials","volume":"217","author":"V Eggart","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"key":"ref694","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/01.pra.0000445247.54048.68","article-title":"Therapeutic Drug Monitoring (TDM) in psychiatry (part I): why studies attempting\n                    to correlate drug concentration and antidepressant response don't work","volume":"20","author":"S H Preskorn","year":"2014","journal-title":"J Psychiatr Pract"},{"key":"ref695","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/FTD.0000000000001142","article-title":"Update Lessons from PET Imaging Part II: A Systematic Critical Review on\n                    Therapeutic Plasma Concentrations of Antidepressants","volume":"46","author":"X M Hart","year":"2024","journal-title":"Ther Drug Monit"},{"key":"ref696","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0893-133X(02)00368-8","article-title":"A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and\n                    naltrexone","volume":"27","author":"B J Mason","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"ref697","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/FTD.0b013e3181e18638","article-title":"Acamprosate determinations in plasma and cerebrospinal fluid after multiple\n                    dosing measured by liquid chromatography-mass spectroscopy: a pharmacokinetic\n                    study in healthy volunteers","volume":"32","author":"A Hammarberg","year":"2010","journal-title":"Ther Drug Monit"},{"key":"ref698","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1248\/cpb.c16-00866","article-title":"Bioequivalence and Pharmacokinetic Profiles of Agomelatine 25-mg Tablets in\n                    Healthy Chinese Subjects: A Four-Way Replicate Crossover Study Demonstrating\n                    High Intra- and Inter-Individual Variations","volume":"65","author":"C Li","year":"2017","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"ref699","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jchromb.2015.09.018","article-title":"Development and validation a LC-MS\/MS method for the simultaneous determination\n                    of agomelatine and its metabolites, 7-desmethyl-agomelatine and\n                    3-hydroxy-agomelatine in human plasma: Application to a bioequivalence\n                    study","volume":"1003","author":"M Li","year":"2015","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"ref700","doi-asserted-by":"crossref","first-page":"e109300","DOI":"10.1371\/journal.pone.0109300","article-title":"Evaluation of the highly variable agomelatine pharmacokinetics in Chinese\n                    healthy subjects to support bioequivalence study","volume":"9","author":"Q Pei","year":"2014","journal-title":"PLoS One"},{"key":"ref701","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/bcp.13902","article-title":"A semiphysiological population pharmacokinetic model of agomelatine and its\n                    metabolites in Chinese healthy volunteers","volume":"85","author":"F Xie","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"ref702","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/j.1552-4604.1986.tb03526.x","article-title":"Pharmacokinetics and clinical effects of alprazolam following single and\n                    multiple oral doses in patients with panic disorder","volume":"26","author":"D A Ciraulo","year":"1986","journal-title":"J Clin Pharmacol"},{"key":"ref703","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00004714-199002000-00005","article-title":"The relationship of alprazolam dose to steady-state plasma concentrations","volume":"10","author":"D A Ciraulo","year":"1990","journal-title":"J Clin Psychopharmacol"},{"key":"ref704","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1176\/ajp.149.11.1556","article-title":"Alprazolam plasma concentrations and treatment response in panic disorder and\n                    agoraphobia","volume":"149","author":"I M Lesser","year":"1992","journal-title":"Am J Psychiatry"},{"key":"ref705","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/00004714-199102000-00007","article-title":"Alprazolam levels and response in panic disorder: preliminary results","volume":"11","author":"M Z Wincor","year":"1991","journal-title":"J Clin Psychopharmacol"},{"key":"ref706","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/clpt.1988.158","article-title":"Comparative single-dose kinetics and dynamics of lorazepam, alprazolam,\n                    prazepam, and placebo","volume":"44","author":"D J Greenblatt","year":"1988","journal-title":"Clin Pharmacol Ther"},{"key":"ref707","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s40263-019-00651-1","article-title":"Effects of Renal Impairment on the Pharmacokinetics of Once-Daily Amantadine\n                    Extended-Release Tablets","volume":"33","author":"T deVries","year":"2019","journal-title":"CNS Drugs"},{"key":"ref708","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s40262-018-0663-4","article-title":"Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered\n                    Once Daily at Bedtime for the Treatment of Dyskinesia","volume":"58","author":"R A Hauser","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"ref709","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/BF03160936","article-title":"QT prolongation and Torsades de Pointes following overdose of ziprasidone and\n                    amantadine","volume":"3","author":"A F Manini","year":"2007","journal-title":"J Med Toxicol"},{"key":"ref710","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.parkreldis.2008.08.005","article-title":"Plasma amantadine concentrations in patients with Parkinson's disease","volume":"15","author":"N Nishikawa","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"ref711","doi-asserted-by":"crossref","first-page":"e0155649","DOI":"10.1371\/journal.pone.0155649","article-title":"Co-Prescription of QT-Interval Prolonging Drugs: An Analysis in a Large Cohort\n                    of Geriatric Patients","volume":"11","author":"S Sch\u00e4chtele","year":"2016","journal-title":"PLoS One"},{"key":"ref712","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.euroneuro.2003.09.001","article-title":"Plasma amisulpride levels in schizophrenia or schizoaffective disorder","volume":"14","author":"N Bergemann","year":"2004","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref713","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1176\/appi.ajp.160.8.1413","article-title":"Is regionally selective D2\/D3 dopamine occupancy sufficient for atypical\n                    antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of\n                    amisulpride-treated patients","volume":"160","author":"R A Bressan","year":"2003","journal-title":"Am J Psychiatry"},{"key":"ref714","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1258\/rsmmsl.48.2.173","article-title":"Fatality due to amisulpride toxicity: a case report","volume":"48","author":"M J Lynch","year":"2008","journal-title":"Med Sci Law"},{"key":"ref715","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1055\/s-2008-1076727","article-title":"Striatal D2\/D3 receptor occupancy, clinical response and side effects with\n                    amisulpride: an iodine-123-iodobenzamide SPET study","volume":"41","author":"E M Meisenzahl","year":"2008","journal-title":"Pharmacopsychiatry"},{"key":"ref716","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.jpsychires.2005.10.003","article-title":"Therapeutic drug monitoring for optimizing amisulpride therapy in patients with\n                    schizophrenia","volume":"41","author":"M J M\u00fcller","year":"2007","journal-title":"J Psychiatr Res"},{"key":"ref717","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1600-0447.1998.tb10044.x","article-title":"Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of\n                    schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study\n                    Grou","volume":"98","author":"A Puech","year":"1998","journal-title":"Acta Psychiatr Scand"},{"key":"ref718","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/j.1600-0447.2009.01429.x","article-title":"Amisulpride - dose, plasma concentration, occupancy and response: implications\n                    for therapeutic drug monitoring","volume":"120","author":"A Sparshatt","year":"2009","journal-title":"Acta Psychiatr Scand"},{"key":"ref719","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1017\/S1461145704004353","article-title":"High striatal occupancy of D2-like dopamine receptors by amisulpride in the\n                    brain of patients with schizophrenia","volume":"7","author":"I Vernaleken","year":"2004","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref720","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/YIC.0000000000000420","article-title":"Amisulpride steady-state plasma concentration and adverse reactions in patients\n                    with schizophrenia: a study based on therapeutic drug monitoring data","volume":"37","author":"K Qu","year":"2022","journal-title":"Int Clin Psychopharmacol"},{"key":"ref721","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/bcp.14246","article-title":"A systematic review and combined meta-analysis of concentration of oral\n                    amisulpride","volume":"86","author":"L Li","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"ref722","doi-asserted-by":"crossref","first-page":"102694","DOI":"10.1016\/j.ajp.2021.102694","article-title":"Study on the relationship among dose, concentration and clinical response in\n                    Chinese schizophrenic patients treated with Amisulpride","volume":"62","author":"F Sun","year":"2021","journal-title":"Asian J Psychiatr"},{"key":"ref723","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.2147\/DDDT.S327506","article-title":"Modeling and Simulation for Individualized Therapy of Amisulpride in Chinese\n                    Patients with Schizophrenia: Focus on Interindividual Variability, Therapeutic\n                    Reference Range and the Laboratory Alert Level","volume":"15","author":"S Huang","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"ref724","doi-asserted-by":"crossref","first-page":"103699","DOI":"10.1016\/j.ajp.2023.103699","article-title":"A 5-year retrospective study of amisulpride steady-state plasma concentration in\n                    patients with schizophrenia in real-life settings based on therapeutic drug\n                    monitoring data","volume":"87","author":"J Ding","year":"2023","journal-title":"Asian Journal of Psychiatry"},{"key":"ref725","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1055\/s-2007-1017018","article-title":"Pharmacokinetics of amitriptyline and amitriptylinoxide after intravenous or\n                    oral administration in humans","volume":"21","author":"J G Filser","year":"1988","journal-title":"Pharmacopsychiatry"},{"key":"ref726","first-page":"287","article-title":"Therapeutic drug monitoring of tricyclic antidepressants in everyday clinical\n                    practice","volume":"2007","author":"B Pfuhlmann","journal-title":"J Neural Transm Suppl"},{"key":"ref727","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1097\/PEC.0b013e31826cebfb","article-title":"Significant toxicity in a young female after low-dose tricyclic antidepressant\n                    ingestion","volume":"28","author":"C A Grover","year":"2012","journal-title":"Pediatr Emerg Care"},{"key":"ref728","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1046\/j.1365-2125.1999.00973.x","article-title":"Pharmacokinetic and pharmacodynamic characterization of OROS and\n                    immediate-release amitriptyline","volume":"48","author":"S K Gupta","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"ref729","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/j.1440-1819.2008.01838.x","article-title":"Plasma amitriptyline level after acute administration, and driving performance\n                    in healthy volunteers","volume":"62","author":"K Iwamoto","year":"2008","journal-title":"Psychiatry Clin Neurosci"},{"key":"ref730","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/BF00637499","article-title":"Overdosage of antidepressants: clinical and pharmacokinetic aspects","volume":"23","author":"O L Pedersen","year":"1982","journal-title":"Eur J Clin Pharmacol"},{"key":"ref731","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s13181-011-0158-2","article-title":"Prolonged toxicity after amitriptyline overdose in a patient deficient in CYP2D6\n                    activity","volume":"7","author":"J C Smith","year":"2011","journal-title":"J Med Toxicol"},{"key":"ref732","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/108705470000300403","article-title":"Methyiphenidate vs. amphetamine: Comparative review","volume":"3","author":"L E Arnold","year":"2000","journal-title":"Journal of Attention Disorders"},{"key":"ref733","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.clinthera.2010.02.011","article-title":"Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite,\n                    d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in\n                    children with attention-deficit\/hyperactivity disorder: A single-dose,\n                    randomized, open-label, crossover study","volume":"32","author":"S W Boellner","year":"2010","journal-title":"Clinical Therapeutics"},{"key":"ref734","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1097\/01.CHI.0000046850.56865.CB","article-title":"Pharmacokinetics of SLI381 (ADDERALL XR), an extended-release formulation of\n                    Adderall","volume":"42","author":"J J McGough","year":"2003","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"ref735","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2147\/NDT.S9749","article-title":"Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to\n                    d-amphetamine","volume":"6","author":"M Pennick","year":"2010","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref736","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1126\/science.168.3938.1487","article-title":"Amphetamine: differentiation by d and l isomers of behavior involving brain\n                    norepinephrine or dopamine","volume":"168","author":"K M Taylor","year":"1970","journal-title":"Science"},{"key":"ref737","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.dmpk.2020.08.005","article-title":"Population pharmacokinetic and exposure-response analyses of d-amphetamine after\n                    administration of lisdexamfetamine dimesylate in Japanese pediatric ADHD\n                    patients","volume":"35","author":"Y Tsuda","year":"2020","journal-title":"Drug Metab Pharmacokinet"},{"key":"ref738","first-page":"293","volume-title":"Psychostimulants and Other Drugs Used in the Treatment of\n                    Attention-Deficit\/Hyperactivity Disorder (ADHD), in Psychiatric Drugs in\n                    Children and Adolescents: Basic Pharmacology and Practical Applications, M.\n                    Gerlach, A. Warnke, and L. Greenhill, Editors","author":"S Walitza","year":"2014"},{"key":"ref739","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1007\/s00213-022-06233-2","article-title":"Therapeutic Reference Range for Aripiprazole in Schizophrenia Revised: a\n                    Systematic Review and Metaanalysis","volume":"239","author":"X M Hart","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"key":"ref740","first-page":"141","article-title":"Novel Atypical Antipsychotics: Metabolism and Therapeutic Drug Monitoring (TDM).\n                    Curr Drug Metab","volume":"16","author":"R Mandrioli","year":"2015"},{"key":"ref741","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.2147\/PPA.S235104","article-title":"Transdermal Asenapine in Schizophrenia: A Systematic Review","volume":"14","author":"B Carrithers","year":"2020","journal-title":"Patient Prefer Adherence"},{"issue":"03","key":"ref742","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1177\/1087054716661235","article-title":"Non-Linear Pharmacokinetics of Atomoxetine in Adult Japanese Patients With\n                    ADHD","volume":"24","author":"A Sugimoto","year":"2020","journal-title":"J Atten Disord"},{"key":"ref743","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/JCP.0000000000001383","article-title":"Pharmacokinetic Profile of the Asenapine Transdermal System (HP-3070)","volume":"41","author":"K Suzuki","year":"2021","journal-title":"J Clin Psychopharmacol"},{"key":"ref744","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1089\/104454603321666199","article-title":"Atomoxetine pharmacokinetics in children and adolescents with attention deficit\n                    hyperactivity disorder","volume":"13","author":"J W Witcher","year":"2003","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"ref745","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00702-022-02483-8","article-title":"Therapeutic drug monitoring of atomoxetine in children and adolescents with\n                    attention-deficit\/ hyperactivity disorder: a naturalistic study","volume":"129","author":"K Ruppert","year":"2022","journal-title":"J Neural Transm (Vienna)"},{"key":"ref746","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/00007691-198709000-00015","article-title":"Electrochemical detection of benperidol in serum for drug monitoring in\n                    humans","volume":"9","author":"M Furlanut","year":"1987","journal-title":"Ther Drug Monit"},{"key":"ref747","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s40262-022-01155-w","article-title":"Allopregnanolone Concentrations in Breast Milk and Plasma from Healthy\n                    Volunteers Receiving Brexanolone Injection, With Population Pharmacokinetic\n                    Modeling of Potential Relative Infant Dose","volume":"61","author":"J Wald","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"ref748","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00228-020-03021-9","article-title":"An open-label, positron emission tomography study of the striatal D(2)\/D(3)\n                    receptor occupancy and pharmacokinetics of single-dose oral brexpiprazole in\n                    healthy participants","volume":"77","author":"D F Wong","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"key":"ref749","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/s41386-019-0590-6","article-title":"A positron emission tomography occupancy study of brexpiprazole at dopamine D(2)\n                    and D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors, and serotonin reuptake\n                    transporters in subjects with schizophrenia","volume":"45","author":"R R Girgis","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"ref750","doi-asserted-by":"crossref","first-page":"832209","DOI":"10.3389\/fpsyt.2022.832209","article-title":"Molecular Imaging of Dopamine Partial Agonists in Humans: Implications for\n                    Clinical Practice","volume":"13","author":"X M Hart","year":"2022","journal-title":"Front Psychiatry"},{"key":"ref751","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/jcph.979","article-title":"Pharmacokinetics and Safety of Brexpiprazole Following Multiple-Dose\n                    Administration to Japanese Patients With Schizophrenia","volume":"58","author":"J Ishigooka","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"ref753","first-page":"397","volume-title":"Brexpiprazole: a new dopamine D\u2082receptor partial agonist for the treatment of\n                    schizophrenia and major depressive disorder","author":"L Citrome","year":"2015"},{"key":"ref754","doi-asserted-by":"crossref","first-page":"394","DOI":"10.2133\/dmpk.DMPK-14-RG-010","article-title":"Brivaracetam single and multiple rising oral dose study in healthy Japanese\n                    participants: influence of CYP2C19 genotype","volume":"29","author":"A Stockis","year":"2014","journal-title":"Drug Metab Pharmacokinet"},{"key":"ref755","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1124\/dmd.107.017129","article-title":"Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in\n                    healthy subjects","volume":"36","author":"M L Sargentini-Maier","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"ref756","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1111\/epi.16500","article-title":"Influence of dose and antiepileptic comedication on brivaracetam serum\n                    concentrations in patients with epilepsy","volume":"61","author":"A Hagemann","year":"2020","journal-title":"Epilepsia"},{"key":"ref757","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1600-0447.1986.tb06268.x","article-title":"Bromazepam and lorazepam in generalized anxiety: a placebo-controlled study with\n                    measurement of drug plasma concentrations","volume":"74","author":"R Fontaine","year":"1986","journal-title":"Acta Psychiatr Scand"},{"issue":"03","key":"ref758","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/j.1600-0773.1998.tb01416.x","article-title":"Prolactin response to bromperidol treatment in schizophrenic patients","volume":"82","author":"N Yasui","year":"1998","journal-title":"Pharmacol Toxicol"},{"key":"ref759","first-page":"417","article-title":"Plasma concentrations of antipsychotic drugs in psychiatric inpatients","volume":"51","author":"H Tokunaga","year":"1997","journal-title":"Nihon Hoigaku Zasshi"},{"key":"ref760","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0278-5846(01)00218-4","article-title":"Therapeutic effects of bromperidol on the five dimensions of schizophrenic\n                    symptoms","volume":"26","author":"N Yasui-Furukori","year":"2002","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref761","first-page":"121","article-title":"Clinical efficacy, extrapyramidal symptoms and serum levels: influence of\n                    administration schedules and concomitant drugs on serum bromperidol\n                    concentrations","volume":"38","author":"Y Fujii","year":"1984","journal-title":"Folia Psychiatr Neurol Jpn"},{"key":"ref762","first-page":"291s","article-title":"Comparative pharmacokinetics of brotizolam and triazolam in healthy\n                    subjects","volume":"16","author":"R Jochemsen","year":"1983","journal-title":"Br J Clin Pharmacol"},{"key":"ref763","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/j.1365-2125.2004.02208.x","article-title":"Effect of itraconazole on the pharmacokinetics and pharmacodynamics of a single\n                    oral dose of brotizolam","volume":"58","author":"T Osanai","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"ref764","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2125.1986.tb05175.x","article-title":"Kinetic and dynamic interaction of brotizolam and ethanol","volume":"21","author":"J M Scavone","year":"1986","journal-title":"Br J Clin Pharmacol"},{"key":"ref765","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jsat.2014.10.010","article-title":"The impact of recent cocaine use on plasma levels of methadone and buprenorphine\n                    in patients with and without HIV-infection","volume":"51","author":"J M Tetrault","year":"2015","journal-title":"J Subst Abuse Treat"},{"key":"ref766","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1007\/s00213-022-06202-9","article-title":"Lower buprenorphine elimination rate constant is associated with lower opioid\n                    use","volume":"239","author":"H F Elarabi","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"key":"ref767","doi-asserted-by":"crossref","first-page":"1052113","DOI":"10.3389\/fphar.2022.1052113","article-title":"Buprenorphine exposure levels to optimize treatment outcomes in opioid use\n                    disorder","volume":"13","author":"C M Laffont","year":"2022","journal-title":"Front Pharmacol"},{"key":"ref768","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00406-019-01091-0","article-title":"Buprenorphine-cannabis interaction in patients undergoing opioid maintenance\n                    therapy","volume":"271","author":"C Vierke","year":"2021","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"ref770","doi-asserted-by":"crossref","first-page":"e0240584","DOI":"10.1371\/journal.pone.0240584","article-title":"Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A\n                    systematic review and network meta-analysis","volume":"15","author":"J Elliott","year":"2020","journal-title":"PLoS One"},{"key":"ref771","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/14622200110042852","article-title":"Relationship between drug exposure and the efficacy and safety of bupropion\n                    sustained release for smoking cessation","volume":"3","author":"J A Johnston","year":"2001","journal-title":"Nicotine Tob Res"},{"key":"ref772","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/FTD.0000000000000042","article-title":"Serum concentrations of hydroxybupropion for dose optimization of depressed\n                    patients treated with bupropion","volume":"36","author":"A K Laib","year":"2014","journal-title":"Ther Drug Monit"},{"key":"ref773","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1001\/archpsyc.1988.01800260055007","article-title":"Bupropion in depression. II. The role of metabolites in clinical outcome","volume":"45","author":"R N Golden","year":"1988","journal-title":"Arch Gen Psychiatry"},{"key":"ref774","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1111\/j.1360-0443.2008.02348.x","article-title":"A randomized trial of short psychotherapy versus sustained-release bupropion for\n                    smoking cessation","volume":"103","author":"G Zernig","year":"2008","journal-title":"Addiction"},{"key":"ref775","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1177\/00912700122010681","article-title":"A comparative multidose pharmacokinetic study of buspirone extended-release\n                    tablets with a reference immediate-release product","volume":"41","author":"A Sakr","year":"2001","journal-title":"J Clin Pharmacol"},{"key":"ref776","doi-asserted-by":"crossref","first-page":"R136","DOI":"10.1186\/cc11441","article-title":"Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other\n                    xenobiotics","volume":"16","author":"M Schulz","year":"2012","journal-title":"Crit Care"},{"key":"ref777","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/S0009-9236(97)90038-2","article-title":"Plasma buspirone concentrations are greatly increased by erythromycin and\n                    itraconazole","volume":"62","author":"K T Kivist\u00f6","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"ref778","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/BF00195914","article-title":"Disposition kinetics of buspirone in patients with renal or hepatic impairment\n                    after administration of single and multiple doses","volume":"46","author":"R H Barbhaiya","year":"1994","journal-title":"Eur J Clin Pharmacol"},{"key":"ref779","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/j.1552-4604.1989.tb03240.x","article-title":"Pharmacokinetics of buspirone in elderly subjects","volume":"29","author":"R E Gammans","year":"1989","journal-title":"J Clin Pharmacol"},{"key":"ref781","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s40263-020-00741-5","article-title":"Critical Aspects Affecting Cannabidiol Oral Bioavailability and Metabolic\n                    Elimination, and Related Clinical Implications","volume":"34","author":"E Perucca","year":"2020","journal-title":"CNS Drugs"},{"key":"ref782","doi-asserted-by":"crossref","first-page":"637801","DOI":"10.3389\/fphar.2021.637801","article-title":"Cannabidiol in Pharmacoresistant Epilepsy: Clinical Pharmacokinetic Data From an\n                    Expanded Access Program","volume":"12","author":"M Contin","year":"2021","journal-title":"Front Pharmacol"},{"key":"ref783","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.yebeh.2019.03.042","article-title":"Higher cannabidiol plasma levels are associated with better seizure response\n                    following treatment with a pharmaceutical grade cannabidiol","volume":"95","author":"J P Szaflarski","year":"2019","journal-title":"Epilepsy Behav"},{"key":"ref784","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/JCP.0b013e3181674608","article-title":"Clinical experience with carbamazepine overdose: relationship between serum\n                    concentration and neurological severity","volume":"28","author":"N Brahmi","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"ref785","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/BF00314982","article-title":"Carbamazepine and its 10,11-epoxide metabolite in acute mania: clinical and\n                    pharmacokinetic correlates","volume":"41","author":"P Petit","year":"1991","journal-title":"Eur J Clin Pharmacol"},{"key":"ref786","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/FTD.0000000000000546","article-title":"Therapeutic Drug Monitoring of Antiepileptic Drugs in Epilepsy: A 2018\n                    Update","volume":"40","author":"P N Patsalos","year":"2018","journal-title":"Ther Drug Monit"},{"issue":"10","key":"ref787","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.3390\/jcm13102757","article-title":"Cenobamate Plasma Levels in Patients with Epilepsy: Correlation with Efficacy\n                    and Tolerability?","volume":"13","author":"BJ Steinhoff","year":"2024","journal-title":"J Clin Med"},{"key":"ref788","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/FTD.0000000000001152","article-title":"Recommendation for a Therapeutic Reference Range of Cariprazine-A Short\n                    Communication","volume":"46","author":"F Sattaf","year":"2024","journal-title":"Ther Drug Monit"},{"issue":"03","key":"ref789","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.therap.2024.12.001","article-title":"Polyintoxication with cenobamate, perampanel, and carbamazepine: A complex case\n                    report","volume":"80","author":"A Destere","year":"2025","journal-title":"Therapie"},{"key":"ref790","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1007\/s00213-016-4382-y","article-title":"Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients\n                    with schizophrenia using PET with the D3\/D2 receptor ligand\n                    [(11)C]-(+)-PHNO","volume":"233","author":"R R Girgis","year":"2016","journal-title":"Psychopharmacology (Berl)"},{"key":"ref792","doi-asserted-by":"crossref","first-page":"1239152","DOI":"10.3389\/fphar.2023.1239152","article-title":"Cenobamate as add-on therapy for drug resistant epilepsies: effectiveness, drug\n                    to drug interactions and neuropsychological impact. What have we learned from\n                    real word evidence?","volume":"14","author":"N Pietrafusa","year":"2023","journal-title":"Front Pharmacol"},{"key":"ref793","doi-asserted-by":"crossref","first-page":"107185","DOI":"10.1016\/j.eplepsyres.2023.107185","article-title":"Pharmacokinetics of cenobamate as monotherapy compared with adjunctive\n                    therapy","volume":"195","author":"V Vashi","year":"2023","journal-title":"Epilepsy Res"},{"key":"ref794","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1023\/A:1009935116877","article-title":"Drug levels: therapeutic and toxic serum\/plasma concentrations of common\n                    drugs","volume":"15","author":"R Regenthal","year":"1999","journal-title":"J Clin Monit Comput"},{"key":"ref795","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s13054-020-02915-5","article-title":"Revisited: Therapeutic and toxic blood concentrations of more than 1100 drugs\n                    and other xenobiotics","volume":"24","author":"M Schulz","year":"2020","journal-title":"Crit Care"},{"key":"ref796","first-page":"5","article-title":"[The relative bioavailability and pharmacokinetics of chloral hydrate and its\n                    metabolites]","volume":"48","author":"T Zimmermann","year":"1998","journal-title":"Arzneimittelforschung"},{"key":"ref797","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3109\/15563658408992574","article-title":"Blood concentrations and clinical findings following overdose of\n                    chlordiazepoxide alone and chlordiazepoxide plus ethanol","volume":"22","author":"D N Bailey","year":"1984","journal-title":"J Toxicol Clin Toxicol"},{"key":"ref798","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1365-2125.1977.tb00666.x","article-title":"Plasma concentrations of benzodiazepines","volume":"4","author":"A J Bond","year":"1977","journal-title":"Br J Clin Pharmacol"},{"key":"ref799","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/BF01064807","article-title":"Pharmacokinetic and biopharmaceutic profile of chlordiazepoxide HC1 in healthy\n                    subjects: multiple-dose oral administration","volume":"5","author":"H G Boxenbaum","year":"1977","journal-title":"J Pharmacokinet Biopharm"},{"key":"ref800","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00003088-197803050-00004","article-title":"Clinical pharmacokinetics of chlordiazepoxide","volume":"3","author":"D J Greenblatt","year":"1978","journal-title":"Clin Pharmacokinet"},{"key":"ref801","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1176\/ajp.136.1.18","article-title":"Relationship of plasma levels of chlordiazepoxide and metabolites to clinical\n                    response","volume":"136","author":"K M Lin","year":"1979","journal-title":"Am J Psychiatry"},{"key":"ref802","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0924-977X(98)00005-4","article-title":"The use of a side effect as a qualitative indicator of plasma chlorpromazine\n                    levels","volume":"9","author":"M Chetty","year":"1999","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref803","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/cpt1973146978","article-title":"Effects of mode of management on plasma chlorpromazine in psychiatric\n                    patients","volume":"14","author":"L Rivera-Calimlim","year":"1973","journal-title":"Clin Pharmacol Ther"},{"key":"ref804","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/schbul\/17.2.197","article-title":"Neuroleptic plasma levels","volume":"17","author":"T Van Putten","year":"1991","journal-title":"Schizophr Bull"},{"key":"ref805","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00023210-200418050-00004","article-title":"Citalopram concentrations and response in obsessive-compulsive disorder.\n                    Preliminary results","volume":"18","author":"S R Bareggi","year":"2004","journal-title":"CNS Drugs"},{"key":"ref806","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/BF00544066","article-title":"Relationship between clinical effects, serum drug concentration and serotonin\n                    uptake inhibition in depressed patients treated with citalopram. A double-blind\n                    comparison of three dose levels","volume":"28","author":"L Bjerkenstedt","year":"1985","journal-title":"Eur J Clin Pharmacol"},{"key":"ref807","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/FTD.0000000000000101","article-title":"Effect of proton pump inhibitors on the serum concentrations of the selective\n                    serotonin reuptake inhibitors citalopram, escitalopram, and sertraline","volume":"37","author":"C Gjestad","year":"2015","journal-title":"Ther Drug Monit"},{"key":"ref808","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/00007691-200310000-00010","article-title":"Routine therapeutic drug monitoring in patients treated with 10-360 mg\/day\n                    citalopram","volume":"25","author":"Y Le Bloc'h","year":"2003","journal-title":"Ther Drug Monit"},{"key":"ref809","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1055\/s-0033-1354370","article-title":"Early improvement and serum concentrations of citalopram to predict\n                    antidepressant drug response of patients with major depression","volume":"46","author":"E Ostad Haji","year":"2013","journal-title":"Pharmacopsychiatry"},{"key":"ref810","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/JCP.0b013e318218f503","article-title":"Association between citalopram serum levels and clinical improvement of patients\n                    with major depression","volume":"31","author":"E Ostad Haji","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"ref811","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/00004714-200208000-00012","article-title":"Serum levels of citalopram and its main metabolites in adolescent patients\n                    treated in a naturalistic clinical setting","volume":"22","author":"M Reis","year":"2002","journal-title":"J Clin Psychopharmacol"},{"key":"ref812","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/00007691-200304000-00007","article-title":"Therapeutic drug monitoring of racemic citalopram: a 5-year experience in\n                    Sweden, 1992-1997","volume":"25","author":"M Reis","year":"2003","journal-title":"Ther Drug Monit"},{"key":"ref813","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/JCP.0b013e318204b117","article-title":"Antidepressant exposure as a predictor of clinical outcomes in the Treatment of\n                    Resistant Depression in Adolescents (TORDIA) study","volume":"31","author":"D J Sakolsky","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"ref814","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s00702-012-0952-2","article-title":"Effects of gender and age on serum concentrations of antidepressants under\n                    naturalistic conditions","volume":"120","author":"S Unterecker","year":"2013","journal-title":"J Neural Transm (Vienna)"},{"key":"ref815","doi-asserted-by":"crossref","first-page":"51s","DOI":"10.1111\/j.1365-2125.1979.tb04665.x","article-title":"Pharmacokinetics of single and multiple doses of clobazam in humans","volume":"7","author":"W Rupp","year":"1979","journal-title":"Br J Clin Pharmacol"},{"key":"ref816","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1017\/S031716710003064X","article-title":"Add-on trial of clobazam in intractable adult epilepsy with plasma level\n                    correlations","volume":"17","author":"A Guberman","year":"1990","journal-title":"Can J Neurol Sci"},{"key":"ref817","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/FTD.0b013e31822fbf7c","article-title":"Therapeutic drug monitoring for drugs used in the treatment of substance-related\n                    disorders: literature review using a therapeutic drug monitoring appropriateness\n                    rating scale","volume":"33","author":"S Br\u00fcnen","year":"2011","journal-title":"Ther Drug Monit"},{"key":"ref818","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/00007691-200206000-00021","article-title":"Serum concentration of chlormethiazole and therapeutic effect in acute alcohol\n                    withdrawal syndrome: an open clinical trial","volume":"24","author":"S Ulrich","year":"2002","journal-title":"Ther Drug Monit"},{"key":"ref819","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1046\/j.0306-5251.2003.01850.x","article-title":"Population pharmacokinetics of clomethiazole and its effect on the natural\n                    course of sedation in acute stroke patients","volume":"56","author":"P H Zingmark","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"ref820","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1055\/s-2004-815509","article-title":"Severe adverse drug reactions of antidepressants: results of the German\n                    multicenter drug surveillance program AMS","volume":"37","author":"D Degner","year":"2004","journal-title":"Pharmacopsychiatry"},{"key":"ref821","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s002280050572","article-title":"Clomipramine concentration as a predictor of delayed response: a naturalistic\n                    study","volume":"54","author":"M Gex-Fabry","year":"1999","journal-title":"Eur J Clin Pharmacol"},{"key":"ref822","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1192\/bjp.134.4.390","article-title":"Clinical response and tricyclic plasma levels during treatment with\n                    clomipramine","volume":"134","author":"L Della Corte","year":"1979","journal-title":"Br J Psychiatry"},{"key":"ref823","first-page":"695","article-title":"Double-blind trial with oral versus intravenous clomipramine in primary\n                    depression","volume":"18","author":"C Faravelli","year":"1983","journal-title":"Biol Psychiatry"},{"key":"ref824","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/YIC.0000000000000050","article-title":"Clomipramine demethylation rate is important on the outcome of\n                    obsessive-compulsive disorder treatment","volume":"30","author":"T Marcourakis","year":"2015","journal-title":"Int Clin Psychopharmacol"},{"key":"ref825","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00004714-199008000-00005","article-title":"Clomipramine in obsessive-compulsive disorder: clinical response and plasma\n                    levels","volume":"10","author":"M R Mavissakalian","year":"1990","journal-title":"J Clin Psychopharmacol"},{"key":"ref826","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1192\/bjp.136.2.161","article-title":"Clomipramine and exposure for compulsive rituals: II. Plasma levels, side\n                    effects and outcome","volume":"136","author":"R S Stern","year":"1980","journal-title":"Br J Psychiatry"},{"key":"ref827","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1001\/archpsyc.1983.04390010015002","article-title":"Obsessive-compulsive disorder. A double-blind trial of clomipramine and\n                    clorgyline","volume":"40","author":"T R Insel","year":"1983","journal-title":"Arch Gen Psychiatry"},{"key":"ref828","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000069089","article-title":"Comparative single-dose pharmacokinetics of clonazepam following intravenous,\n                    intramuscular and oral administration to healthy volunteers","volume":"49","author":"C Crevoisier","year":"2003","journal-title":"Eur Neurol"},{"key":"ref829","first-page":"219","article-title":"[Therapeutic drug monitoring of clonazepam]","volume":"65","author":"D Debruyne","year":"2010","journal-title":"Therapie"},{"key":"ref830","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s40120-023-00567-5","article-title":"Bioequivalence Study of Two Tablet Formulations of Clonazepam 2 mg: A\n                    Randomized, Open-Label, Crossover Study in Healthy Mexican Volunteers Under\n                    Fasting Conditions","volume":"13","author":"L Genis-Najera","year":"2024","journal-title":"Neurol Ther"},{"key":"ref831","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1600-0404.1987.tb03545.x","article-title":"Clinical effects and plasma concentrations of long-term clonazepam monotherapy\n                    in previously untreated epileptics","volume":"76","author":"H Naito","year":"1987","journal-title":"Acta Neurol Scand"},{"key":"ref832","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF00434406","article-title":"Pharmacokinetics of dipotassium chlorazepate in patients after repeated 50 mg\n                    oral doses","volume":"71","author":"A Bertler","year":"1980","journal-title":"Psychopharmacology (Berl)"},{"key":"ref833","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/j.1552-4604.1988.tb03228.x","article-title":"Desmethyldiazepam pharmacokinetics: studies following intravenous and oral\n                    desmethyldiazepam, oral clorazepate, and intravenous diazepam","volume":"28","author":"D J Greenblatt","year":"1988","journal-title":"J Clin Pharmacol"},{"key":"ref834","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/BF01735933","article-title":"Desmethyldiazepam kinetics after intravenous, intramuscular, and oral\n                    administration of clorazepate dipotassium","volume":"60","author":"H R Ochs","year":"1982","journal-title":"Klin Wochenschr"},{"key":"ref835","first-page":"411","article-title":"Plasma concentrations and clinical effects after single oral doses of prazepam,\n                    clorazepate, and diazepam","volume":"45","author":"R I Shader","year":"1984","journal-title":"J Clin Psychiatry"},{"key":"ref836","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1192\/bjp.2023.27","article-title":"Optimising plasma clozapine levels to improve treatment response: an individual\n                    patient data meta-analysis and receiver operating characteristic curve\n                    analysis","volume":"222","author":"K Northwood","year":"2023","journal-title":"Br J Psychiatry"},{"key":"ref837","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1177\/2045125311405566","article-title":"Clozapine-related EEG changes and seizures: dose and plasma-level\n                    relationships","volume":"1","author":"S Varma","year":"2011","journal-title":"Ther Adv Psychopharmacol"},{"key":"ref838","volume-title":"The Maudsley prescribing guidelines in psychiatry","author":"D M Taylor","year":"2025"},{"key":"ref839","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1080\/17512433.2019.1617695","article-title":"A comprehensive review of the clinical utility of and a combined analysis of the\n                    clozapine\/norclozapine ratio in therapeutic drug monitoring for adult\n                    patients","volume":"12","author":"G Schoretsanitis","year":"2019","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref841","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1176\/ajp.153.12.1579","article-title":"Response of patients with treatment-refractory schizophrenia to clozapine within\n                    three serum level ranges","volume":"153","author":"C VanderZwaag","year":"1996","journal-title":"Am J Psychiatry"},{"key":"ref842","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00213-020-05746-y","article-title":"A systematic review and meta-analysis of the association between clozapine and\n                    norclozapine serum levels and peripheral adverse drug reactions","volume":"238","author":"MS A Tan","year":"2021","journal-title":"Psychopharmacology (Berl)"},{"key":"ref843","doi-asserted-by":"crossref","first-page":"e13248","DOI":"10.1111\/jsr.13248","article-title":"Effect of the novel dual orexin receptor antagonist daridorexant on night-time\n                    respiratory function and sleep in patients with moderate chronic obstructive\n                    pulmonary disease","volume":"30","author":"M L Boof","year":"2021","journal-title":"J Sleep Res"},{"key":"ref844","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s40261-021-01062-1","article-title":"Impact of Daridorexant, a Dual Orexin Receptor Antagonist, on Cardiac\n                    Repolarization Following Bedtime Dosing: Results from a Thorough QT Study Using\n                    Concentration-QT Analysis","volume":"41","author":"U Schilling","year":"2021","journal-title":"Clin Drug Investig"},{"key":"ref845","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1007\/s40263-020-00768-8","article-title":"Pharmacological Interactions between the Dual Orexin Receptor Antagonist\n                    Daridorexant and Ethanol in a Double-Blind, Randomized, Placebo-Controlled,\n                    Double-Dummy, Four-Way Crossover Phase I Study in Healthy Subjects","volume":"34","author":"B Berger","year":"2020","journal-title":"CNS Drugs"},{"key":"ref846","first-page":"44","article-title":"Effect of the new dual orexin receptor antagonist daridorexant on nighttime\n                    respiratory function and sleep in patients with mild and moderate obstructive\n                    sleep apnea","author":"M L Boof","year":"2021","journal-title":"Sleep"},{"key":"ref847","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1111\/cts.13079","article-title":"Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not\n                    affected by renal impairment","volume":"14","author":"B Berger","year":"2021","journal-title":"Clin Transl Sci"},{"key":"ref848","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1177\/0269881119882854","article-title":"Clinical pharmacology of the dual orexin receptor antagonist ACT-541468 in\n                    elderly subjects: Exploration of pharmacokinetics, pharmacodynamics and\n                    tolerability following single-dose morning and repeated-dose evening\n                    administration","volume":"34","author":"C Muehlan","year":"2020","journal-title":"J Psychopharmacol"},{"key":"ref849","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0304-3959(99)00082-2","article-title":"Effects of noradrenergic and serotonergic antidepressants on chronic low back\n                    pain intensity","volume":"83","author":"J H Atkinson","year":"1999","journal-title":"Pain"},{"key":"ref850","first-page":"160","article-title":"Tricyclic antidepressant-induced seizures and plasma drug concentration","volume":"53","author":"S H Preskorn","year":"1992","journal-title":"J Clin Psychiatry"},{"key":"ref851","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s002280050220","article-title":"Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical\n                    response to desipramine: a prospective study","volume":"51","author":"E Spina","year":"1997","journal-title":"Eur J Clin Pharmacol"},{"key":"ref852","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/00004850-199612000-00002","article-title":"2-Hydroxydesipramine and desipramine plasma levels: how are they related to\n                    antidepressant response?","volume":"11","author":"S L Stern","year":"1996","journal-title":"Int Clin Psychopharmacol"},{"key":"ref853","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00213-023-06484-7","article-title":"Venlafaxine's therapeutic reference range in the treatment of depression\n                    revised: a systematic review and meta-analysis","volume":"241","author":"X M Lense","year":"2024","journal-title":"Psychopharmacology (Berl)"},{"key":"ref854","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2143\/ACB.3323","article-title":"Plasma level monitoring of the major metabolites of diacetylmorphine (heroin) by\n                    the \"chasing the dragon\" route in severe heroin addicts","volume":"68","author":"N Dubois","year":"2013","journal-title":"Acta Clin Belg"},{"key":"ref855","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/jat\/bkv001","article-title":"Estimation of the Time Interval between the Administration of Heroin and the\n                    Sampling of Blood in Chronic Inhalers","volume":"39","author":"N Dubois","year":"2015","journal-title":"J Anal Toxicol"},{"key":"ref856","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/BF00426470","article-title":"Benzodiazepine overdosage: plasma concentrations and clinical outcome","volume":"73","author":"M Divoll","year":"1981","journal-title":"Psychopharmacology (Berl)"},{"key":"ref857","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/clpt.1992.123","article-title":"Pharmacokinetics and pharmacodynamics of oral diazepam: effect of dose, plasma\n                    concentration, and time","volume":"52","author":"H Friedman","year":"1992","journal-title":"Clin Pharmacol Ther"},{"key":"ref858","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1097\/00007691-198911000-00007","article-title":"A large-sample study of diazepam pharmacokinetics","volume":"11","author":"D J Greenblatt","year":"1989","journal-title":"Ther Drug Monit"},{"key":"ref859","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/cpdd.767","article-title":"Evaluation of Pharmacokinetics and Dose Proportionality of Diazepam After\n                    Intranasal Administration of NRL-1 to Healthy Volunteers","volume":"9","author":"S Tanimoto","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"key":"ref860","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/clpt.1989.3","article-title":"The pharmacodynamics of diphenhydramine-induced drowsiness and changes in mental\n                    performance","volume":"45","author":"F Gengo","year":"1989","journal-title":"Clin Pharmacol Ther"},{"key":"ref861","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/j.1552-4604.1990.tb01871.x","article-title":"Diphenhydramine: pharmacokinetics and pharmacodynamics in elderly adults, young\n                    adults, and children","volume":"30","author":"K J Simons","year":"1990","journal-title":"J Clin Pharmacol"},{"key":"ref862","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/clpt.1984.213","article-title":"Elimination kinetics of disulfiram in alcoholics after single and repeated\n                    doses","volume":"36","author":"M D Faiman","year":"1984","journal-title":"Clin Pharmacol Ther"},{"key":"ref863","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/FTD.0000000000000152","article-title":"Therapeutic drug monitoring for patients with Alzheimer dementia to improve\n                    treatment with donepezil","volume":"37","author":"G Hefner","year":"2015","journal-title":"Ther Drug Monit"},{"key":"ref864","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/FTD.0000000000000823","article-title":"Impact of CYP2D6, CYP3A5, and ABCB1 Polymorphisms on Plasma Concentrations of\n                    Donepezil and Its Metabolite in Patients With Alzheimer Disease","volume":"43","author":"Y Kagawa","year":"2021","journal-title":"Ther Drug Monit"},{"key":"ref865","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.2147\/DDDT.S247259","article-title":"Therapeutic Drug Monitoring of Rivastigmine and Donepezil Under Consideration of\n                    CYP2D6 Genotype-Dependent Metabolism of Donepezil","volume":"14","author":"M Ortner","year":"2020","journal-title":"Drug Des Devel Ther"},{"key":"ref866","first-page":"209","article-title":"Influence of CYP2D6, CYP3A5, ABCB1, APOE polymorphisms and nongenetic factors on\n                    donepezil treatment in patients with Alzheimer's disease and vascular\n                    dementia","volume":"12","author":"T Yaowaluk","year":"2019","journal-title":"Pharmgenomics Pers Med"},{"key":"ref867","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/MAJ.0b013e318255a8f9","article-title":"Effect of CYP2D6*10 and APOE polymorphisms on the efficacy of donepezil in\n                    patients with Alzheimer's disease","volume":"345","author":"Y Zhong","year":"2013","journal-title":"Am J Med Sci"},{"key":"ref868","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3389\/fphar.2020.00691","article-title":"Serum Concentrations of Cholinesterase Inhibitors in Patients With\n                    Alzheimer's Dementia Are Frequently Below the Recommended Levels","volume":"11","author":"M Ortner","year":"2020","journal-title":"Front Pharmacol"},{"key":"ref869","doi-asserted-by":"crossref","first-page":"379","DOI":"10.33549\/physiolres.930435","article-title":"QT dispersion and electrical heart field morphology in patients treated with\n                    dosulepin","volume":"53","author":"O Kittnar","year":"2004","journal-title":"Physiol Res"},{"key":"ref870","first-page":"123","article-title":"Dothiepin. A review of its pharmacodynamic and pharmacokinetic properties, and\n                    therapeutic efficacy in depressive illness","volume":"38","author":"S G Lancaster","year":"1989","journal-title":"Drugs"},{"key":"ref871","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/00007691-199310000-00001","article-title":"Plasma concentrations of dothiepin and its metabolites are not correlated with\n                    clinical efficacy in major depressive illness","volume":"15","author":"K F Ilett","year":"1993","journal-title":"Ther Drug Monit"},{"key":"ref872","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/FTD.0b013e318184525b","article-title":"Toxicokinetics of dothiepin: 2 case reports","volume":"30","author":"E E Roelofsen","year":"2008","journal-title":"Ther Drug Monit"},{"key":"ref873","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/00004714-200108000-00011","article-title":"Doxepin plasma concentrations: is there really a therapeutic range?","volume":"21","author":"S Leucht","year":"2001","journal-title":"J Clin Psychopharmacol"},{"key":"ref874","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s40268-018-0232-1","article-title":"A Phase I Study of the Pharmacokinetics and Pharmacodynamics of Intranasal\n                    Doxylamine in Subjects with Chronic Intermittent Sleep Impairment","volume":"18","author":"M Allison","year":"2018","journal-title":"Drugs R D"},{"key":"ref875","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s40268-013-0015-7","article-title":"Pharmacokinetic dose proportionality between two strengths (12.5 mg and 25 mg)\n                    of doxylamine hydrogen succinate film-coated tablets in fasting state: a\n                    single-dose, randomized, two-period crossover study in healthy volunteers","volume":"13","author":"S Videla","year":"2013","journal-title":"Drugs R D"},{"key":"ref876","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2165\/11641640-000000000-00000","article-title":"Food effects on the pharmacokinetics of doxylamine hydrogen succinate 25\u2009mg\n                    film-coated tablets: a single-dose, randomized, two-period crossover study in\n                    healthy volunteers","volume":"12","author":"S Videla","year":"2012","journal-title":"Drugs R D"},{"key":"ref877","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/j.1552-4604.1985.tb02875.x","article-title":"The pharmacokinetics of doxylamine: use of automated gas chromatography with\n                    nitrogen-phosphorus detection","volume":"25","author":"H Friedman","year":"1985","journal-title":"J Clin Pharmacol"},{"key":"ref879","doi-asserted-by":"crossref","first-page":"104077","DOI":"10.1016\/j.nsa.2024.104077","article-title":"Therapeutic reference range for duloxetine in the treatment of depression\n                    revised: A systematic review and meta-analysis","volume":"3","author":"F Amann","year":"2024","journal-title":"Neuroscience Applied"},{"key":"ref880","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.pnpbp.2019.01.001","article-title":"Duloxetine plasma level and antidepressant response","volume":"92","author":"D De Donatis","year":"2019","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref881","doi-asserted-by":"crossref","first-page":"972141","DOI":"10.3389\/fpsyt.2022.972141","article-title":"Systematic review and meta-analysis on the therapeutic reference range for\n                    escitalopram: Blood concentrations, clinical effects and serotonin transporter\n                    occupancy","volume":"13","author":"L Eichentopf","year":"2022","journal-title":"Front Psychiatry"},{"key":"ref882","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s40268-016-0148-6","article-title":"An Updated Overview on Therapeutic Drug Monitoring of Recent Antiepileptic","volume":"16","author":"S Jacob","year":"2016","journal-title":"Drugs. Drugs R D"},{"key":"ref883","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s40265-016-0570-7","article-title":"Eslicarbazepine Acetate Monotherapy: A Review in Partial-Onset Seizures","volume":"76","author":"M Shirley","year":"2016","journal-title":"Drugs"},{"key":"ref884","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/BF00428318","article-title":"Single- and multiple-dose kinetics of estazolam, a triazolo benzodiazepine","volume":"66","author":"M D Allen","year":"1979","journal-title":"Psychopharmacology (Berl)"},{"key":"ref885","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0278-5846(02)00357-3","article-title":"Effects of the CYP2C19 genotype and cigarette smoking on the single oral dose\n                    pharmacokinetics and pharmacodynamics of estazolam","volume":"27","author":"T Aoshima","year":"2003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref886","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/hup.936","article-title":"Next-day cognition, psychomotor function, and driving-related skills following\n                    nighttime administration of eszopiclone","volume":"23","author":"J Boyle","year":"2008","journal-title":"Hum Psychopharmacol"},{"key":"ref887","first-page":"441","article-title":"Eszopiclone: its use in the treatment of insomnia","volume":"3","author":"J M Monti","year":"2007","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref888","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s12325-009-0026-5","article-title":"The role of eszopiclone in the treatment of insomnia","volume":"26","author":"A K Morin","year":"2009","journal-title":"Adv Ther"},{"key":"ref889","first-page":"263","volume-title":"Eszopiclone: an update on its use in insomnia","author":"R T Owen","year":"2011"},{"key":"ref890","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1055\/s-0032-1327570","article-title":"Pharmacokinetics and safety of eszopiclone in healthy Chinese volunteers","volume":"62","author":"F Wu","year":"2012","journal-title":"Arzneimittelforschung"},{"key":"ref891","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1528-1157.1996.tb00026.x","article-title":"Felbamate levels in patients with epilepsy","volume":"37","author":"C L Harden","year":"1996","journal-title":"Epilepsia"},{"key":"ref892","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/bja\/52.4.437","article-title":"Comparison of the subjective effects and plasma concentrations following oral\n                    and i.m. administration of flunitrazepam in volunteers","volume":"52","author":"R S Clarke","year":"1980","journal-title":"Br J Anaesth"},{"key":"ref893","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.forsciint.2014.01.005","article-title":"Sedative and hypnotic drugs--fatal and non-fatal reference blood\n                    concentrations","volume":"236","author":"A K J\u00f6nsson","year":"2014","journal-title":"Forensic Sci Int"},{"key":"ref894","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00004850-199300810-00004","article-title":"Relationship between antidepressant response and plasma concentrations of\n                    fluoxetine and norfluoxetine","volume":"8","author":"T R Norman","year":"1993","journal-title":"Int Clin Psychopharmacol"},{"key":"ref895","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1176\/ajp.154.7.963","article-title":"Fluoxetine and norfluoxetine plasma concentrations in major depression: a\n                    multicenter study","volume":"154","author":"J D Amsterdam","year":"1997","journal-title":"Am J Psychiatry"},{"key":"ref896","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/00007691-198512000-00008","article-title":"Plasma flupentixol concentrations and clinical response in acute\n                    schizophrenia","volume":"7","author":"A E Balant-Gorgia","year":"1985","journal-title":"Ther Drug Monit"},{"key":"ref897","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/FTD.0000000000000585","article-title":"A Compilation of Serum Concentrations of 12 Antipsychotic Drugs in a Therapeutic\n                    Drug Monitoring Setting","volume":"41","author":"A K J\u00f6nsson","year":"2019","journal-title":"Ther Drug Monit"},{"key":"ref899","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00213-006-0611-0","article-title":"Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic\n                    patients treated with flupentixol in comparison with risperidone and\n                    haloperidol","volume":"190","author":"M Reimold","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"key":"ref901","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/BF00422403","article-title":"Fluphenazine pharmacokinetics and therapeutic response","volume":"73","author":"M W Dysken","year":"1981","journal-title":"Psychopharmacology (Berl)"},{"key":"ref902","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1176\/appi.ajp.2016.16040402","article-title":"The Role of Antipsychotic Plasma Levels in the Treatment of Schizophrenia","volume":"174","author":"M Horvitz-Lennon","year":"2017","journal-title":"Am J Psychiatry"},{"key":"ref903","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1176\/ajp.152.5.765","article-title":"Fluphenazine plasma levels, dosage, efficacy, and side effects","volume":"152","author":"D F Levinson","year":"1995","journal-title":"Am J Psychiatry"},{"key":"ref904","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1192\/bjp.158.5.658","article-title":"Plasma levels of fluphenazine in patients receiving fluphenazine decanoate.\n                    Relationship to clinical response","volume":"158","author":"S R Marder","year":"1991","journal-title":"Br J Psychiatry"},{"key":"ref905","first-page":"370","article-title":"Fluphenazine plasma levels and clinical response","volume":"45","author":"M L Mavroidis","year":"1984","journal-title":"J Clin Psychiatry"},{"key":"ref906","doi-asserted-by":"crossref","first-page":"287","DOI":"10.9740\/mhc.2019.07.287","article-title":"A review of a recently published guidelines' \"strong\n                    recommendation\" for therapeutic drug monitoring of olanzapine, haloperidol,\n                    perphenazine, and fluphenazine","volume":"9","author":"C Noel","year":"2019","journal-title":"Ment Health Clin"},{"key":"ref907","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/BF00433729","article-title":"A depot neuroleptic withdrawal study. Plasma concentration of fluphenazine and\n                    flupenthixol and relapse frequency","volume":"78","author":"B Wistedt","year":"1982","journal-title":"Psychopharmacology (Berl)"},{"key":"ref908","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1017\/S1461145798001229","article-title":"D(2)- and 5-HT(2) receptor occupancy in high-dose neuroleptic-treated\n                    patients","volume":"1","author":"S Nyberg","year":"1998","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref909","first-page":"50","article-title":"Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic\n                    approaches","volume":"45","author":"L Ereshefsky","year":"1984","journal-title":"J Clin Psychiatry"},{"key":"ref910","doi-asserted-by":"crossref","first-page":"68s","DOI":"10.1097\/00004714-199008001-00011","article-title":"Plasma concentrations of flurazepam and midazolam in chronic insomniacs during\n                    14-day use and their relationship to therapeutic effects and next-day\n                    performance and mood","volume":"10","author":"E Ellinwood","year":"1990","journal-title":"J Clin Psychopharmacol"},{"key":"ref911","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1002\/jps.2600621205","article-title":"Blood level profile in man following chronic oral administration of flurazepam\n                    hydrochloride","volume":"62","author":"S A Kaplan","year":"1973","journal-title":"J Pharm Sci"},{"key":"ref912","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/01.jcp.0000116646.91923.2f","article-title":"Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and\n                    analysis of CYP1A2 gene","volume":"24","author":"C B Eap","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"ref913","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0924-977X(93)90290-3","article-title":"Plasma concentrations of fluvoxamine and maprotiline in major depression:\n                    implications on therapeutic efficacy and side effects","volume":"3","author":"S Kasper","year":"1993","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref914","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1023\/A:1022410306577","article-title":"Antidepressant response and fluvoxamine plasma concentrations: a pilot\n                    study","volume":"25","author":"F Schwarzenbach","year":"2003","journal-title":"Pharm World Sci"},{"key":"ref915","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1001\/archpsyc.60.4.386","article-title":"High levels of serotonin transporter occupancy with low-dose clomipramine in\n                    comparative occupancy study with fluvoxamine using positron emission\n                    tomography","volume":"60","author":"T Suhara","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"ref916","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/JCP.0b013e3181730850","article-title":"Concentration-response relationship for fluvoxamine using remission as an\n                    endpoint: a receiver operating characteristics curve analysis in major\n                    depression","volume":"28","author":"Y Suzuki","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"ref917","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1002\/phar.2012","article-title":"Factors in Variability of Serial Gabapentin Concentrations in Elderly Patients\n                    with Epilepsy","volume":"37","author":"J M Conway","year":"2017","journal-title":"Pharmacotherapy"},{"key":"ref918","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.seizure.2015.02.017","article-title":"Experience from therapeutic drug monitoring and gender aspects of gabapentin and\n                    pregabalin in clinical practice","volume":"28","author":"C Johannessen Landmark","year":"2015","journal-title":"Seizure"},{"key":"ref919","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1111\/bcp.15352","article-title":"Fatalities associated with gabapentinoids in England (2004-2020)","volume":"88","author":"N J Kalk","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"ref920","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/FTD.0000000000000935","article-title":"Interindividual Variability in the Bioavailability of Gabapentin Enacarbil\n                    Extended Release in Healthy Adults: An Analysis of Data From 6 Phase I\n                    Studies","volume":"44","author":"R Lal","year":"2022","journal-title":"Ther Drug Monit"},{"key":"ref921","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/ane.13075","article-title":"Therapeutic drug monitoring of gabapentin in various indications","volume":"139","author":"M Larsen Burns","year":"2019","journal-title":"Acta Neurol Scand"},{"key":"ref922","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2165\/00003088-200241100-00003","article-title":"Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors","volume":"41","author":"M W Jann","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"ref923","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1177\/0091270005274551","article-title":"Steady-state pharmacokinetics of galantamine are not affected by addition of\n                    memantine in healthy subjects","volume":"45","author":"C Yao","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"ref924","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/FTD.0b013e318282ff02","article-title":"Relationship of CYP2D6, CYP3A, POR, and ABCB1 genotypes with galantamine plasma\n                    concentrations","volume":"35","author":"M Noetzli","year":"2013","journal-title":"Ther Drug Monit"},{"key":"ref925","doi-asserted-by":"crossref","first-page":"e6887","DOI":"10.7717\/peerj.6887","article-title":"Galantamine plasma concentration and cognitive response in Alzheimer's\n                    disease","volume":"7","author":"Y T Lin","year":"2019","journal-title":"PeerJ"},{"key":"ref927","doi-asserted-by":"crossref","first-page":"e21214","DOI":"10.1016\/j.heliyon.2023.e21214","article-title":"A bibliometric and thematic analysis of the trends in the research on ginkgo\n                    biloba extract from 1985 to 2022","volume":"9","author":"H J Ji","year":"2023","journal-title":"Heliyon"},{"key":"ref928","doi-asserted-by":"crossref","first-page":"155352","DOI":"10.1016\/j.phymed.2024.155352","article-title":"The molecular mechanisms of ginkgo (Ginkgo biloba) activity in signaling\n                    pathways: A comprehensive review","volume":"126","author":"A Mohammadi Zonouz","year":"2024","journal-title":"Phytomedicine"},{"key":"ref929","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00702-024-02749-3","article-title":"Multi-target drugs for the treatment of cognitive impairment and fatigue in\n                    post-COVID syndrome: focus on Ginkgo biloba and Rhodiola rosea","volume":"131","author":"J K Mueller","year":"2024","journal-title":"J Neural Transm (Vienna)"},{"key":"ref930","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jad.2016.12.048","article-title":"Clinical use of Hypericum perforatum (St John's wort) in depression: A\n                    meta-analysis","volume":"210","author":"Q X Ng","year":"2017","journal-title":"J Affect Disord"},{"key":"ref931","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00210-023-02602-6","article-title":"Critical analysis of ginkgo preparations: comparison of approved drugs and\n                    dietary supplements marketed in Germany","volume":"397","author":"M Trabert","year":"2024","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref932","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1055\/s-0031-1298536","article-title":"Phenotyping studies to assess the effects of phytopharmaceuticals on in vivo\n                    activity of main human cytochrome p450 enzymes","volume":"78","author":"G Zadoyan","year":"2012","journal-title":"Planta Med"},{"key":"ref933","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s40261-017-0527-y","article-title":"Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of\n                    Guanfacine Extended-Release Formulation in Healthy Japanese and Caucasian Male\n                    Adults","volume":"37","author":"Y Matsuo","year":"2017","journal-title":"Clin Drug Investig"},{"key":"ref934","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1089\/cap.2020.0033","article-title":"Pediatric Guanfacine Toxicity with Severely Elevated Plasma Concentration","volume":"30","author":"J W Downs","year":"2020","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"ref935","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archpsyc.1988.01800250087012","article-title":"Central D2-dopamine receptor occupancy in schizophrenic patients treated with\n                    antipsychotic drugs","volume":"45","author":"L Farde","year":"1988","journal-title":"Arch Gen Psychiatry"},{"key":"ref936","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/BF02244811","article-title":"Time course of D2-dopamine receptor occupancy examined by PET after single oral\n                    doses of haloperidol","volume":"106","author":"A L Nordstr\u00f6m","year":"1992","journal-title":"Psychopharmacology (Berl)"},{"key":"ref937","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/JCP.0000000000001131","article-title":"Dopamine D2 Receptor Occupancy Estimated From Plasma Concentrations of Four\n                    Different Antipsychotics and the Subjective Experience of Physical and Mental\n                    Well-Being in Schizophrenia: Results From the Randomized NeSSy Trial","volume":"39","author":"T Veselinovi\u0107","year":"2019","journal-title":"J Clin Psychopharmacol"},{"key":"ref938","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/00004714-199410000-00003","article-title":"Haloperidol: therapeutic window in schizophrenia","volume":"14","author":"D J Palao","year":"1994","journal-title":"J Clin Psychopharmacol"},{"key":"ref939","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1055\/s-2007-1014421","article-title":"Haloperidol and lorazepam combined: clinical effects and drug plasma levels in\n                    the treatment of acute schizophrenic psychosis","volume":"25","author":"A Stevens","year":"1992","journal-title":"Pharmacopsychiatry"},{"key":"ref940","first-page":"13","article-title":"Haloperidol blood levels and effects in schizophrenia and schizoaffective\n                    disorder: a progress report","volume":"26","author":"J Volavka","year":"1990","journal-title":"Psychopharmacol Bull"},{"key":"ref941","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00007691-198204000-00007","article-title":"Haloperidol plasma level monitoring in neuropsychiatric patients","volume":"4","author":"P L Morselli","year":"1982","journal-title":"Ther Drug Monit"},{"key":"ref942","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s002130050277","article-title":"The relationship between D2 receptor occupancy and plasma levels on low dose\n                    oral haloperidol: a PET study","volume":"131","author":"S Kapur","year":"1997","journal-title":"Psychopharmacology (Berl)"},{"key":"ref943","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s002139900333","article-title":"Predicting haloperidol occupancy of central dopamine D2 receptors from plasma\n                    levels","volume":"149","author":"P B Fitzgerald","year":"2000","journal-title":"Psychopharmacology (Berl)"},{"key":"ref944","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1097\/JCP.0b013e3182a4ee2c","article-title":"Population pharmacokinetic-pharmacodynamic modeling of haloperidol in patients\n                    with schizophrenia using positive and negative syndrome rating scale","volume":"33","author":"V Pilla Reddy","year":"2013","journal-title":"J Clin Psychopharmacol"},{"key":"ref945","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/JCP.0b013e31827c0314","article-title":"A thorough QTc study of 3 doses of iloperidone including metabolic inhibition\n                    via CYP2D6 and\/or CYP3A4 and a comparison to quetiapine and ziprasidone","volume":"33","author":"S G Potkin","year":"2013","journal-title":"J Clin Psychopharmacol"},{"key":"ref946","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00213-005-0098-0","article-title":"Imipramine dose in relation to therapeutic plasma level: are clinical trials\n                    using imipramine as a positive control flawed?","volume":"181","author":"T K Birkenh\u00e4ger","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"ref947","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/archpsyc.1977.01770140087010","article-title":"Clinical implications of imipramine plasma levels for depressive illness","volume":"34","author":"A H Glassman","year":"1977","journal-title":"Arch Gen Psychiatry"},{"key":"ref948","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/00004714-199408000-00002","article-title":"Tricyclic antidepressant concentrations in plasma: an estimate of their\n                    sensitivity and specificity as a predictor of response","volume":"14","author":"P J Perry","year":"1994","journal-title":"J Clin Psychopharmacol"},{"key":"ref949","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1097\/AJP.0000000000000497","article-title":"The Impact of Serum Drug Concentration on the Efficacy of Imipramine,\n                    Pregabalin, and their Combination in Painful Polyneuropathy","volume":"33","author":"S H Sindrup","year":"2017","journal-title":"Clin J Pain"},{"key":"ref950","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/s41386-020-0663-6","article-title":"Ketamine metabolites, clinical response, and gamma power in a randomized,\n                    placebo-controlled, crossover trial for treatment-resistant major\n                    depression","volume":"45","author":"C A Farmer","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"ref951","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jpsychires.2019.08.005","article-title":"Ketamine metabolite pilot study in a suicidal depression trial","volume":"117","author":"M F Grunebaum","year":"2019","journal-title":"J Psychiatr Res"},{"key":"ref952","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jpsychires.2019.08.005","article-title":"Corrigendum to\"Ketamine metabolite pilot study in a suicidal depression\n                    trial\"","volume":"117","author":"M F Grunebaum","year":"2019","journal-title":"J Psychiatr Res"},{"key":"ref953","first-page":"287","article-title":"Relationship of ketamine's antidepressant and psychotomimetic effects in\n                    unipolar depression","volume":"34","author":"P Sos","year":"2013","journal-title":"Neuro Endocrinol Lett"},{"key":"ref954","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1038\/npp.2017.94","article-title":"Dose-Related Effects of Adjunctive Ketamine in Taiwanese Patients with\n                    Treatment-Resistant Depression","volume":"42","author":"T P Su","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"ref955","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s41386-018-0253-z","article-title":"Correction: Dose-Related Effects of Adjunctive Ketamine in Taiwanese Patients\n                    with Treatment-Resistant Depression","volume":"44","author":"T P Su","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"ref956","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1097\/FTD.0b013e318290eacc","article-title":"Lacosamide therapeutic monitoring in patients with epilepsy: effect of\n                    concomitant antiepileptic drugs","volume":"35","author":"M Contin","year":"2013","journal-title":"Ther Drug Monit"},{"key":"ref957","first-page":"151","article-title":"[Therapeutic drug monitoring of lacosamide]","volume":"67","author":"D Bentu\u00e9-Ferrer","year":"2012","journal-title":"Therapie"},{"key":"ref958","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/FTD.0000000000000051","article-title":"Lacosamide serum concentrations in adult patients with epilepsy: the influence\n                    of gender, age, dose, and concomitant antiepileptic drugs","volume":"36","author":"S Markoula","year":"2014","journal-title":"Ther Drug Monit"},{"key":"ref959","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.eplepsyres.2011.03.019","article-title":"Fluctuation of lacosamide serum concentrations during the day and occurrence of\n                    adverse drug reactions--first clinical experience","volume":"95","author":"A Sattler","year":"2011","journal-title":"Epilepsy Res"},{"key":"ref960","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/WNF.0000000000000537","article-title":"Therapeutic Drug Monitoring of Lacosamide: Is 10 to 20 mg\/L a Suitable Reference\n                    Range for Patients With Epilepsy?","volume":"46","author":"S Otero Torres","year":"2023","journal-title":"Clin Neuropharmacol"},{"key":"ref961","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1046\/j.1365-2125.1998.00835.x","article-title":"Lamotrigine and therapeutic drug monitoring: retrospective survey following the\n                    introduction of a routine service","volume":"46","author":"R G Morris","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"ref962","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1212\/01.WNL.0000138424.33979.0C","article-title":"Correlating lamotrigine serum concentrations with tolerability in patients with\n                    epilepsy","volume":"63","author":"L J Hirsch","year":"2004","journal-title":"Neurology"},{"key":"ref963","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1097\/FTD.0000000000000088","article-title":"Relationship between plasma concentrations of lamotrigine and its early\n                    therapeutic effect of lamotrigine augmentation therapy in treatment-resistant\n                    depressive disorder","volume":"36","author":"S Kagawa","year":"2014","journal-title":"Ther Drug Monit"},{"key":"ref964","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1055\/s-0034-1375618","article-title":"Therapeutic window of lamotrigine for mood disorders: a naturalistic\n                    retrospective study","volume":"47","author":"Y Katayama","year":"2014","journal-title":"Pharmacopsychiatry"},{"key":"ref965","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1055\/s-0035-1559635","article-title":"Retrospective analysis of therapeutic drug monitoring data for\n                    treatment of bipolar disorder with lamotrigine","volume":"48","author":"S Unholzer","year":"2015","journal-title":"Pharmacopsychiatry"},{"key":"ref966","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1055\/s-0035-1565223","article-title":"Retrospective analysis of therapeutic drug monitoring data for treatment of\n                    bipolar disorder with lamotrigine","volume":"48","author":"S Unholzer","year":"2015","journal-title":"Pharmacopsychiatry"},{"key":"ref967","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1124\/dmd.120.000229","article-title":"Disposition and Metabolism of [(14)C]Lemborexant in Healthy Human Subjects and\n                    Characterization of Its Circulating Metabolites","volume":"49","author":"T Ueno","year":"2021","journal-title":"Drug Metab Dispos"},{"key":"ref968","doi-asserted-by":"crossref","first-page":"e00758","DOI":"10.1002\/prp2.758","article-title":"Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of\n                    lemborexant","volume":"9","author":"S Dayal","year":"2021","journal-title":"Pharmacol Res Perspect"},{"key":"ref969","doi-asserted-by":"crossref","first-page":"e00734","DOI":"10.1002\/prp2.734","article-title":"Effect of severe renal impairment on pharmacokinetics, safety, and tolerability\n                    of lemborexant","volume":"9","author":"I Landry","year":"2021","journal-title":"Pharmacol Res Perspect"},{"key":"ref970","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/cpdd.817","article-title":"Pharmacokinetics, Pharmacodynamics, and Safety of the Dual Orexin Receptor\n                    Antagonist Lemborexant: Findings From Single-Dose and Multiple-Ascending-Dose\n                    Phase 1 Studies in Healthy Adults","volume":"10","author":"I Landry","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"key":"ref971","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/cpdd.953","article-title":"Effects of Lemborexant on the Pharmacokinetics of Oral Contraceptives: Results\n                    From a Phase 1 Drug-Drug Interaction Study in Healthy Females","volume":"10","author":"I Landry","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"key":"ref972","first-page":"42","article-title":"On-the-road driving performance the morning after bedtime administration of\n                    lemborexant in healthy adult and elderly volunteers","author":"A Vermeeren","year":"2019","journal-title":"Sleep"},{"key":"ref973","doi-asserted-by":"crossref","first-page":"zpab011","DOI":"10.1093\/sleepadvances\/zpab011","article-title":"Assessment of morning sleep propensity with lemborexant in adults with insomnia\n                    disorder in a randomized, placebo-controlled crossover study","volume":"2","author":"D Mayleben","year":"2021","journal-title":"Sleep Adv"},{"key":"ref974","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.seizure.2020.03.009","article-title":"Correlation of levetiracetam concentration in peripheral blood mononuclear cells\n                    with clinical efficacy: A sensitive monitoring biomarker in patients with\n                    epilepsy","volume":"78","author":"S A Harby","year":"2020","journal-title":"Seizure"},{"key":"ref975","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/FTD.0b013e318157032d","article-title":"Therapeutic drug monitoring of levetiracetam by high-performance liquid\n                    chromatography with photodiode array ultraviolet detection: preliminary\n                    observations on correlation between plasma concentration and clinical response\n                    in patients with refractory epilepsy","volume":"29","author":"F Lancelin","year":"2007","journal-title":"Ther Drug Monit"},{"key":"ref976","first-page":"14","article-title":"Levetiracetam Therapeutic Drug Monitoring in a Large Cohort of Korean Epileptic\n                    Patients","author":"C Ha","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref977","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1097\/FTD.0000000000000731","article-title":"What Are the Predictors for Achieving Therapeutic Levetiracetam Serum\n                    Concentrations in Adult Neurological Patients?","volume":"42","author":"M O Cotta","year":"2020","journal-title":"Ther Drug Monit"},{"key":"ref978","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1592\/phco.31.10.934","article-title":"Steady-state pharmacokinetics of intravenous levetiracetam in neurocritical care\n                    patients","volume":"31","author":"D D Spencer","year":"2011","journal-title":"Pharmacotherapy"},{"key":"ref979","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2165\/00003088-200443110-00002","article-title":"Clinical pharmacokinetics of levetiracetam","volume":"43","author":"P N Patsalos","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"ref980","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/FTD.0000000000000158","article-title":"Therapeutic Drug Monitoring of Levetiracetam and Lamotrigine: Is There a\n                    Need?","volume":"37","author":"G S Naik","year":"2015","journal-title":"Ther Drug Monit"},{"key":"ref981","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.seizure.2014.02.003","article-title":"Measurement of levetiracetam drug levels to assist with seizure control and\n                    monitoring of drug interactions with other anti-epileptic medications\n                    (AEMs)","volume":"23","author":"D Stepanova","year":"2014","journal-title":"Seizure"},{"key":"ref982","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.braindev.2014.11.008","article-title":"The efficacy of levetiracetam for focal seizures and its blood levels in\n                    children","volume":"37","author":"T Iwasaki","year":"2015","journal-title":"Brain Dev"},{"key":"ref983","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.yebeh.2018.08.026","article-title":"Levetiracetam circulating concentrations and response in status epilepticus","volume":"88","author":"M Perrenoud","year":"2018","journal-title":"Epilepsy Behav"},{"key":"ref984","first-page":"43","article-title":"Effective Levetiracetam doses and serum concentrations: age effects","author":"I E Leppik","year":"2002","journal-title":"Epilepsia"},{"key":"ref985","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/j.1528-1167.2008.01974.x","article-title":"Population pharmacokinetics of levetiracetam and dosing recommendation in\n                    children with epilepsy","volume":"50","author":"S Chhun","year":"2009","journal-title":"Epilepsia"},{"key":"ref986","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.seizure.2023.05.010","article-title":"Therapeutic drug monitoring and the therapeutic reference range of levetiracetam\n                    for Chinese patients: Problems and issues","volume":"109","author":"M Shi","year":"2023","journal-title":"Seizure"},{"key":"ref987","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.seizure.2009.05.007","article-title":"Levetiracetam in children with refractory epilepsy: lack of correlation between\n                    plasma concentration and efficacy","volume":"18","author":"P C Giroux","year":"2009","journal-title":"Seizure"},{"key":"ref988","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2165\/00003088-200847050-00004","article-title":"Retrospective population pharmacokinetic analysis of levetiracetam in children\n                    and adolescents with epilepsy: dosing recommendations","volume":"47","author":"N Toublanc","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"ref989","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.braindev.2023.01.007","article-title":"Clinical value of therapeutic drug monitoring for levetiracetam in pediatric\n                    patients with epilepsy","volume":"45","author":"Y Yamamoto","year":"2023","journal-title":"Brain Dev"},{"key":"ref990","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s00702-024-02828-5","article-title":"Therapeutic drug monitoring in Parkinson's disease","volume":"131","author":"T M\u00fcller","year":"2024","journal-title":"J Neural Transm (Vienna)"},{"key":"ref991","doi-asserted-by":"crossref","first-page":"811","DOI":"10.3233\/JPD-202262","article-title":"Quantitative Assessment of Motor Response to a Low Subacute Levodopa Dose in the\n                    Differential Diagnosis of Parkinsonisms at Disease Onset: Data from the\n                    BoProPark Cohort","volume":"11","author":"M Contin","year":"2021","journal-title":"J Parkinsons Dis"},{"key":"ref992","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/ana.410210409","article-title":"Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's\n                    disease","volume":"21","author":"G Fabbrini","year":"1987","journal-title":"Ann Neurol"},{"key":"ref993","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1002\/mds.23861","article-title":"Crossover comparison of IPX066 and a standard levodopa formulation in advanced\n                    Parkinson's disease","volume":"26","author":"R A Hauser","year":"2011","journal-title":"Mov Disord"},{"key":"ref994","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/BF00607681","article-title":"R.E. Strandjord, and S. Sigfusson, Pharmacokinetics and relative bioavailability\n                    of levomepromazine after repeated administration of tablets and syru","volume":"11","author":"S G Dahl","year":"1977","journal-title":"Eur J Clin Pharmacol"},{"key":"ref995","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.clpt.2005.08.011","article-title":"Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and\n                    response to treatment","volume":"78","author":"S Crettol","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"ref996","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1007\/s40262-016-0415-2","article-title":"Population Genetic-Based Pharmacokinetic Modeling of Methadone and its\n                    Relationship with the QTc Interval in Opioid-Dependent Patients","volume":"55","author":"C Csajka","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"ref997","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00228-009-0706-8","article-title":"Cannabis and benzodiazepines as determinants of methadone trough plasma\n                    concentration variability in maintenance treatment: a transnational study","volume":"65","author":"R Hallinan","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"ref998","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s40261-014-0182-5","article-title":"Effect of hepatic impairment on the pharmacokinetics of levomilnacipran\n                    following a single oral dose of a levomilnacipran extended-release capsule in\n                    human participants","volume":"34","author":"L Chen","year":"2014","journal-title":"Clin Drug Investig"},{"key":"ref999","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.2147\/DDDT.S85418","article-title":"Effect of renal impairment on the pharmacokinetics of levomilnacipran following\n                    a single oral dose of levomilnacipran extended-release capsule in humans","volume":"9","author":"L Chen","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"ref1000","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/j.clinthera.2015.07.005","article-title":"Levomilnacipran Pharmacokinetics in Healthy Volunteers Versus Patients with\n                    Major Depressive Disorder and Implications for Norepinephrine and Serotonin\n                    Reuptake Inhibition","volume":"37","author":"L Chen","year":"2015","journal-title":"Clin Ther"},{"key":"ref1001","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/acps.13346","article-title":"Lithium concentration and recurrence risk during maintenance treatment of\n                    bipolar disorder: Multicenter cohort and meta-analysis","volume":"144","author":"C W Hsu","year":"2021","journal-title":"Acta Psychiatr Scand"},{"key":"ref1002","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.euroneuro.2022.01.112","article-title":"Differences in the prophylactic effect of serum lithium levels on depression and\n                    mania in bipolar disorder: A dose-response meta-analysis","volume":"58","author":"C W Hsu","year":"2022","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref1003","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/bdi.12714","article-title":"Delphi survey of maintenance lithium treatment in older adults with bipolar\n                    disorder: An ISBD task force report","volume":"21","author":"K I Shulman","year":"2019","journal-title":"Bipolar Disord"},{"key":"ref1004","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40345-023-00317-4","article-title":"High lithium concentration at delivery is a potential risk factor for adverse\n                    outcomes in breastfed infants: a retrospective cohort study","volume":"11","author":"E Whaites Heinonen","year":"2023","journal-title":"Int J Bipolar Disord"},{"key":"ref1005","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1055\/s-2001-15873","article-title":"Lithium augmentation in depressive patients not responding to selective\n                    serotonin reuptake inhibitors","volume":"34","author":"D Zullino","year":"2001","journal-title":"Pharmacopsychiatry"},{"key":"ref1006","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/bja\/53.5.517","article-title":"Plasma concentrations and clinical effects of lorazepam after oral\n                    administration","volume":"53","author":"E G Bradshaw","year":"1981","journal-title":"Br J Anaesth"},{"key":"ref1007","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/JCP.0000000000001715","article-title":"Characterization of Extended-Release Lorazepam: Pharmacokinetic Results Across\n                    Phase 1 Clinical Studies","volume":"43","author":"S J Mathew","year":"2023","journal-title":"J Clin Psychopharmacol"},{"key":"ref1008","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/BF03189433","article-title":"The pharmacokinetics and biotransformation of the new benzodiazepine\n                    lormetazepam in humans. I. Absorption, distribution, elimination and metabolism\n                    of lormetazepam-5-14C","volume":"4","author":"M H\u00fcmpel","year":"1979","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"ref1009","first-page":"99","article-title":"Lormetazepam--plasma concentrations in volunteers following sublingual and oral\n                    dosing","volume":"1","author":"D K Luscombe","year":"1984","journal-title":"Psychopharmacology Suppl"},{"key":"ref1010","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1365-2125.1984.tb05018.x","article-title":"Pharmacodynamic correlates of modified absorption: studies with\n                    lormetazepam","volume":"18","author":"D M Pierce","year":"1984","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"ref1011","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1016\/j.clinthera.2015.11.001","article-title":"Pharmacokinetics and Tolerability of Lurasidone in Children and Adolescents With\n                    Psychiatric Disorders","volume":"37","author":"R L Findling","year":"2025","journal-title":"Clin Ther"},{"key":"ref1012","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1097\/FTD.0000000000000048","article-title":"Effect of smoking on the pharmacokinetics of inhaled loxapine","volume":"36","author":"L H Takahashi","year":"2014","journal-title":"Ther Drug Monit"},{"key":"ref1013","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/s41386-018-0251-1","article-title":"Dopamine D(2) receptor occupancy of lumateperone (ITI-007): a Positron Emission\n                    Tomography Study in patients with schizophrenia","volume":"44","author":"K E Vanover","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"ref1014","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/hup.2338","article-title":"Effect of food on the pharmacokinetics of lurasidone: results of two randomized,\n                    open-label, crossover studies","volume":"28","author":"S Preskorn","year":"2013","journal-title":"Hum Psychopharmacol"},{"key":"ref1015","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00213-013-3103-z","article-title":"Determination of dopamine D\u2082 receptor occupancy by lurasidone using positron\n                    emission tomography in healthy male subjects","volume":"229","author":"D F Wong","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"key":"ref1016","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/pcn.13466","article-title":"Therapeutic Drug Monitoring of Lurasidone in Patients with Schizophrenia or\n                    Bipolar Disorder: A preliminary study","volume":"76","author":"C Y Huang","year":"2022","journal-title":"Psychiatry Clin Neurosci"},{"key":"ref1017","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1055\/s-2007-1019532","article-title":"Response to maprotiline treatment in depressive patients relationship to urinary\n                    MHPG excretion and plasma drug level","volume":"15","author":"H J Gaertner","year":"1982","journal-title":"Pharmacopsychiatria"},{"key":"ref1018","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/00007691-198612000-00003","article-title":"Plasma levels of maprotiline and zimelidine and their relationship to clinical\n                    response in depressed patients","volume":"8","author":"P D Hrdina","year":"1986","journal-title":"Ther Drug Monit"},{"key":"ref1019","first-page":"247","article-title":"Serum levels of maprotiline and its adverse effects on depressed patients","volume":"41","author":"K Kurata","year":"1987","journal-title":"Jpn J Psychiatry Neurol"},{"key":"ref1020","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1177\/070674378302800710","article-title":"Seizures associated with high maprotiline serum concentrations","volume":"28","author":"G Molnar","year":"1983","journal-title":"Can J Psychiatry"},{"key":"ref1021","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.seizure.2009.11.005","article-title":"Seizure risk associated with neuroactive drugs: data from the WHO adverse drug\n                    reactions database","volume":"19","author":"E Kumlien","year":"2010","journal-title":"Seizure"},{"key":"ref1022","first-page":"284","article-title":"Serum medazepam, diazepam, and N-desmethyldiazepam levels after single and\n                    multiple oral doses of medazepam","volume":"9","author":"M Viukari","year":"1977","journal-title":"Ann Clin Res"},{"key":"ref1023","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1600-079X.2011.00958.x","article-title":"Melatonin pharmacokinetics following two different oral surge-sustained release\n                    doses in older adults","volume":"52","author":"N S Gooneratne","year":"2012","journal-title":"J Pineal Res"},{"key":"ref1025","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/01.yic.0000166405.49473.70","article-title":"Antipsychotic drugs and QT prolongation","volume":"20","author":"C St\u00f6llberger","year":"2005","journal-title":"Int Clin Psychopharmacol"},{"key":"ref1026","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/JCP.0000000000000645","article-title":"Memantine Plasma Concentrations Among Patients With Dementia","volume":"37","author":"I H Gomolin","year":"2017","journal-title":"J Clin Psychopharmacol"},{"key":"ref1027","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2165\/00002512-200320060-00005","article-title":"Memantine","volume":"20","author":"B Jarvis","year":"2003","journal-title":"Drugs Aging"},{"key":"ref1028","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.clinthera.2008.04.005","article-title":"Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese\n                    volunteers using an analytic method of liquid chromatography-tandem mass\n                    spectrometry","volume":"30","author":"M Y Liu","year":"2008","journal-title":"Clin Ther"},{"key":"ref1029","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/FTD.0b013e31821126cf","article-title":"Simultaneous determination of antidementia drugs in human plasma for therapeutic\n                    drug monitoring","volume":"33","author":"M Noetzli","year":"2011","journal-title":"Ther Drug Monit"},{"key":"ref1030","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13011-021-00367-w","article-title":"Subjective symptoms and serum methadone concentrations: what should guide dose\n                    adjustments in methadone maintenance treatment? A naturalistic cohort study from\n                    Norway","volume":"16","author":"F Chalabianloo","year":"2021","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"ref1031","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/archinternmed.2010.26","article-title":"Substitution of (R,S)-methadone by (R)-methadone: Impact on QTc interval","volume":"170","author":"N Ansermot","year":"2010","journal-title":"Arch Intern Med"},{"key":"ref1032","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1046\/j.1365-2125.2000.00272.x","article-title":"Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance\n                    patients","volume":"50","author":"D J Foster","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"ref1033","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.drugalcdep.2005.06.005","article-title":"Therapeutic thresholds in methadone maintenance treatment: a receiver operating\n                    characteristic analysis","volume":"81","author":"R Hallinan","year":"2006","journal-title":"Drug Alcohol Depend"},{"key":"ref1034","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s002130050963","article-title":"Rated well-being in relation to plasma concentrations of l- and d-methadone in\n                    satisfied and dissatisfied patients on methadone maintenance treatment","volume":"143","author":"A J Hiltunen","year":"1999","journal-title":"Psychopharmacology (Berl)"},{"key":"ref1035","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1369-1600.2011.00349.x","article-title":"CYP2B6 SNPs are associated with methadone dose required for effective treatment\n                    of opioid addiction","volume":"18","author":"O Levran","year":"2013","journal-title":"Addict Biol"},{"key":"ref1036","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1007\/BF02244255","article-title":"Psychophysiological reactions in methadone maintenance patients do not correlate\n                    with methadone plasma levels","volume":"103","author":"N Loimer","year":"1991","journal-title":"Psychopharmacology (Berl)"},{"key":"ref1037","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1176\/ajp.144.10.1349","article-title":"Inadequate plasma concentrations in some high-dose methadone maintenance\n                    patients","volume":"144","author":"F S Tennant","year":"1987","journal-title":"Am J Psychiatry"},{"key":"ref1038","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/phar.2498","article-title":"Methadone-associated QT interval prolongation in patients undergoing maintenance\n                    therapy in an urban opioid treatment program","volume":"41","author":"E N Titus-Lay","year":"2021","journal-title":"Pharmacotherapy"},{"key":"ref1039","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/ajad.12423","article-title":"Methadone maintenance dose\/weight ratio, long QTc, and EKG screening","volume":"25","author":"J Westermeyer","year":"2016","journal-title":"Am J Addict"},{"key":"ref1040","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/BF00315479","article-title":"Steady-state pharmacokinetics of methadone in opioid addicts","volume":"44","author":"K Wolff","year":"1993","journal-title":"Eur J Clin Pharmacol"},{"key":"ref1041","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00115-007-2325-x","article-title":"[Therapeutic drug monitoring in epileptology and psychiatry]","volume":"79","author":"C Brandt","year":"2008","journal-title":"Nervenarzt"},{"key":"ref1042","doi-asserted-by":"publisher","first-page":"51S","DOI":"10.1111\/j.1365-2125.1983.tb02271.x","article-title":"Relationship between plasma concentration and effect of midazolam after oral and\n                    intravenous administration","volume":"16","author":"C Crevoisier","year":"1983","journal-title":"British Journal of Clinical Pharmacology"},{"key":"ref1043","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s13318-016-0346-1","article-title":"Methylphenidate for Treating ADHD: A Naturalistic Clinical Study of\n                    Methylphenidate Blood Concentrations in Children and Adults With Optimized\n                    Dosage","volume":"42","author":"M D Cherm\u00e1","year":"2017","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"ref1044","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1097\/JCP.0b013e3181744aa6","article-title":"Does chirality matter? pharmacodynamics of enantiomers of methylphenidate in\n                    patients with attention-deficit\/hyperactivity disorder","volume":"28","author":"D Quinn","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"ref1045","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1089\/cap.2008.0128","article-title":"Plasma methylphenidate concentrations in youths treated with high-dose osmotic\n                    release oral system formulation","volume":"20","author":"J R Stevens","year":"2010","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"ref1046","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/00007691-199802000-00002","article-title":"Steady state concentrations of the enantiomers of mianserin and\n                    desmethylmianserin in poor and in homozygous and heterozygous extensive\n                    metabolizers of debrisoquine","volume":"20","author":"C B Eap","year":"1998","journal-title":"Ther Drug Monit"},{"key":"ref1047","doi-asserted-by":"crossref","first-page":"71s","DOI":"10.1111\/j.1365-2125.1978.tb04579.x","article-title":"Relationship between mianserin plasma levels and antidepressant effect in a\n                    double-blind trial comparing a single night-time and divided daily dose\n                    regimens","volume":"5","author":"S Montgomery","year":"1978","journal-title":"Br J Clin Pharmacol"},{"key":"ref1048","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1365-2125.2008.03201.x","article-title":"Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in\n                    humans: usefulness of saliva as matrix for CYP3A phenotyping","volume":"66","author":"B Link","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"ref1049","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/aas.14077","article-title":"Serum concentration of oral midazolam as pediatric preanesthetic medication and\n                    factors related to the sedation level","volume":"66","author":"H Matsuda","year":"2022","journal-title":"Acta Anaesthesiol Scand"},{"key":"ref1050","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jflm.2007.12.006","article-title":"Fatal intoxication with milnacipran","volume":"15","author":"L Fanton","year":"2008","journal-title":"J Forensic Leg Med"},{"key":"ref1051","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/hup.484","article-title":"Milnacipran plasma levels and antidepressant response in Japanese major\n                    depressive patients","volume":"18","author":"H Higuchi","year":"2003","journal-title":"Hum Psychopharmacol"},{"key":"ref1052","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s13181-011-0167-1","article-title":"Cardiotoxicity and serotonin syndrome complicating a milnacipran overdose","volume":"7","author":"M Levine","year":"2011","journal-title":"J Med Toxicol"},{"key":"ref1053","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s40262-015-0355-2","article-title":"Single- and Multiple-Dose Milnacipran Pharmacokinetics in Healthy Han Chinese\n                    Volunteers","volume":"55","author":"C J Ruan","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"ref1054","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1055\/s-2005-864120","article-title":"Relationship between mirtazapine dose, plasma concentration, response, and side\n                    effects in clinical practice","volume":"38","author":"K Grasm\u00e4der","year":"2005","journal-title":"Pharmacopsychiatry"},{"key":"ref1055","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/01.ftd.0000158873.54100.d4","article-title":"Inter- and intraindividual pharmacokinetic variations of mirtazapine and its\n                    N-demethyl metabolite in patients treated for major depressive disorder: a\n                    6-month therapeutic drug monitoring study","volume":"27","author":"M Reis","year":"2005","journal-title":"Ther Drug Monit"},{"key":"ref1056","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1055\/s-0034-1383655","article-title":"Therapeutic drug monitoring of mirtazapine in a routine outpatient setting in\n                    Asian psychiatric patients","volume":"47","author":"W Myung","year":"2014","journal-title":"Pharmacopsychiatry"},{"key":"ref1057","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/00007691-200402000-00015","article-title":"Therapeutic drug monitoring of the antidepressant mirtazapine and its\n                    N-demethylated metabolite in human serum","volume":"26","author":"M Shams","year":"2004","journal-title":"Ther Drug Monit"},{"key":"ref1058","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/00007691-200406000-00010","article-title":"Therapeutic drug monitoring of mirtazapine and its metabolite\n                    desmethylmirtazapine by HPLC with fluorescence detection","volume":"26","author":"I Meineke","year":"2004","journal-title":"Ther Drug Monit"},{"key":"ref1059","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/jat\/30.9.687","article-title":"Therapeutic and toxic concentrations of mirtazapine","volume":"30","author":"C Kirkton","year":"2006","journal-title":"J Anal Toxicol"},{"key":"ref1060","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/JCP.0b013e3182664d98","article-title":"Multicenter study on the clinical effectiveness, pharmacokinetics, and\n                    pharmacogenetics of mirtazapine in depression","volume":"32","author":"E Jaquenoud Sirot","year":"2012","journal-title":"J Clin Psychopharmacol"},{"key":"ref1061","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s002130050754","article-title":"Clinical pharmacology of moclobemide during chronic administration of high doses\n                    to healthy subjects","volume":"140","author":"J Dingemanse","year":"1998","journal-title":"Psychopharmacology (Berl)"},{"key":"ref1062","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/BF00442818","article-title":"Plasma moclobemide and metabolites: lack of correlation with clinical response\n                    and biogenic amines","volume":"99","author":"J Fritze","year":"1989","journal-title":"Psychopharmacology (Berl)"},{"key":"ref1063","doi-asserted-by":"crossref","first-page":"84s","DOI":"10.1097\/00004714-199508001-00014","article-title":"Moclobemide: relationships between dose, drug concentration in plasma, and\n                    occurrence of adverse events","volume":"15","author":"T W Guentert","year":"1995","journal-title":"J Clin Psychopharmacol"},{"key":"ref1064","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s002130050481","article-title":"Inhibition of dextromethorphan metabolism by moclobemide","volume":"135","author":"S H\u00e4rtter","year":"1998","journal-title":"Psychopharmacology (Berl)"},{"key":"ref1065","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1365-2125.2008.03326.x","article-title":"Moclobemide monotherapy vs. combined therapy with valproic acid or carbamazepine\n                    in depressive patients: a pharmacokinetic interaction study","volume":"67","author":"A Rakic Ignjatovic","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"ref1066","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/BF02806017","article-title":"Initial monoamine oxidase-A inhibition by moclobemide does not predict the\n                    therapeutic response in patients with major depression. A double blind,\n                    randomized study","volume":"127","author":"F Radat","year":"1996","journal-title":"Psychopharmacology (Berl)"},{"key":"ref1067","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/FTD.0b013e31819114ea","article-title":"Serum concentrations of antidepressant drugs in a naturalistic setting:\n                    compilation based on a large therapeutic drug monitoring database","volume":"31","author":"M Reis","year":"2009","journal-title":"Ther Drug Monit"},{"key":"ref1068","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1365-2710.2008.00934.x","article-title":"Pharmacokinetics and tolerability of modafinil tablets in Chinese subjects","volume":"33","author":"P Xu","year":"2008","journal-title":"J Clin Pharm Ther"},{"key":"ref1069","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1185\/030079906X80378","article-title":"Pharmacodynamic effects on alertness of single doses of armodafinil in healthy\n                    subjects during a nocturnal period of acute sleep loss","volume":"22","author":"D F Dinges","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"ref1070","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s40261-022-01214-x","article-title":"Pharmacokinetics of Morphine Sulfate Orodispersible Tablets and Bioequivalence\n                    with Immediate-Release Oral Morphine Sulfate Formulations in Healthy Adult\n                    Subjects Under Fasting Conditions: Single-Dose Comparative Bioavailability\n                    Studies","volume":"42","author":"N Atrux-Tallau","year":"2022","journal-title":"Clin Drug Investig"},{"key":"ref1071","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/FTD.0000000000001112","article-title":"Oxycodone, Morphine, and Fentanyl in Patients With Chronic Pain: Proposal of\n                    Dose-Specific Concentration Ranges","volume":"45","author":"C H Thaulow","year":"2023","journal-title":"Ther Drug Monit"},{"key":"ref1072","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0376-8716(03)00190-X","article-title":"Comparative pharmacodynamics and pharmacokinetics of methadone and slow-release\n                    oral morphine for maintenance treatment of opioid dependence","volume":"72","author":"T B Mitchell","year":"2003","journal-title":"Drug Alcohol Depend"},{"key":"ref1073","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1124\/jpet.118.256115","article-title":"Fighting Fire with Fire: Development of Intranasal Nalmefene to Treat Synthetic\n                    Opioid Overdose","volume":"371","author":"P Krieter","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"ref1074","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/cpdd.1312","article-title":"Pharmacokinetic Properties of an FDA-approved Intranasal Nalmefene Formulation\n                    for the Treatment of Opioid Overdose","volume":"13","author":"R Crystal","year":"2024","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"02","key":"ref1075","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1097\/adm.0000000000001247","article-title":"Clinical Implications of the Relationship Between Naltrexone Plasma Levels and\n                    the Subjective Effects of Heroin in Humans","volume":"18","author":"F Castillo","year":"2023","journal-title":"J Add Med"},{"issue":"03","key":"ref1076","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.biopsych.2010.04.003","article-title":"Risk Factors for Craving and Relapse in Heroin Users Treated with Oral or\n                    Implant Naltrexone","volume":"68","author":"Gary K Hulse","year":"2010","journal-title":"Biol Psychiatry"},{"key":"ref1077","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/alcalc\/agy067","article-title":"Therapeutic Drug Monitoring of Naltrexone and 6\u03b2-Naltrexol During Anti-craving\n                    Treatment in Alcohol Dependence: Reference Ranges","volume":"54","author":"S Br\u00fcnen","year":"2019","journal-title":"Alcohol Alcohol"},{"key":"ref1078","first-page":"1385","article-title":"Serum 6-beta-naltrexol levels are related to alcohol responses in heavy\n                    drinkers","volume":"24","author":"M E McCaul","year":"2000","journal-title":"Alcohol Clin Exp Res"},{"key":"ref1079","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/clpt.2013.159","article-title":"Genetic and pharmacokinetic determinants of response to transdermal nicotine in\n                    white, black, and Asian nonsmokers","volume":"94","author":"D A Dempsey","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"ref1080","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/ntr\/ntr044","article-title":"Nicotine delivery and subjective effects of Swedish portion snus compared with 4\n                    mg nicotine polacrilex chewing gum","volume":"13","author":"E Lunell","year":"2011","journal-title":"Nicotine Tob Res"},{"key":"ref1081","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/BF00635899","article-title":"Residual effect of single and repeated doses of midazolam and nitrazepam in\n                    relation to their plasma concentrations","volume":"29","author":"O B Godtilbsen","year":"1986","journal-title":"Eur J Clin Pharmacol"},{"key":"ref1082","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/BF00563100","article-title":"Human pharmacokinetics of nitrazepam: effect of age and diseases","volume":"15","author":"L Kangas","year":"1979","journal-title":"Eur J Clin Pharmacol"},{"key":"ref1083","first-page":"307","article-title":"Influence of food and of age on nitrazepam kinetics","volume":"1","author":"V Holm","year":"1982","journal-title":"Drug Nutr Interact"},{"key":"ref1084","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1600-0773.1977.tb02124.x","article-title":"Plasma nitrazepam concentrations after an acute intake and their correlation to\n                    sedation and serum growth hormone levels","volume":"41","author":"L Kangas","year":"1977","journal-title":"Acta Pharmacol Toxicol (Copenh)"},{"key":"ref1085","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/bmj.4.5726.18","article-title":"Correlation of subjective side effects with plasma concentrations of\n                    nortriptyline","volume":"4","author":"M Asberg","year":"1970","journal-title":"Br Med J"},{"key":"ref1086","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1136\/bmj.3.5770.331","article-title":"Relationship between plasma level and therapeutic effect of nortriptyline","volume":"3","author":"M Asberg","year":"1971","journal-title":"Br Med J"},{"key":"ref1087","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ejps.2011.08.003","article-title":"Risk assessment of accidental nortriptyline poisoning: the importance of\n                    cytochrome P450 for nortriptyline elimination investigated using a\n                    population-based pharmacokinetic simulator","volume":"44","author":"J Jornil","year":"2011","journal-title":"Eur J Pharm Sci"},{"key":"ref1088","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1600-0447.1985.tb02582.x","article-title":"Relationship of free nortriptyline levels to therapeutic response","volume":"72","author":"P J Perry","year":"1985","journal-title":"Acta Psychiatr Scand"},{"key":"ref1089","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00003088-198713060-00003","article-title":"The relationship between antidepressant response and tricyclic antidepressant\n                    plasma concentrations. A retrospective analysis of the literature using logistic\n                    regression analysis","volume":"13","author":"P J Perry","year":"1987","journal-title":"Clin Pharmacokinet"},{"issue":"03","key":"ref1090","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S0920-1211(98)00012-6","article-title":"Hyponatremia induced by oxcarbazepine in children","volume":"30","author":"B Peter","year":"1998","journal-title":"Epilepsy Research"},{"issue":"02","key":"ref1091","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.eplepsyres.2006.01.011","article-title":"Relationship between serum mono-hydroxy-carbazepine concentrations and adverse\n                    effects in patients with epilepsy on high-dose oxcarbazepine therapy","volume":"69","author":"S Salvatore","year":"2006","journal-title":"Epilepsy Research"},{"key":"ref1092","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4088\/JCP.22r14626","article-title":"Therapeutic Reference Range for Olanzapine in Schizophrenia: Systematic Review\n                    on Blood Concentrations, Clinical Effects, and Dopamine Receptor Occupancy","volume":"84","author":"K Wesner","year":"2023","journal-title":"J Clin Psychiatry"},{"key":"ref1093","doi-asserted-by":"crossref","first-page":"116236","DOI":"10.1016\/j.biopha.2024.116236","article-title":"Association between olanzapine plasma concentrations and treatment response: A\n                    systematic review, meta-analysis and individual participant data\n                    meta-analysis","volume":"172","author":"J Hadjoudj","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"ref1094","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/jat\/22.3.215","article-title":"Identification and determination of opipramol metabolites in plasma and\n                    urine","volume":"22","author":"M Lappenberg-Pelzer","year":"1998","journal-title":"J Anal Toxicol"},{"key":"ref1095","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/BF01721923","article-title":"Disposition of oxazepam in relation to age, sex, and cigarette smoking","volume":"59","author":"H R Ochs","year":"1981","journal-title":"Klin Wochenschr"},{"key":"ref1096","first-page":"105","article-title":"Oxcarbazepine: preliminary clinical and pharmacokinetic studies on a new\n                    anticonvulsant","volume":"24","author":"W D Hooper","year":"1987","journal-title":"Clin Exp Neurol"},{"key":"ref1097","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.2165\/00003088-200342120-00002","article-title":"Clinical pharmacokinetics of oxcarbazepine","volume":"42","author":"T W May","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"ref1098","doi-asserted-by":"crossref","first-page":"100680","DOI":"10.1016\/j.bj.2023.100680","article-title":"Clinical impact of therapeutic drug monitoring for newer anti-seizure\n                    medications in patients with epilepsy: A real-world observation study","volume":"47","author":"S N Lim","year":"2024","journal-title":"Biomed J"},{"key":"ref1099","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2147\/DDDT.S154388","article-title":"Reference ranges for antiepileptic drugs revisited: a practical approach to\n                    establish national guidelines","volume":"12","author":"A Reimers","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"ref1100","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s13318-021-00750-9","article-title":"Oxycodone-Related Deaths: The Significance of Pharmacokinetic and\n                    Pharmacodynamic Drug Interactions","volume":"47","author":"G Jakobsson","year":"2022","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"ref1101","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/jat\/bkaa051","article-title":"Oxycodone Concentrations and Metabolic Ratios in Femoral Blood from Fatal\n                    Intoxications and Other Causes of Death using LC-MS-MS","volume":"45","author":"G Jakobsson","year":"2021","journal-title":"J Anal Toxicol"},{"key":"ref1102","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00213-007-1029-z","article-title":"Dose-finding study of paliperidone ER based on striatal and extrastriatal\n                    dopamine D2 receptor occupancy in patients with schizophrenia","volume":"197","author":"R Arakawa","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"key":"ref1103","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s00228-010-0812-7","article-title":"Serum concentrations of paliperidone versus risperidone and clinical\n                    effects","volume":"66","author":"Y Nazirizadeh","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"ref1104","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s00406-021-01257-9","article-title":"Clinical response in patients treated with once-monthly paliperidone palmitate:\n                    analysis of a therapeutic drug monitoring (TDM) database","volume":"271","author":"G Schoretsanitis","year":"2021","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"ref1105","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1007\/s40262-021-01044-8","article-title":"Pharmacokinetic Correlates of Once-Monthly Paliperidone Palmitate-Related\n                    Adverse Drug Reactions","volume":"60","author":"G Schoretsanitis","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"ref1106","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0924-9338(00)00536-8","article-title":"Long-term treatment of chronic schizophrenia with risperidone: a study with\n                    plasma levels","volume":"16","author":"M C Mauri","year":"2001","journal-title":"Eur Psychiatry"},{"key":"ref1107","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/JCP.0000000000001566","article-title":"Therapeutic Drug Monitoring of Paliperidone in Patients With Schizophrenia in\n                    Taiwan","volume":"42","author":"C C Chiu","year":"2022","journal-title":"J Clin Psychopharmacol"},{"key":"ref1108","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.pnpbp.2007.02.003","article-title":"Time course of response to paroxetine: influence of plasma level","volume":"31","author":"M Gex-Fabry","year":"2007","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref1109","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3109\/13651509909024771","article-title":"Long term efficacy of paroxetine in major depression: A study with plasma\n                    levels","volume":"3","author":"M C Mauri","year":"1999","journal-title":"Int J Psychiatry Clin Pract"},{"key":"ref1110","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/FTD.0000000000000036","article-title":"Therapeutic reference range for plasma concentrations of paroxetine in patients\n                    with major depressive disorders","volume":"36","author":"T Tomita","year":"2014","journal-title":"Ther Drug Monit"},{"key":"ref1111","doi-asserted-by":"crossref","first-page":"105165","DOI":"10.1016\/j.ebiom.2024.105165","article-title":"Dose adjustment of paroxetine based on CYP2D6 activity score inferred\n                    metabolizer status in Chinese Han patients with depressive or anxiety disorders:\n                    a prospective study and cross-ethnic meta-analysis","volume":"104","author":"Y Liao","year":"2024","journal-title":"EBioMedicine"},{"key":"ref1112","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1111\/epi.12240","article-title":"Concentration-effect relationships with perampanel in patients with\n                    pharmacoresistant partial-onset seizures","volume":"54","author":"B E Gidal","year":"2013","journal-title":"Epilepsia"},{"key":"ref1113","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.yebeh.2014.03.013","article-title":"The practical impact of altered dosing on perampanel plasma concentrations:\n                    pharmacokinetic modeling from clinical studies","volume":"35","author":"B E Gidal","year":"2014","journal-title":"Epilepsy Behav"},{"key":"ref1114","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1055\/s-2007-1019491","article-title":"Prediction and evaluation criteria in perazine therapy of acute\n                    schizophrenics","volume":"16","author":"U Breyer-Pfaff","year":"1983","journal-title":"Pharmacokinetic data. Pharmacopsychiatria"},{"key":"ref1115","first-page":"1302","article-title":"[Relationship between perazine serum concentration and clinical results in\n                    long-term treated schizophrenic outpatients (author's transl)]","volume":"28","author":"A Pietzcker","year":"1978","journal-title":"Arzneimittelforschung"},{"key":"ref1116","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s00213-004-1802-1","article-title":"A cross-validation study on the relationship between central D2 receptor\n                    occupancy and serum perphenazine concentration","volume":"175","author":"M Talvik","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"ref1117","first-page":"154","article-title":"Phenelzine plasma levels, pharmacokinetics, and clinical outcome","volume":"17","author":"D Robinson","year":"1981","journal-title":"Psychopharmacol Bull"},{"key":"ref1118","first-page":"505","article-title":"D.S. Robinson, and A. Nies, Phenelzine measurement in human plasma: a sensitive\n                    GLC-ECD procedure","volume":"2","author":"T B Cooper","year":"1978","journal-title":"Commun Psychopharmacol"},{"key":"ref1119","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jchromb.2016.04.006","article-title":"Highly sensitive LC-MS\/MS-ESI method for determination of phenelzine in human\n                    plasma and its application to a human pharmacokinetic study","volume":"1022","author":"R R Kallem","year":"2016","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"ref1120","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/jat\/12.2.98","article-title":"Quantitative determination of phenelzine in human fluids by gas chromatography\n                    with nitrogen specific detection","volume":"12","author":"M Lichtenwalner","year":"1988","journal-title":"J Anal Toxicol"},{"key":"ref1121","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/jat\/19.4.265","article-title":"Two fatalities involving phenelzine","volume":"19","author":"M R Lichtenwalner","year":"1995","journal-title":"J Anal Toxicol"},{"key":"ref1122","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/00007691-200206000-00010","article-title":"How high can we go with phenytoin?","volume":"24","author":"E Kozer","year":"2002","journal-title":"Ther Drug Monit"},{"key":"ref1123","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1001\/archneur.1964.00460240074010","article-title":"Diphenylhydantoin Metabolism, Blood Levels, And Toxicity","volume":"11","author":"H Kutt","year":"1964","journal-title":"Arch Neurol"},{"key":"ref1124","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1528-1157.1959.tb04274.x","article-title":"Aspects of the pharmacology of phenytoin (dilantin) and phenobarbital relevant\n                    to their dosage in the treatment of epilepsy","volume":"1","author":"F Buchthal","year":"1960","journal-title":"Epilepsia"},{"key":"ref1125","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1001\/archneur.1960.03840120030004","article-title":"Clinical and electroencephalographic correlations with serum levels of\n                    diphenylhydanotin","volume":"2","author":"F Buchthal","year":"1960","journal-title":"Arch Neurol"},{"key":"ref1126","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1097\/JCP.0000000000001611","article-title":"Pimavanserin Exposure-Response Analyses in Patients With Schizophrenia: Results\n                    From the Phase 2 ADVANCE Study","volume":"42","author":"M Darwish","year":"2022","journal-title":"J Clin Psychopharmacol"},{"key":"ref1127","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1017\/S1461145707007869","article-title":"PET analysis of the 5-HT2A receptor inverse agonist ACP-103 in human brain","volume":"11","author":"A L Nordstrom","year":"2008","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref1128","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1177\/0091270007299431","article-title":"Pharmacokinetics, tolerability, and safety of ACP-103 following single or\n                    multiple oral dose administration in healthy volunteers","volume":"47","author":"K E Vanover","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"ref1130","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s40262-020-00894-y","article-title":"Pipamperone Population Pharmacokinetics Related to Effectiveness and Side\n                    Effects in Children and Adolescents","volume":"59","author":"S M Kloosterboer","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"ref1131","first-page":"430","article-title":"Pharmacokinetics of pipamperone from three different tablet formulations","volume":"52","author":"G E Potgieter","year":"2002","journal-title":"Arzneimittelforschung"},{"key":"ref1132","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40263-020-00703-x","article-title":"Pitolisant: A Review in Narcolepsy with or without Cataplexy","volume":"34","author":"Y N Lamb","year":"2020","journal-title":"CNS Drugs"},{"key":"ref1133","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.sleep.2019.10.024","article-title":"Pharmacokinetics of pitolisant in children and adolescents with narcolepsy","volume":"66","author":"M Lecendreux","year":"2020","journal-title":"Sleep Med"},{"key":"ref1134","doi-asserted-by":"crossref","first-page":"3464","DOI":"10.1111\/bph.15067","article-title":"Exploring occupancy of the histamine H(3) receptor by pitolisant in humans using\n                    PET","volume":"177","author":"P Rusjan","year":"2020","journal-title":"Br J Pharmacol"},{"key":"ref1135","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/j.1476-5381.2011.01286.x","article-title":"The histamine H3 receptor: from discovery to clinical trials with\n                    pitolisant","volume":"163","author":"J C Schwartz","year":"2011","journal-title":"Br J Pharmacol"},{"key":"ref1136","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/clpt.1980.150","article-title":"Desmethyldiazepam kinetics in the elderly after oral prazepam","volume":"28","author":"M D Allen","year":"1980","journal-title":"Clin Pharmacol Ther"},{"key":"ref1137","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/00004850-199100640-00004","article-title":"Comparison of performance of healthy volunteers given prazepam alone or combined\n                    with ethanol","volume":"6","author":"C Girre","year":"1991","journal-title":"Relation to drug plasma concentrations. Int Clin\n                    Psychopharmacol"},{"key":"ref1138","first-page":"186","article-title":"Comparison of sublingual and oral prazepam in normal subjects. II.\n                    Pharmacokinetic and pharmacodynamic data","volume":"19","author":"P Jacqmin","year":"1988","journal-title":"Neuropsychobiology"},{"key":"ref1139","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/BF00563121","article-title":"Pharmacokinetics of prazepam in man","volume":"16","author":"M T Smith","year":"1979","journal-title":"Eur J Clin Pharmacol"},{"key":"ref1140","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/01.ftd.0000158874.54100.1a","article-title":"Analysis of pregabalin at therapeutic concentrations in human plasma\/serum by\n                    reversed-phase HPLC","volume":"27","author":"D Berry","year":"2005","journal-title":"Ther Drug Monit"},{"key":"ref1141","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1528-1157.1970.tb03905.x","article-title":"A clinical study of serum primidone levels","volume":"11","author":"H E Booker","year":"1970","journal-title":"Epilepsia"},{"key":"ref1142","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2125.1990.tb03820.x","article-title":"The disposition of primidone in elderly patients","volume":"30","author":"C Martines","year":"1990","journal-title":"Br J Clin Pharmacol"},{"key":"ref1144","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1365-2125.1983.tb01501.x","article-title":"Pharmacokinetics of promethazine and its sulphoxide metabolite after intravenous\n                    and oral administration to man","volume":"15","author":"G Taylor","year":"1983","journal-title":"Br J Clin Pharmacol"},{"key":"ref1145","first-page":"1","article-title":"[QTc prolongation induced by intravenous sedation with Haloperidol, Prothipendyl\n                    and Lorazepam]","volume":"28","author":"J Scharfetter","year":"2014","journal-title":"Neuropsychiatr"},{"key":"ref1146","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00702-020-02291-y","article-title":"Pharmacodynamic Drug-Drug interactions of QT-prolonging drugs in hospitalized\n                    psychiatric patients","volume":"128","author":"G Hefner","year":"2021","journal-title":"J Neural Transm (Vienna)"},{"key":"ref1147","first-page":"158","article-title":"[Suicide with prothipendyl]","volume":"193","author":"M Wu","year":"1994","journal-title":"Arch Kriminol"},{"key":"ref1148","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/bcpt.14074","article-title":"Doses, serum concentrations and diagnoses of Norwegian quetiapine users\n                    2001-2019 in a therapeutic drug monitoring material","volume":"135","author":"H Breivik","year":"2024","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref1149","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.3390\/jox14040085","article-title":"Acute Quetiapine Intoxication: Relationship Between Ingested Dose, Serum\n                    Concentration and Clinical Presentation-Structured Literature Review and\n                    Analysis","volume":"14","author":"M Dobravc Verbi\u010d","year":"2024","journal-title":"J Xenobiot"},{"key":"ref1150","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1111\/bcp.15734","article-title":"A machine learning model for predicting blood concentration of quetiapine in\n                    patients with schizophrenia and depression based on real-world data","volume":"89","author":"Y Hao","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"ref1151","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/FTD.0000000000000582","article-title":"Concentration-Effect Relationships of Psychoactive Drugs and the Problem to\n                    Calculate Therapeutic Reference Ranges","volume":"41","author":"C Hiemke","year":"2019","journal-title":"Ther Drug Monit"},{"key":"ref1152","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jad.2022.12.107","article-title":"Relationship between serum concentration and clinical response of quetiapine in\n                    adolescents and adults with bipolar disorders in acute stage: a prospective\n                    observational study","volume":"324","author":"S Yang","year":"2023","journal-title":"J Affect Disord"},{"key":"ref1153","doi-asserted-by":"crossref","first-page":"e4510","DOI":"10.1002\/bmc.4510","article-title":"LC-MS\/MS method for simultaneous determination of ramelteon and its metabolite\n                    M-II in human plasma: Application to a clinical pharmacokinetic study in healthy\n                    Chinese volunteers","volume":"33","author":"Y Zhu","year":"2019","journal-title":"Biomed Chromatogr"},{"key":"ref1154","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1177\/0091270006298602","article-title":"Age and gender effects on the pharmacokinetics and pharmacodynamics of\n                    ramelteon, a hypnotic agent acting via melatonin receptors MT1 and MT2","volume":"47","author":"D J Greenblatt","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"ref1155","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/00007691-200304000-00006","article-title":"Determination of serum reboxetine enantiomers in patients on chronic medication\n                    with racemic reboxetine","volume":"25","author":"D Ohman","year":"2003","journal-title":"Ther Drug Monit"},{"key":"ref1156","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s40262-018-0664-3","article-title":"Clinical Pharmacokinetics of Atypical Antipsychotics: An Update","volume":"57","author":"M C Mauri","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"ref1157","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1176\/ajp.156.6.869","article-title":"Suggested minimal effective dose of risperidone based on PET-measured D2 and\n                    5-HT2A receptor occupancy in schizophrenic patients","volume":"156","author":"S Nyberg","year":"1999","journal-title":"Am J Psychiatry"},{"key":"ref1158","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1600-0404.1998.tb00645.x","article-title":"Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in\n                    Alzheimer's disease","volume":"97","author":"N R Cutler","year":"1998","journal-title":"Acta Neurol Scand"},{"key":"ref1159","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2165\/00044011-200828060-00004","article-title":"Steady-state pharmacokinetics of rivastigmine in patients with mild to moderate\n                    Alzheimer's disease not affected by co-administration of memantine: an\n                    open-label, crossover, single-centre study","volume":"28","author":"J Shua-Haim","year":"2008","journal-title":"Clin Drug Investig"},{"key":"ref1160","first-page":"161","article-title":"[Therapeutic drug monitoring of rufinamide]","volume":"67","author":"D Bentu\u00e9-Ferrer","year":"2012","journal-title":"Therapie"},{"key":"ref1161","first-page":"101","volume-title":"Chapter 5 - Therapeutic Drug Monitoring of Newer Antiepileptic Drugs, in\n                    Clinical Challenges in Therapeutic Drug Monitoring, W. Clarke and A. Dasgupta,\n                    Editors","author":"G A McMillin","year":"2016"},{"key":"ref1162","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/FTD.0000000000000977","article-title":"Therapeutic Drug Monitoring for Rufinamide in Japanese Patients With Epilepsy:\n                    Focus on Drug Interactions, Tolerability, and Clinical Effectiveness","volume":"44","author":"Y Yamamoto","year":"2022","journal-title":"Ther Drug Monit"},{"key":"ref1163","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1212\/01.wnl.0000303813.95800.0d","article-title":"Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome","volume":"70","author":"T Glauser","year":"2008","journal-title":"Neurology"},{"key":"ref1164","doi-asserted-by":"crossref","first-page":"152301","DOI":"10.1016\/j.comppsych.2022.152301","article-title":"Therapeutic drug monitoring of sertraline in children and adolescents: A\n                    naturalistic study with insights into the clinical response and treatment of\n                    obsessive-compulsive disorder","volume":"115","author":"E Tini","year":"2022","journal-title":"Compr Psychiatry"},{"key":"ref1165","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/FTD.0b013e31827a1aad","article-title":"The relation between dosage, serum concentrations, and clinical outcome in\n                    children and adolescents treated with sertraline: a naturalistic study","volume":"35","author":"R Taurines","year":"2013","journal-title":"Ther Drug Monit"},{"key":"ref1166","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/s41386-019-0554-x","article-title":"Impact of CYP2C19 genotype on sertraline exposure in 1200 Scandinavian\n                    patients","volume":"45","author":"L S Br\u00e5ten","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"ref1167","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/hup.502","article-title":"Long-term efficacy and therapeutic drug monitoring of sertraline in major\n                    depression","volume":"18","author":"M C Mauri","year":"2003","journal-title":"Hum Psychopharmacol"},{"key":"ref1168","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s40266-020-00784-9","article-title":"Use of Antidepressants in Older People during a 10-Year Period: An Observational\n                    Study on Prescribed Doses and Serum Levels","volume":"37","author":"K Tveit","year":"2020","journal-title":"Drugs Aging"},{"key":"ref1169","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2165\/00003088-199700321-00004","article-title":"Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and\n                    young male and female volunteers","volume":"32","author":"R A Ronfeld","year":"1997","journal-title":"Clin Pharmacokinet"},{"key":"ref1170","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.biopsych.2005.08.010","article-title":"Acute occupancy of brain serotonin transporter by sertraline as measured by\n                    [11C]DASB and positron emission tomography","volume":"59","author":"R V Parsey","year":"2006","journal-title":"Biol Psychiatry"},{"key":"ref1172","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s40262-019-00736-6","article-title":"Physiologically Based Pharmacokinetic Modelling of Hyperforin to Predict Drug\n                    Interactions with St John's Wort","volume":"58","author":"J Adiwidjaja","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"ref1173","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1055\/s-2007-979344","article-title":"Oral bioavailability of hyperforin from hypericum extracts in rats and human\n                    volunteers","volume":"31","author":"A Biber","year":"1998","journal-title":"Pharmacopsychiatry"},{"key":"ref1174","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1055\/s-2007-979527","article-title":"Hypericin and pseudohypericin: pharmacokinetics and effects on photosensitivity\n                    in humans","volume":"30","author":"J Brockm\u00f6ller","year":"1997","journal-title":"Pharmacopsychiatry"},{"key":"ref1175","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/bph.14936","article-title":"Clinical relevance of St. John's wort drug interactions revisited","volume":"177","author":"S Nicolussi","year":"2020","journal-title":"Br J Pharmacol"},{"key":"ref1176","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/FTD.0000000000001069","article-title":"Utility of Therapeutic Drug Monitoring in Identifying Clinically Significant\n                    Interactions Between St. John's Wort and Prescription Drugs","volume":"45","author":"V Steenkamp","year":"2023","journal-title":"Ther Drug Monit"},{"key":"ref1177","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/FTD.0b013e31825dc4a6","article-title":"Concentrations of stiripentol in children and adults with epilepsy: the\n                    influence of dose, age, and comedication","volume":"34","author":"T W May","year":"2012","journal-title":"Ther Drug Monit"},{"key":"ref1178","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1111\/j.1528-1157.1999.tb02048.x","article-title":"Stiripentol: efficacy and tolerability in children with epilepsy","volume":"40","author":"J Perez","year":"1999","journal-title":"Epilepsia"},{"key":"ref1179","first-page":"506","article-title":"[Sulpiride poisoning--case report confirmed with the quantitative determination\n                    of the xenobiotic serum level]","volume":"68","author":"K Ciszowski","year":"2011","journal-title":"Przegl Lek"},{"key":"ref1180","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1055\/s-2001-15194","article-title":"Serum levels of sulpiride enantiomers after oral treatment with racemic\n                    sulpiride in psychiatric patients: a pilot study","volume":"34","author":"M J M\u00fcller","year":"2001","journal-title":"Pharmacopsychiatry"},{"key":"ref1181","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0920-1211(02)00054-2","article-title":"Sulthiame in adults with refractory epilepsy and learning disability: an open\n                    trial","volume":"50","author":"M J Koepp","year":"2002","journal-title":"Epilepsy Res"},{"key":"ref1182","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00007691-199406000-00005","article-title":"Pharmacokinetics of sulthiame in epileptic patients","volume":"16","author":"T W May","year":"1994","journal-title":"Ther Drug Monit"},{"key":"ref1183","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/BF00315502","article-title":"Development of a population pharmacokinetic database for tianeptine","volume":"45","author":"TH Grasela","year":"1993","journal-title":"Eur J Clin Pharmacol"},{"key":"ref1184","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/JCP.0000000000001439","article-title":"Effects of Bedtime Dosing With Suvorexant and Zolpidem on Balance and\n                    Psychomotor Performance in Healthy Elderly Participants During the Night and in\n                    the Morning","volume":"41","author":"H Bland","year":"2021","journal-title":"J Clin Psychopharmacol"},{"key":"ref1185","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.5665\/sleep.5168","article-title":"On-the-Road Driving Performance the Morning after Bedtime Use of Suvorexant 20\n                    and 40 mg: A Study in Non-Elderly Healthy Volunteers","volume":"38","author":"A Vermeeren","year":"2015","journal-title":"Sleep"},{"key":"ref1186","doi-asserted-by":"crossref","first-page":"882","DOI":"10.3109\/00498254.2015.1129565","article-title":"In vitro and in vivo characterisation of the metabolism and disposition of\n                    suvorexant in humans","volume":"46","author":"D Cui","year":"2016","journal-title":"Xenobiotica"},{"key":"ref1187","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/jcph.440","article-title":"Pharmacokinetics of the dual melatonin receptor agonist tasimelteon in subjects\n                    with hepatic or renal impairment","volume":"55","author":"R Torres","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"ref1188","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/bja\/66.1.20","article-title":"Temazepam absorption in patients before surgery","volume":"66","author":"H E Hosie","year":"1991","journal-title":"Br J Anaesth"},{"key":"ref1189","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0140-6736(86)92528-6","article-title":"Fatal temazepam overdoses","volume":"2","author":"A R Forrest","year":"1986","journal-title":"Lancet"},{"key":"ref1190","doi-asserted-by":"crossref","first-page":"31s","DOI":"10.1111\/j.1365-2125.1979.tb00452.x","article-title":"Bioavailability of temazepam in soft gelatin capsules","volume":"8","author":"L M Fuccella","year":"1979","journal-title":"Br J Clin Pharmacol"},{"key":"ref1191","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/BF00544571","article-title":"Pharmacokinetics of temazepam after day-time and night-time oral\n                    administration","volume":"33","author":"F O M\u00fcller","year":"1987","journal-title":"Eur J Clin Pharmacol"},{"key":"ref1192","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/archneur.55.1.56","article-title":"Tiagabine for complex partial seizures: a randomized, add-on, dose-response\n                    trial","volume":"55","author":"B M Uthman","year":"1998","journal-title":"Arch Neurol"},{"key":"ref1193","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/BF02244131","article-title":"Pharmacokinetic and pharmacodynamic interaction between the antidepressant\n                    tianeptine and oxazepam at steady-state","volume":"101","author":"S Toon","year":"1990","journal-title":"Psychopharmacology (Berl)"},{"key":"ref1194","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2165\/00023210-200115030-00006","article-title":"Tianeptine: a review of its use in depressive disorders","volume":"15","author":"A J Wagstaff","year":"2001","journal-title":"CNS Drugs"},{"key":"ref1195","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/j.1552-4604.1991.tb03703.x","article-title":"Pharmacokinetics of the antidepressant tianeptine at steady state in the\n                    elderly","volume":"31","author":"F Demotes-Mainard","year":"1991","journal-title":"J Clin Pharmacol"},{"key":"ref1196","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1684\/j.1950-6945.2005.tb00128.x","article-title":"Topiramate: a prospective study on the relationship between concentration,\n                    dosage and adverse events in epileptic patients on combination therapy","volume":"7","author":"W Fr\u00f6scher","year":"2005","journal-title":"Epileptic Disord"},{"key":"ref1197","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/acn3.51962","article-title":"Topiramate dosage optimization for effective antiseizure management via\n                    population pharmacokinetic modeling","volume":"11","author":"S Lee","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"key":"ref1198","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/bcp.14985","article-title":"Was it necessary to change the therapeutic range of topiramate?","volume":"88","author":"B Koristkova","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"ref1199","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/JCP.0000000000001866","article-title":"Plasma Concentrations of Tranylcypromine in Depressed Patients With Chronic\n                    Kidney Disease: Two Case Reports","volume":"44","author":"C F\u00f6rst","year":"2024","journal-title":"J Clin Psychopharmacol"},{"key":"ref1200","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/jat\/20.5.301","article-title":"One fatal and one nonfatal intoxication with tranylcypromine. Absence of\n                    amphetamines as metabolites","volume":"20","author":"S Iwersen","year":"1996","journal-title":"J Anal Toxicol"},{"key":"ref1201","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/clpt.1986.205","article-title":"Pharmacokinetics of tranylcypromine in patients who are depressed: relationship\n                    to cardiovascular effects","volume":"40","author":"A G Mallinger","year":"1986","journal-title":"Clin Pharmacol Ther"},{"key":"ref1202","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1097\/FTD.0000000000001137","article-title":"Enantiomer Plasma Concentrations of Tranylcypromine as a Test for Peripheral\n                    Monoamine Oxidase Inhibition","volume":"45","author":"S Ulrich","year":"2023","journal-title":"Ther Drug Monit"},{"key":"ref1203","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.euroneuro.2017.05.007","article-title":"Tranylcypromine in mind (Part I): Review of pharmacology","volume":"27","author":"S Ulrich","year":"2017","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref1204","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/00004714-198908000-00009","article-title":"G. Gnocchi, and G. Delrio, Plasma trazodone concentrations and clinical response\n                    in elderly depressed patients: a preliminary study","volume":"9","author":"P Monteleone","year":"1989","journal-title":"J Clin Psychopharmacol"},{"key":"ref1205","first-page":"77","article-title":"Acute trazodone poisoning: clinical signs and plasma concentrations","volume":"17","author":"J A Henry","year":"1984","journal-title":"Psychopathology"},{"key":"ref1206","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/00007691-200208000-00016","article-title":"Relationship between plasma concentrations of trazodone and its active\n                    metabolite, m-chlorophenylpiperazine, and its clinical effect in depressed\n                    patients","volume":"24","author":"K Mihara","year":"2002","journal-title":"Ther Drug Monit"},{"key":"ref1207","first-page":"231","article-title":"[Evaluation of therapeutic efficacy and pharmacokinetics of controlled release\n                    of trazodone in patients with major depressive disorder]","volume":"35","author":"P Monteleone","year":"1994","journal-title":"Minerva Psichiatr"},{"key":"ref1208","first-page":"406","article-title":"Plasma trazodone concentrations in elderly depressed inpatients: cardiac effects\n                    and short-term efficacy","volume":"7","author":"J E Spar","year":"1987","journal-title":"J Clin Psychopharmacol"},{"key":"ref1209","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/00004850-199510030-00002","article-title":"Effects of various factors on steady state plasma concentrations of trazodone\n                    and its active metabolite m-chlorophenylpiperazine","volume":"10","author":"M Ishida","year":"1995","journal-title":"Int Clin Psychopharmacol"},{"key":"ref1210","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1007\/BF00172629","article-title":"Effects of trazodone on the sleep of depressed subjects--a polygraphic\n                    study","volume":"95","author":"J Mouret","year":"1988","journal-title":"Psychopharmacology (Berl)"},{"key":"ref1211","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1365-2125.1986.tb02951.x","article-title":"Population study of triazolam pharmacokinetics","volume":"22","author":"H Friedman","year":"1986","journal-title":"Br J Clin Pharmacol"},{"key":"ref1212","first-page":"76","article-title":"Age and gender effects on the pharmacokinetics and pharmacodynamics of\n                    triazolam, a cytochrome P450 3A substrate","author":"D J Greenblatt","year":"2004","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"ref1213","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/00004714-198712000-00003","article-title":"A comparative double-blind controlled study of trimipramine and amitriptyline in\n                    major depression: lack of correlation with 5-hydroxytryptamine reuptake\n                    blockade","volume":"7","author":"G Cournoyer","year":"1987","journal-title":"J Clin Psychopharmacol"},{"key":"ref1214","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1055\/s-2003-38087","article-title":"Clinical outcome after trimipramine in patients with delusional depression - a\n                    pilot study","volume":"36","author":"R M Frieboes","year":"2003","journal-title":"Pharmacopsychiatry"},{"key":"ref1215","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1600-0447.1997.tb09912.x","article-title":"The utilization of antidepressants--a key issue in the prevention of suicide: an\n                    analysis of 5281 suicides in Sweden during the period 1992-1994","volume":"96","author":"G Isacsson","year":"1997","journal-title":"Acta Psychiatr Scand"},{"key":"ref1216","first-page":"113","article-title":"Plasma levels and therapeutic response with trimipramine treatment of endogenous\n                    depression","volume":"49","author":"G M Simpson","year":"1988","journal-title":"J Clin Psychiatry"},{"key":"ref1217","first-page":"276","article-title":"[Tricyclic antidepressants and therapeutic monitoring. An experience with\n                    trimipramine]","volume":"47","author":"G Forzy","year":"1989","journal-title":"Ann Pharm Fr"},{"key":"ref1218","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1528-1157.1979.tb04808.x","article-title":"Sodium valproate, serum level and clinical effect in epilepsy: a controlled\n                    study","volume":"20","author":"L Gram","year":"1979","journal-title":"Epilepsia"},{"key":"ref1219","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1176\/appi.ajp.163.2.272","article-title":"Linear relationship of valproate serum concentration to response and optimal\n                    serum levels for acute mania","volume":"163","author":"M H Allen","year":"2006","journal-title":"Am J Psychiatry"},{"key":"ref1220","doi-asserted-by":"crossref","first-page":"101678","DOI":"10.1016\/j.eclinm.2022.101678","article-title":"Comparative effectiveness of valproic acid in different serum concentrations for\n                    maintenance treatment of bipolar disorder: A retrospective cohort study using\n                    target trial emulation framework","volume":"54","author":"Y B Chen","year":"2022","journal-title":"EClinicalMedicine"},{"key":"ref1221","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1111\/ene.15441","article-title":"Valproate in status epilepticus: Correlation between loading dose, serum levels,\n                    and clinical response","volume":"29","author":"S Vijiala","year":"2022","journal-title":"Eur J Neurol"},{"key":"ref1222","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1124\/dmd.123.001539","article-title":"Association of Valproic Acid and Its Main Metabolites' Plasma\n                    Concentrations with Clinical Outcomes among Epilepsy Patients: A 10-Year\n                    Retrospective Study Based on Therapeutic Drug Monitoring","volume":"52","author":"R T Li","year":"2024","journal-title":"Drug Metab Dispos"},{"key":"ref1223","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/bmj.290.6471.815","article-title":"Which drug for the adult epileptic patient: phenytoin or valproate?","volume":"290","author":"D M Turnbull","year":"1985","journal-title":"Br Med J (Clin Res Ed)"},{"key":"ref1224","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1177\/0091270006292624","article-title":"Multiple-dose pharmacokinetics of the selective nicotinic receptor partial\n                    agonist, varenicline, in healthy smokers","volume":"46","author":"H M Faessel","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"ref1225","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1080\/15622975.2021.1938668","article-title":"Venlafaxine and O-desmethylvenlafaxine serum levels are positively associated\n                    with antidepressant response in elder depressed out-patients","volume":"23","author":"D De Donatis","year":"2022","journal-title":"World J Biol Psychiatry"},{"key":"ref1226","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/JCP.0000000000001312","article-title":"Tolerability of High-Dose Venlafaxine After Switch From Escitalopram in\n                    Nonresponding Patients With Major Depressive Disorder","volume":"41","author":"J Engelmann","year":"2021","journal-title":"J Clin Psychopharmacol"},{"key":"ref1227","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1177\/0269881120936509","article-title":"Higher venlafaxine serum concentrations necessary for clinical improvement? Time\n                    to re-evaluate the therapeutic reference range of venlafaxine","volume":"34","author":"M Scherf-Clavel","year":"2020","journal-title":"J Psychopharmacol"},{"key":"ref1228","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1600-0404.1983.tb04812.x","article-title":"Gamma-vinyl-GABA: a single-blind trial in patients with epilepsy","volume":"68","author":"L Gram","year":"1983","journal-title":"Acta Neurol Scand"},{"key":"ref1229","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40261-013-0061-5","article-title":"Pharmacokinetics of vilazodone in patients with mild or moderate renal\n                    impairment","volume":"33","author":"R Boinpally","year":"2013","journal-title":"Clin Drug Investig"},{"key":"ref1230","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/bcpt.12513","article-title":"A Population Pharmacokinetic-Pharmacodynamic Meta-Analysis of Vortioxetine in\n                    Patients with Major Depressive Disorder","volume":"118","author":"H Naik","year":"2016","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref1231","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s00213-023-06362-2","article-title":"Evidence of trospium's ability to mitigate cholinergic adverse events\n                    related to xanomeline: phase 1 study results","volume":"240","author":"A Breier","year":"2023","journal-title":"Psychopharmacology (Berl)"},{"key":"ref1232","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2165\/00003495-200060020-00014","article-title":"Zaleplon: a review of its use in the treatment of insomnia","volume":"60","author":"M Dooley","year":"2000","journal-title":"Drugs"},{"key":"ref1233","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2165\/00003088-200443040-00002","article-title":"Comparative pharmacokinetics and pharmacodynamics of short-acting\n                    hypnosedatives: zaleplon, zolpidem and zopiclone","volume":"43","author":"D R Drover","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"ref1234","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/S0149-2918(00)83043-X","article-title":"Pharmacokinetics, pharmacodynamics, and relative pharmacokinetic\/pharmacodynamic\n                    profiles of zaleplon and zolpidem","volume":"22","author":"D Drover","year":"2000","journal-title":"Clin Ther"},{"key":"ref1235","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0009-9236(98)90139-4","article-title":"Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo","volume":"64","author":"D J Greenblatt","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"ref1236","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2165\/00023210-200317070-00004","article-title":"Clinically important drug interactions with zopiclone, zolpidem and\n                    zaleplon","volume":"17","author":"L M Hesse","year":"2003","journal-title":"CNS Drugs"},{"key":"ref1237","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1097\/FTD.0b013e31818ac8ba","article-title":"Therapeutic drug monitoring of ziprasidone in a clinical treatment setting","volume":"30","author":"M D Cherm\u00e1","year":"2008","journal-title":"Ther Drug Monit"},{"key":"ref1238","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.eurpsy.2008.09.003","article-title":"The use of ziprasidone in clinical practice: analysis of pharmacokinetic and\n                    pharmacodynamic aspects from data of a drug monitoring survey","volume":"24","author":"F Vogel","year":"2009","journal-title":"Eur Psychiatry"},{"key":"ref1239","doi-asserted-by":"crossref","first-page":"360","DOI":"10.4306\/pi.2017.14.3.360","article-title":"An Inter-Ethnic Comparison Study of Ziprasidone Plasma Levels, Dosage and\n                    Clinical Response in Patients with Schizophrenia","volume":"14","author":"D Lv","year":"2017","journal-title":"Psychiatry Investig"},{"key":"ref1240","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1097\/JCP.0b013e31818ba2f6","article-title":"Striatal and extrastriatal D2\/D3-receptor-binding properties of ziprasidone: a\n                    positron emission tomography study with [18F]Fallypride and [11C]raclopride\n                    (D2\/D3-receptor occupancy of ziprasidone)","volume":"28","author":"I Vernaleken","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"ref1241","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00213-013-3012-1","article-title":"Dopamine D\u2082\/\u2083 occupancy of ziprasidone across a day: a within-subject PET\n                    study","volume":"228","author":"T Suzuki","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"key":"ref1242","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1176\/appi.ajp.161.5.818","article-title":"A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients\n                    with schizophrenia treated with therapeutic doses of ziprasidone","volume":"161","author":"D Mamo","year":"2004","journal-title":"Am J Psychiatry"},{"key":"ref1243","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/JCP.0b013e3182977308","article-title":"High-dose oral ziprasidone versus conventional dosing in schizophrenia patients\n                    with residual symptoms: the ZEBRAS study","volume":"33","author":"D C Goff","year":"2013","journal-title":"J Clin Psychopharmacol"},{"key":"ref1244","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1055\/s-2007-973835","article-title":"Ziprasidone outcome and tolerability: a practical clinical trial with plasma\n                    drug levels","volume":"40","author":"M C Mauri","year":"2007","journal-title":"Pharmacopsychiatry"},{"key":"ref1245","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.12740\/PP\/65307","article-title":"Therapeutic drug monitoring of atypical antipsychotics","volume":"51","author":"A E Urban","year":"2017","journal-title":"Psychiatr Pol"},{"key":"ref1246","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s40262-019-00797-7","article-title":"Correction to: Clinical Pharmacokinetics of Atypical Antipsychotics: An\n                    Update","volume":"58","author":"M C Mauri","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"ref1247","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s12272-018-1065-8","article-title":"Effects of genetic polymorphisms of CYP2C19 on the pharmacokinetics of\n                    zolpidem","volume":"41","author":"J Y Byeon","year":"2018","journal-title":"Arch Pharm Res"},{"key":"ref1248","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s12272-018-1070-y","article-title":"The influences of CYP2C9*1\/*3 genotype on the pharmacokinetics of zolpidem","volume":"41","author":"J Y Byeon","year":"2018","journal-title":"Arch Pharm Res"},{"key":"ref1249","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1080\/15389588.2020.1724977","article-title":"The implementation of per-se limits for driving under the influence of\n                    benzodiazepines and related drugs: No increased risk for arrest during\n                    therapeutic use in Norway","volume":"21","author":"A S Christophersen","year":"2020","journal-title":"Traffic Inj Prev"},{"key":"ref1250","first-page":"24927","article-title":"Zolpidem: Efficacy and Side Effects for Insomnia","volume":"9","author":"A N Edinoff","year":"2021","journal-title":"Health Psychol Res"},{"key":"ref1251","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMp1307972","article-title":"Zolpidem and driving impairment--identifying persons at risk","volume":"369","author":"R H Farkas","year":"2013","journal-title":"N Engl J Med"},{"key":"ref1252","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.aap.2009.01.011","article-title":"Impairment related to blood drug concentrations of zopiclone and zolpidem\n                    compared to alcohol in apprehended drivers","volume":"41","author":"I Gustavsen","year":"2009","journal-title":"Accid Anal Prev"},{"key":"ref1253","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1007\/s12272-020-01250-1","article-title":"Relationship between plasma exposure of zolpidem and CYP2D6 genotype in healthy\n                    Korean subjects","volume":"43","author":"E H Jung","year":"2020","journal-title":"Arch Pharm Res"},{"key":"ref1254","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s12272-020-01302-6","article-title":"Correction to: Relationship between plasma exposure of zolpidem and CYP2D6\n                    genotype in healthy Korean subjects","volume":"44","author":"E H Jung","year":"2021","journal-title":"Arch Pharm Res"},{"key":"ref1255","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s12272-019-01201-5","article-title":"Effects of steady-state clarithromycin on the pharmacokinetics of zolpidem in\n                    healthy subjects","volume":"42","author":"C M Lee","year":"2019","journal-title":"Arch Pharm Res"},{"key":"ref1256","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1520\/JFS14919J","article-title":"Zolpidem and driving impairment","volume":"46","author":"B K Logan","year":"2001","journal-title":"J Forensic Sci"},{"key":"ref1257","first-page":"142","article-title":"Clinical pharmacokinetics and pharmacodynamics of zolpidem","volume":"29","author":"P Salv\u00e0","year":"1995","journal-title":"Therapeutic implications. Clin Pharmacokinet"},{"key":"ref1258","doi-asserted-by":"crossref","first-page":"19150","DOI":"10.1038\/s41598-021-98689-z","article-title":"Effect of CYP3A4 metabolism on sex differences in the pharmacokinetics and\n                    pharmacodynamics of zolpidem","volume":"11","author":"S Yoon","year":"2021","journal-title":"Sci Rep"},{"key":"ref1259","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1111\/j.1528-1157.2000.tb02950.x","article-title":"Controversies in blood-level monitoring: reexamining its role in the treatment\n                    of epilepsy","volume":"41","author":"T A Glauser","year":"2000","journal-title":"Epilepsia"},{"key":"ref1260","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/00007691-199812000-00001","article-title":"Clinical pharmacology and therapeutic drug monitoring of zonisamide","volume":"20","author":"T Mimaki","year":"1998","journal-title":"Ther Drug Monit"},{"key":"ref1261","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.seizure.2004.04.020","article-title":"Zonisamide monotherapy with once-daily dosing in children with cryptogenic\n                    localization-related epilepsies: clinical effects and pharmacokinetic\n                    studies","volume":"13","author":"H Miura","year":"2004","journal-title":"Seizure"},{"issue":"03","key":"ref1262","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/j.1528-1157.1985.tb05408.x","article-title":"Zonisamide in epilepsy: a pilot study","volume":"26","author":"A J Wilensky","year":"1985","journal-title":"Epilepsia"},{"issue":"01","key":"ref1263","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/j.1528-1157.1987.tb03624.x","article-title":"Zonisamide (CI-912) and cognition: results from preliminary study","volume":"28","author":"S Berent","year":"1987","journal-title":"Epilepsia"},{"key":"ref1264","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1528-1157.2000.tb02209.x","article-title":"Developmental and therapeutic pharmacology of antiepileptic drugs","volume":"41","author":"H Miura","year":"2000","journal-title":"Epilepsia"},{"key":"ref1265","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2165\/00003088-199529060-00004","article-title":"Clinical pharmacokinetics of zopiclone","volume":"29","author":"C Fernandez","year":"1995","journal-title":"Clin Pharmacokinet"},{"key":"ref1266","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.forsciint.2017.07.004","article-title":"Zopiclone concentrations in oral fluid and blood after, administration of\n                    therapeutic doses of zopiclone","volume":"278","author":"K Hjelmeland","year":"2017","journal-title":"Forensic Sci Int"},{"key":"ref1267","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00213-022-06075-y","article-title":"Residual effects of zopiclone on driving performance using a standardized\n                    driving simulator among healthy volunteers","volume":"239","author":"K Iwamoto","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"key":"ref1268","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/00007691-199404000-00002","article-title":"Adverse effects of zotepine and their relationship to serum concentrations of\n                    the drug and prolactin","volume":"16","author":"T Kondo","year":"1994","journal-title":"Ther Drug Monit"},{"key":"ref1269","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/00007691-199802000-00021","article-title":"Single oral dose kinetics of zotepine and its relationship to prolactin response\n                    and side effects","volume":"20","author":"O Tanaka","year":"1998","journal-title":"Ther Drug Monit"},{"key":"ref1270","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s002130100813","article-title":"In vivo (123)I IBZM SPECT imaging of striatal dopamine 2 receptor occupancy in\n                    schizophrenic patients","volume":"157","author":"C Barnas","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"key":"ref1271","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s00213-002-1082-6","article-title":"Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and\n                    SPECT predicted the occurrence of EPS in patients treated with atypical\n                    antipsychotics and haloperidol","volume":"162","author":"J Tauscher","year":"2002","journal-title":"Psychopharmacology (Berl)"},{"key":"ref1272","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/00007691-199412000-00002","article-title":"Search for a therapeutic range for serum zuclopenthixol concentrations in\n                    schizophrenic patients","volume":"16","author":"M Kj\u00f8lbye","year":"1994","journal-title":"Ther Drug Monit"},{"key":"ref1273","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/BF00432722","article-title":"Zuclopenthixol decanoate in schizophrenia: serum levels and clinical state","volume":"87","author":"A J\u00f8rgensen","year":"1985","journal-title":"Psychopharmacology (Berl)"},{"key":"ref1274","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/00004850-199511000-00003","article-title":"Central D2 receptor occupancy and effects of zuclopenthixol acetate in\n                    humans","volume":"10","author":"S Nyberg","year":"1995","journal-title":"Int Clin Psychopharmacol"},{"key":"ref1276","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/FTD.0000000000000830","article-title":"Therapeutic Drug Monitoring of Long-Acting Injectable Antipsychotic Drugs","volume":"43","author":"G Schoretsanitis","year":"2021","journal-title":"Ther Drug Monit"},{"key":"ref1277","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s40262-019-00801-0","article-title":"SAGE-217, A Novel GABA(A) Receptor Positive Allosteric Modulator: Clinical\n                    Pharmacology and Tolerability in Randomized Phase I Dose-Finding Studies","volume":"59","author":"E Hoffmann","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"ref1278","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/npr2.12359","article-title":"Pharmacokinetics, safety, and tolerability of single and multiple doses of\n                    zuranolone in Japanese and White healthy subjects: A phase 1 clinical trial","volume":"43","author":"T Sonoyama","year":"2023","journal-title":"Neuropsychopharmacol Rep"},{"key":"ref1279","doi-asserted-by":"crossref","first-page":"787043","DOI":"10.3389\/fpsyt.2021.787043","article-title":"Therapeutic Reference Ranges for Psychotropic Drugs: A Protocol for Systematic\n                    Reviews","volume":"12","author":"X M Hart","year":"2021","journal-title":"Front Psychiatry"},{"key":"ref1281","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1177\/0269881109104849","article-title":"Clinical response to risperidone in relation to plasma drug concentrations in\n                    acutely exacerbated schizophrenic patients","volume":"24","author":"N Yasui-Furukori","year":"2010","journal-title":"J Psychopharmacol"},{"key":"ref1282","first-page":"686","article-title":"Venlafaxine and O-desmethylvenlafaxine serum levels are positively associated\n                    with antidepressant response in elder depressed out-patients","volume":"22","author":"D De Donatis","year":"2021","journal-title":"World J Biol Psychiatry"},{"key":"ref1283","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1055\/a-2039-2829","article-title":"Low Escitalopram Concentrations in Patients with Depression predict Treatment\n                    Failure: A Naturalistic Retrospective Study","volume":"56","author":"X M Hart","year":"2023","journal-title":"Pharmacopsychiatry"},{"key":"ref1284","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/FTD.0000000000000962","article-title":"Dose-Related Reference Range as a Tool in Therapeutic Drug Monitoring","volume":"44","author":"E Haen","year":"2022","journal-title":"Ther Drug Monit"},{"key":"ref1285","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1097\/00007691-200312000-00006","article-title":"Investigation of target plasma concentration-effect relationships for olanzapine\n                    in schizophrenia","volume":"25","author":"L Fellows","year":"2003","journal-title":"Ther Drug Monit"},{"key":"ref1286","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/tpj.2009.32","article-title":"Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic\n                    polymorphisms influence therapeutic outcome","volume":"10","author":"B Laika","year":"2010","journal-title":"Pharmacogenomics J"},{"key":"ref1287","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jad.2012.12.001","article-title":"What does the HAMD mean?","volume":"148","author":"S Leucht","year":"2013","journal-title":"J Affect Disord"},{"key":"ref1288","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jad.2017.09.042","article-title":"Translating the HAM-D into the MADRS and vice versa with equipercentile\n                    linking","volume":"226","author":"S Leucht","year":"2018","journal-title":"J Affect Disord"},{"key":"ref1289","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jad.2016.12.041","article-title":"What does the MADRS mean? Equipercentile linking with the CGI using a company\n                    database of mirtazapine studies","volume":"210","author":"S Leucht","year":"2017","journal-title":"J Affect Disord"},{"key":"ref1290","first-page":"e45098","article-title":"Comparison of Hamilton Depression Rating Scale and Montgomery-\u00c5sberg Depression\n                    Rating Scale: Baked Straight From a Randomized Study","volume":"15","author":"N S Santi","year":"2023","journal-title":"Cureus"},{"key":"ref1291","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jclinepi.2020.04.022","article-title":"Hamilton scale and MADRS are interchangeable in meta-analyses but can disagree\n                    at trial level","volume":"124","author":"L Guizzaro","year":"2020","journal-title":"J Clin Epidemiol"},{"key":"ref1292","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0140-6736(86)90837-8","article-title":"Statistical methods for assessing agreement between two methods of clinical\n                    measurement","volume":"1","author":"J M Bland","year":"1986","journal-title":"Lancet"},{"key":"ref1293","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jclinepi.2020.03.018","article-title":"A new statistical methodology overcame the defects of the Bland-Altman\n                    method","volume":"124","author":"P Taff\u00e9","year":"2020","journal-title":"J Clin Epidemiol"},{"key":"ref1294","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jclinepi.2021.04.004","article-title":"When can the Bland & Altman limits of agreement method be used and when it\n                    should not be used","volume":"137","author":"P Taff\u00e9","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"ref1295","first-page":"e71346","article-title":"Revisiting Depression Rating Scales: Analysis of a Randomized Trial","volume":"16","author":"N S Santi","year":"2024","journal-title":"Cureus"},{"key":"ref1296","doi-asserted-by":"crossref","first-page":"816339","DOI":"10.3389\/fpsyt.2022.816339","article-title":"What Is the Minimum Clinically Important Change in Negative Symptoms of\n                    Schizophrenia? PANSS Based Post-hoc Analyses of a Phase III Clinical Trial","volume":"13","author":"P Czobor","year":"2022","journal-title":"Front Psychiatry"},{"key":"ref1297","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/schbul\/sbp124","article-title":"Should the PANSS be rescaled?","volume":"36","author":"M Obermeier","year":"2010","journal-title":"Schizophr Bull"},{"key":"ref1298","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.npp.1301147","article-title":"Linking the PANSS, BPRS, and CGI: clinical implications","volume":"31","author":"S Leucht","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"ref1299","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of Brief Psychiatric Rating Scale scores","volume":"187","author":"S Leucht","year":"2005","journal-title":"Br J Psychiatry"},{"key":"ref1300","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"S Leucht","year":"2005","journal-title":"Schizophr Res"},{"key":"ref1301","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4088\/JCP.13049su1c.02","article-title":"Measurements of response, remission, and recovery in schizophrenia and examples\n                    for their clinical application","volume":"75","author":"S Leucht","year":"2014","journal-title":"J Clin Psychiatry"},{"issue":"03","key":"ref1302","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1176\/appi.ajp.162.3.441","article-title":"Remission in Schizophrenia: Proposed Criteria and Rationale for Consensus","volume":"162","author":"NC Andreasen","year":"2005","journal-title":"The American Journal of Psychiatry"},{"key":"ref1303","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/00004714-200106000-00010","article-title":"Therapeutic drug monitoring of clozapine in relapse prevention: a five-year\n                    prospective study","volume":"21","author":"I Gaertner","year":"2001","journal-title":"J Clin Psychopharmacol"},{"key":"ref1304","volume-title":"Biopharmazie - Grundlagen der Pharmakokinetik","author":"H Wunderli-Allenspach","year":"2004"},{"key":"ref1305","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1177\/0091270006293757","article-title":"Dose-proportional pharmacokinetics of d-threo-methylphenidate after a\n                    repeated-action release dosage form","volume":"47","author":"D Tuerck","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"ref1306","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2165\/00003088-198510040-00006","article-title":"Doxepin plasma concentrations in clinical practice. Could there be a\n                    pharmacokinetic explanation for low concentrations?","volume":"10","author":"P R Joyce","year":"1985","journal-title":"Clin Pharmacokinet"},{"key":"ref1307","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/j.1552-4604.1989.tb03410.x","article-title":"Nonlinear kinetics of trimipramine in depressed patients","volume":"29","author":"M N Musa","year":"1989","journal-title":"J Clin Pharmacol"},{"key":"ref1308","doi-asserted-by":"crossref","first-page":"494","DOI":"10.3109\/09540261.2013.836475","article-title":"The value of drug and metabolite concentration in blood as a biomarker of\n                    psychopharmacological therapy","volume":"25","author":"G Hefner","year":"2013","journal-title":"Int Rev Psychiatry"},{"key":"ref1309","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1055\/s-2007-1004591","article-title":"Estimating the size of the effects of co-medications on plasma clozapine\n                    concentrations using a model that controls for clozapine doses and confounding\n                    variables","volume":"41","author":"F J Diaz","year":"2008","journal-title":"Pharmacopsychiatry"},{"key":"ref1310","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/FTD.0000000000000272","article-title":"Therapeutic Drug Monitoring of Clobazam and Its Metabolite-Impact of Age and\n                    Comedication on Pharmacokinetic Variability","volume":"38","author":"M L Burns","year":"2016","journal-title":"Ther Drug Monit"},{"key":"ref1311","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00007691-199402000-00001","article-title":"The use of therapeutic drug monitoring data to document kinetic drug\n                    interactions: an example with amitriptyline and nortriptyline","volume":"16","author":"M Jerling","year":"1994","journal-title":"Ther Drug Monit"},{"key":"ref1312","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1055\/s-0030-1267178","article-title":"Clozapine plasma level monitoring for prediction of rehospitalization\n                    schizophrenic outpatients","volume":"44","author":"V Stieffenhofer","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"ref1313","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/00007691-199710000-00001","article-title":"Vigabatrin serum concentration to dosage ratio: influence of age and associated\n                    antiepileptic drugs","volume":"19","author":"J A Armijo","year":"1997","journal-title":"Ther Drug Monit"},{"key":"ref1314","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/FTD.0000000000000868","article-title":"Therapeutic Drug Monitoring of Psychotropics as a Diagnostic Tool for CYP2D6\n                    Poor Metabolizer Phenotype","volume":"43","author":"S V Ganesh","year":"2021","journal-title":"Ther Drug Monit"},{"key":"ref1315","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1080\/15622970701361255","article-title":"Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side\n                    effects","volume":"9","author":"K M Kirschbaum","year":"2008","journal-title":"World J Biol Psychiatry"},{"key":"ref1316","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.schres.2013.06.041","article-title":"Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult\n                    schizophrenia: an open-label, parallel-arm, multiple-dose study","volume":"150","author":"S Mallikaarjun","year":"2013","journal-title":"Schizophr Res"},{"key":"ref1317","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1097\/01.ftd.0000249944.42859.bf","article-title":"Pharmacokinetic variability of aripiprazole and the active metabolite\n                    dehydroaripiprazole in psychiatric patients","volume":"28","author":"E Molden","year":"2006","journal-title":"Ther Drug Monit"},{"key":"ref1318","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/cpt.2791","article-title":"Estimating the In Vivo Function of CYP2D6 Alleles through Population\n                    Pharmacokinetic Modeling of Brexpiprazole","volume":"113","author":"T Frederiksen","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"ref1319","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1521-0391.2013.12052.x","article-title":"Effects of HCV seropositive status on buprenorphine pharmacokinetics in\n                    opioid-dependent individuals","volume":"23","author":"C L Masson","year":"2014","journal-title":"Am J Addict"},{"key":"ref1320","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1097\/01.chi.0000237704.05143.bd","article-title":"Steady-state clinical pharmacokinetics of bupropion extended-release in\n                    youths","volume":"45","author":"W B Daviss","year":"2006","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"ref1321","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/01.ftd.0000197093.92559.7a","article-title":"Acute antidepressant response and plasma levels of bupropion and metabolites in\n                    a pediatric-aged sample: an exploratory study","volume":"28","author":"W B Daviss","year":"2006","journal-title":"Ther Drug Monit"},{"key":"ref1322","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0006-3223(97)00520-9","article-title":"Bupropion slow-release response in depression: diagnosis and biochemistry","volume":"44","author":"P J Goodnick","year":"1998","journal-title":"Biol Psychiatry"},{"key":"ref1323","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/j.clinthera.2005.11.011","article-title":"Bupropion for major depressive disorder: Pharmacokinetic and formulation\n                    considerations","volume":"27","author":"J W Jefferson","year":"2005","journal-title":"Clin Ther"},{"key":"ref1324","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1177\/0091270008314254","article-title":"Stereoselective bupropion hydroxylation as an in vivo phenotypic probe for\n                    cytochrome P4502B6 (CYP2B6) activity","volume":"48","author":"E D Kharasch","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"ref1325","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1177\/0091270006292250","article-title":"Pharmacokinetics of a newly identified active metabolite of buspirone after\n                    administration of buspirone over its therapeutic dose range","volume":"46","author":"R C Dockens","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"ref1326","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1177\/0091270008319792","article-title":"Pharmacokinetic interaction between efavirenz and carbamazepine after\n                    multiple-dose administration in healthy subjects","volume":"48","author":"P Ji","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"ref1327","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.braindev.2004.02.010","article-title":"A major influence of CYP2C19 genotype on the steady-state concentration of\n                    N-desmethylclobazam","volume":"26","author":"K Kosaki","year":"2004","journal-title":"Brain Dev"},{"key":"ref1328","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/FTD.0b013e3181dad1fb","article-title":"Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation\n                    to prescribed dose and other factors: data from a therapeutic drug monitoring\n                    service, 1993-2007","volume":"32","author":"L Couchman","year":"2010","journal-title":"Ther Drug Monit"},{"key":"ref1329","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/FTD.0b013e31815f4e72","article-title":"Clozapine and norclozapine concentrations in serum and plasma samples from\n                    schizophrenic patients","volume":"30","author":"J Hermida","year":"2008","journal-title":"Ther Drug Monit"},{"key":"ref1330","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.clinbiochem.2008.01.020","article-title":"Evaluation of three dosing models for the prediction of steady-state trough\n                    clozapine concentrations","volume":"41","author":"E Paz","year":"2008","journal-title":"Clin Biochem"},{"key":"ref1331","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1046\/j.1365-2125.1996.03642.x","article-title":"Disposition of diazepam in young and elderly subjects after acute and chronic\n                    dosing","volume":"42","author":"R J Herman","year":"1996","journal-title":"Br J Clin Pharmacol"},{"key":"ref1332","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s002130050260","article-title":"Doxepin and its metabolites in plasma and cerebrospinal fluid in depressed\n                    patients","volume":"131","author":"M Deuschle","year":"1997","journal-title":"Psychopharmacology (Berl)"},{"key":"ref1333","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/00008571-200210000-00010","article-title":"Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and\n                    Z-doxepin in healthy volunteers","volume":"12","author":"J Kirchheiner","year":"2002","journal-title":"Pharmacogenetics"},{"key":"ref1334","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00228-002-0448-3","article-title":"Pharmacokinetics of doxepin and desmethyldoxepin: an evaluation with the\n                    population approach","volume":"58","author":"M Meyer-Barner","year":"2002","journal-title":"Eur J Clin Pharmacol"},{"key":"ref1335","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1097\/FTD.0b013e31815b3f62","article-title":"Therapeutic drug monitoring of escitalopram in an outpatient setting","volume":"29","author":"M Reis","year":"2007","journal-title":"Ther Drug Monit"},{"key":"ref1336","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1111\/bcp.16156","article-title":"Combined effect of CYP2C19 and CYP2D6 genotypes on escitalopram serum\n                    concentration and its metabolic ratio in a European patient population","volume":"90","author":"P Faraj","year":"2024","journal-title":"Br J Clin Pharmacol"},{"key":"ref1337","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00213-003-1430-1","article-title":"Relationship between clinical effects of fluvoxamine and the steady-state plasma\n                    concentrations of fluvoxamine and its major metabolite fluvoxamino acid in\n                    Japanese depressed patients","volume":"167","author":"G Gerstenberg","year":"2003","journal-title":"Psychopharmacology (Berl)"},{"key":"ref1338","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/FTD.0000000000000242","article-title":"Determination of Common Antipsychotics in Quantisal-Collected Oral Fluid by\n                    UHPLC-MS\/MS: Method Validation and Applicability for Therapeutic Drug\n                    Monitoring","volume":"38","author":"L Patteet","year":"2016","journal-title":"Ther Drug Monit"},{"key":"ref1339","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1055\/s-2005-871240","article-title":"Serum concentrations of haloperidol pyridinium metabolites and the relationship\n                    with tardive dyskinesia and parkinsonism: a cross-section study in psychiatric\n                    patients","volume":"38","author":"S Ulrich","year":"2005","journal-title":"Pharmacopsychiatry"},{"key":"ref1340","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/BF00614194","article-title":"Steady-state levels of imipramine and its metabolites: significance of\n                    dose-dependent kinetics","volume":"30","author":"K Br\u00f8sen","year":"1986","journal-title":"Eur J Clin Pharmacol"},{"key":"ref1341","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/BF00608215","article-title":"Steady-state concentrations of imipramine and its metabolites in relation to the\n                    sparteine\/debrisoquine polymorphism","volume":"30","author":"K Br\u00f8sen","year":"1986","journal-title":"Eur J Clin Pharmacol"},{"key":"ref1342","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/00004714-198802000-00009","article-title":"Multiple-dose pharmacokinetics of imipramine and its major active and conjugated\n                    metabolites in depressed patients","volume":"8","author":"T A Sutfin","year":"1988","journal-title":"J Clin Psychopharmacol"},{"key":"ref1343","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s002280050306","article-title":"Non-response to maprotiline caused by ultra-rapid metabolism that is different\n                    from CYP2D6?","volume":"52","author":"S V Vormfelde","year":"1997","journal-title":"Eur J Clin Pharmacol"},{"key":"ref1344","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/00007691-200208000-00010","article-title":"Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in\n                    the naturalistic clinical setting","volume":"24","author":"E Skogh","year":"2002","journal-title":"Ther Drug Monit"},{"key":"ref1345","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/00004714-200004000-00010","article-title":"Pharmacologic profile of perphenazine's metabolites","volume":"20","author":"R A Sweet","year":"2000","journal-title":"J Clin Psychopharmacol"},{"key":"ref1346","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/FTD.0b013e31821160c4","article-title":"Pharmacokinetic variability of quetiapine and the active metabolite\n                    N-desalkylquetiapine in psychiatric patients","volume":"33","author":"G V Bakken","year":"2011","journal-title":"Ther Drug Monit"},{"key":"ref1347","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/FTD.0b013e3182603f62","article-title":"Plasma concentrations of quetiapine, N-desalkylquetiapine, o-desalkylquetiapine,\n                    7-hydroxyquetiapine, and quetiapine sulfoxide in relation to quetiapine dose,\n                    formulation, and other factors","volume":"34","author":"D S Fisher","year":"2012","journal-title":"Ther Drug Monit"},{"key":"ref1348","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/FTD.0b013e31828d221f","article-title":"Quetiapine and norquetiapine serum concentrations and clinical effects in\n                    depressed patients under augmentation therapy with quetiapine","volume":"35","author":"E Ostad Haji","year":"2013","journal-title":"Ther Drug Monit"},{"key":"ref1349","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1089\/cap.2007.0084","article-title":"Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine,\n                    norquetiapine, and other quetiapine metabolites in pediatric and adult patients\n                    with psychotic disorders","volume":"18","author":"H R Winter","year":"2008","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"ref1350","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1111\/bcp.15849","article-title":"Impact of age, sex and cytochrome P450 genotype on quetiapine and\n                    N-desalkylquetiapine serum concentrations: A study based on real-world data from\n                    8118 patients","volume":"89","author":"V Solhaug","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"ref1351","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1055\/s-2007-973836","article-title":"A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and\n                    inducers) variables that may influence plasma risperidone levels","volume":"40","author":"J Leon","year":"2007","journal-title":"Pharmacopsychiatry"},{"key":"ref1352","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/FTD.0000000000000251","article-title":"Risperidone and Venlafaxine Metabolic Ratios Strongly Predict a CYP2D6 Poor\n                    Metabolizing Genotype","volume":"38","author":"B Mannheimer","year":"2016","journal-title":"Ther Drug Monit"},{"key":"ref1353","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/01.ftd.0000162868.84596.c3","article-title":"Metabolic ratios of psychotropics as indication of cytochrome P450 2D6\/2C19\n                    genotype","volume":"27","author":"J van der Weide","year":"2005","journal-title":"Ther Drug Monit"},{"key":"ref1354","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1600-0447.2006.00840.x","article-title":"Serum concentrations of risperidone and 9-OH risperidone following intramuscular\n                    injection of long-acting risperidone compared with oral risperidone\n                    medication","volume":"114","author":"R Nesv\u00e5g","year":"2006","journal-title":"Acta Psychiatr Scand"},{"key":"ref1355","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jchromb.2004.10.020","article-title":"Simplified ultraviolet liquid chromatographic method for determination of\n                    sertindole, dehydrosertindole and norsertindole, in human plasma","volume":"814","author":"M Canal-Raffin","year":"2005","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"ref1356","first-page":"443","article-title":"Compliance with SSRI medication during 6 months of treatment for major\n                    depression: an evaluation by determination of repeated serum drug\n                    concentrations","volume":"82","author":"M Reis","year":"2004","journal-title":"J Affect Disord"},{"key":"ref1357","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0378-4347(93)E0366-X","article-title":"Determination of trimipramine and its demethylated and hydroxylated metabolites\n                    in plasma by gas chromatography-mass spectrometry","volume":"652","author":"C B Eap","year":"1994","journal-title":"J Chromatogr"},{"key":"ref1358","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/00007691-200208000-00014","article-title":"Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in\n                    an everyday clinical setting","volume":"24","author":"M Reis","year":"2002","journal-title":"Ther Drug Monit"},{"key":"ref1359","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1365-2710.2006.00763.x","article-title":"CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine","volume":"31","author":"M E Shams","year":"2006","journal-title":"J Clin Pharm Ther"},{"key":"ref1360","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1007\/s00213-014-3825-6","article-title":"The influences of CYP2D6 genotypes and drug interactions on the pharmacokinetics\n                    of venlafaxine: exploring predictive biomarkers for treatment outcomes","volume":"232","author":"F Jiang","year":"2015","journal-title":"Psychopharmacology (Berl)"},{"key":"ref1361","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00228-010-0829-y","article-title":"Differential outcomes from metabolic ratios in the identification of CYP2D6\n                    phenotypes--focus on venlafaxine and O-desmethylvenlafaxine","volume":"66","author":"M Kandasamy","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"ref1362","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00228-014-1664-3","article-title":"Risperidone metabolic ratio as a biomarker of individual CYP2D6 genotype in\n                    schizophrenic patients","volume":"70","author":"B Mannheimer","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"ref1363","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1097\/FTD.0000000000000991","article-title":"Identification of Escitalopram Metabolic Ratios as Potential Biomarkers for\n                    Predicting CYP2C19 Poor Metabolizers","volume":"44","author":"P Faraj","year":"2022","journal-title":"Ther Drug Monit"},{"key":"ref1364","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/JCP.0b013e318058244d","article-title":"The crucial role of the therapeutic window in understanding the clinical\n                    relevance of the poor versus the ultrarapid metabolizer phenotypes in subjects\n                    taking drugs metabolized by CYP2D6 or CYP2C19","volume":"27","author":"J de Leon","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"ref1365","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/JCP.0000000000001387","article-title":"Dose-Dependent Inhibition of CYP2D6 by Bupropion in Patients With\n                    Depression","volume":"41","author":"K Hole","year":"2021","journal-title":"J Clin Psychopharmacol"},{"key":"ref1366","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/1043-6618(92)90231-Y","article-title":"Pharmacokinetic and pharmacodynamic significance of antidepressant drug\n                    metabolites","volume":"26","author":"S Caccia","year":"1992","journal-title":"Pharmacol Res"},{"key":"ref1367","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2165\/00023210-199707040-00003","article-title":"The Role of Metabolites of Antidepressants in the Treatment of Depression","volume":"7","author":"M V Rudorfer","year":"1997","journal-title":"CNS Drugs"},{"key":"ref1368","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1001\/jama.2013.282818","article-title":"Ingredients of successful interventions to improve medication adherence","volume":"310","author":"L L Zullig","year":"2013","journal-title":"Jama"},{"key":"ref1369","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1365-2125.2007.02893.x","article-title":"Compliance, concordance, adherence","volume":"63","author":"J K Aronson","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"ref1370","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/JCP.0b013e3180582426","article-title":"All-cause treatment discontinuation in schizophrenia during treatment with\n                    olanzapine relative to other antipsychotics: an integrated analysis","volume":"27","author":"C M Beasley","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"ref1371","first-page":"5","article-title":"The expert consensus guideline series. Optimizing pharmacologic treatment of\n                    psychotic disorders. Introduction: methods, commentary, and summary","volume":"64","author":"J M Kane","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"ref1372","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1034\/j.1600-0447.2002.1r084.x","article-title":"Treatment non-adherence in affective disorders","volume":"105","author":"R Lingam","year":"2002","journal-title":"Acta Psychiatr Scand"},{"key":"ref1373","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1192\/bjp.179.6.519","article-title":"Spontaneous lapses in dosing during chronic treatment with selective serotonin\n                    reuptake inhibitors","volume":"179","author":"W E Meijer","year":"2001","journal-title":"Br J Psychiatry"},{"key":"ref1374","first-page":"57","article-title":"Empfehlungen f\u00fcr die gutachterliche Bewertung von Medikamentenspiegeln in der\n                    Psychiatrie im gerichtsanh\u00e4ngigen Schadensfall","volume":"16","author":"G Zernig","year":"2009","journal-title":"Psychopharmakotherapie"},{"key":"ref1375","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00228-013-1582-9","article-title":"Risk factors for non-adherence to antidepressant treatment in patients with mood\n                    disorders","volume":"70","author":"C De las Cuevas","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"ref1376","volume-title":"Adherence to long-term therapies : evidence for action","author":"World Health, O.","year":"2003"},{"key":"ref1377","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1176\/appi.ps.55.8.886","article-title":"Partial compliance and risk of rehospitalization among California Medicaid\n                    patients with schizophrenia","volume":"55","author":"P J Weiden","year":"2004","journal-title":"Psychiatr Serv"},{"key":"ref1378","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/01.pra.0000367776.96012.ca","article-title":"Assessment of adherence problems in patients with serious and persistent mental\n                    illness: recommendations from the Expert Consensus Guidelines","volume":"16","author":"D I Velligan","year":"2010","journal-title":"J Psychiatr Pract"},{"key":"ref1379","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1093\/schbul\/sbj075","article-title":"Defining and assessing adherence to oral antipsychotics: a review of the\n                    literature","volume":"32","author":"D I Velligan","year":"2006","journal-title":"Schizophr Bull"},{"key":"ref1380","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jpsychores.2009.05.007","article-title":"Measurement of psychiatric treatment adherence","volume":"69","author":"M Sajatovic","year":"2010","journal-title":"J Psychosom Res"},{"key":"ref1381","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/archinte.165.21.2497","article-title":"Impact of antidepressant drug adherence on comorbid medication use and resource\n                    utilization","volume":"165","author":"W Katon","year":"2005","journal-title":"Arch Intern Med"},{"key":"ref1382","first-page":"379","article-title":"Identification of primary care patients at risk of nonadherence to\n                    antidepressant treatment","volume":"2","author":"A C Akerblad","year":"2008","journal-title":"Patient Prefer Adherence"},{"key":"ref1383","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1176\/ps.2007.58.6.844","article-title":"Validity of electronically monitored medication adherence and conventional\n                    adherence measures in schizophrenia","volume":"58","author":"M J Byerly","year":"2007","journal-title":"Psychiatr Serv"},{"key":"ref1384","first-page":"204","article-title":"Adherence to antidepressant treatment: what the doctor thinks and what the\n                    patient says","volume":"45","author":"N Loayza","year":"2012","journal-title":"Pharmacopsychiatry"},{"key":"ref1385","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.yebeh.2014.09.069","article-title":"The benefits of antiepileptic drug (AED) blood level monitoring to complement\n                    clinical management of people with epilepsy","volume":"42","author":"D Stepanova","year":"2015","journal-title":"Epilepsy Behav"},{"key":"ref1386","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1097\/JCP.0b013e3181fc2cf1","article-title":"Partial compliance as determined from plasma levels of sertraline and its\n                    metabolite in depressed patients in primary care","volume":"30","author":"M Reis","year":"2010","journal-title":"J Clin Psychopharmacol"},{"key":"ref1387","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0009-9120(82)90511-2","article-title":"Monitoring of tricyclic antidepressant therapy","volume":"15","author":"S Dawling","year":"1982","journal-title":"Clin Biochem"},{"key":"ref1388","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/tpj.2012.16","article-title":"ABCB1 gene variants influence tolerance to selective serotonin reuptake\n                    inhibitors in a large sample of Dutch cases with major depressive disorder","volume":"13","author":"O L de Klerk","year":"2013","journal-title":"Pharmacogenomics J"},{"key":"ref1389","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.schres.2011.08.024","article-title":"Early non-adherence to medication and other risk factors for rehospitalization\n                    in schizophrenia and schizoaffective disorder","volume":"133","author":"R Bod\u00e9n","year":"2011","journal-title":"Schizophr Res"},{"key":"ref1390","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5414\/CPP41003","article-title":"Therapeutic drug monitoring of clozapine and relapse--a retrospective study of\n                    routine clinical data","volume":"41","author":"S Ulrich","year":"2003","journal-title":"Int J Clin Pharmacol Ther"},{"key":"ref1391","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2165\/00139709-200423040-00005","article-title":"Developing an analytical toxicology service: principles and guidance","volume":"23","author":"R J Flanagan","year":"2004","journal-title":"Toxicol Rev"},{"key":"ref1392","first-page":"43","article-title":"Influencing CYP enzymes to boost psychiatric treatment: a review on clinical\n                    evidence","volume":"46","author":"F M van Hasselt","year":"2013","journal-title":"Pharmacopsychiatry"},{"key":"ref1393","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/sj.clpt.6100455","article-title":"CYP2D6 phenotype prediction from genotype: which system is the best?","volume":"83","author":"J Kirchheiner","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"ref1394","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/mp.2012.42","article-title":"J. Brockm\u00f6ller, and R. Viviani, Genetic variability of drug-metabolizing\n                    enzymes: the dual impact on psychiatric therapy and regulation of brain\n                    function","volume":"18","author":"J C Stingl","year":"2013","journal-title":"Mol Psychiatry"},{"key":"ref1395","doi-asserted-by":"crossref","first-page":"857","DOI":"10.2217\/pgs-2022-0104","article-title":"Pharmacogenomics in psychiatry - the challenge of cytochrome P450 enzyme\n                    phenoconversion and solutions to assist precision dosing","volume":"23","author":"S Mostafa","year":"2022","journal-title":"Pharmacogenomics"},{"key":"ref1396","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1373\/clinchem.2004.041327","article-title":"Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6\n                    and CYP2C19 identifies patients with low or high risk for side effects in\n                    amitriptyline therapy","volume":"51","author":"W Steimer","year":"2005","journal-title":"Clin Chem"},{"key":"ref1397","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.ridd.2008.10.010","article-title":"Practical guidelines for the use of new generation antipsychotic drugs (except\n                    clozapine) in adult individuals with intellectual disabilities","volume":"30","author":"J de Leon","year":"2009","journal-title":"Res Dev Disabil"},{"key":"ref1398","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/ddrr.119","article-title":"Pharmacotherapy of disruptive behavior in mentally retarded subjects: A review\n                    of the current literature","volume":"16","author":"F H\u00e4ssler","year":"2010","journal-title":"Dev Disabil Res Rev"},{"key":"ref1399","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1055\/a-1625-6388","article-title":"An International Adult Guideline for Making Clozapine Titration Safer by Using\n                    Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine\n                    Levels","volume":"55","author":"J de Leon","year":"2022","journal-title":"Pharmacopsychiatry"},{"key":"ref1400","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1007\/s00213-015-3976-0","article-title":"Inflammation and psychotropic drugs: the relationship between C-reactive protein\n                    and antipsychotic drug levels","volume":"233","author":"G Hefner","year":"2016","journal-title":"Psychopharmacology (Berl)"},{"key":"ref1401","doi-asserted-by":"crossref","first-page":"958","DOI":"10.4088\/JCP.09m05315","article-title":"Comparison of pharmacokinetic profiles of brand-name and generic formulations of\n                    citalopram and venlafaxine: a crossover study","volume":"70","author":"F Chenu","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"ref1402","first-page":"10","article-title":"Study of mental health outcomes associated with different brands of venlafaxine\n                    at the Kumeu medical centre from January 2017 to October 2018","author":"W Ferguson","year":"2020","journal-title":"Ther Adv Psychopharmacol"},{"key":"ref1403","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/cpt.1353","article-title":"Switchability of Gabapentin Formulations: A Randomized Trial to Assess\n                    Bioequivalence Between Neurontin and Gabasandoz on the Individual Subject\n                    Level","volume":"106","author":"G Van Lancker","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"ref1404","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/1741-7015-11-233","article-title":"Improving global health governance to combat counterfeit medicines: a proposal\n                    for a UNODC-WHO-Interpol trilateral mechanism","volume":"11","author":"T K Mackey","year":"2013","journal-title":"BMC Med"},{"key":"ref1405","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1055\/s-2004-815505","article-title":"The AMSP drug safety program: methods and global results","volume":"37","author":"R Grohmann","year":"2004","journal-title":"Pharmacopsychiatry"},{"key":"ref1406","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/FTD.0000000000000692","article-title":"Excretion of Antipsychotics Into the Amniotic Fluid, Umbilical Cord Blood, and\n                    Breast Milk: A Systematic Critical Review and Combined Analysis","volume":"42","author":"G Schoretsanitis","year":"2020","journal-title":"Ther Drug Monit"},{"key":"ref1407","doi-asserted-by":"crossref","first-page":"110228","DOI":"10.1016\/j.pnpbp.2020.110228","article-title":"Antidepressant transfer into amniotic fluid, umbilical cord blood & breast\n                    milk: A systematic review & combined analysis","volume":"107","author":"G Schoretsanitis","year":"2021","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref1408","doi-asserted-by":"crossref","first-page":"110733","DOI":"10.1016\/j.pnpbp.2023.110733","article-title":"Transfer of anticonvulsants and lithium into amniotic fluid, umbilical cord\n                    blood & breast milk: A systematic review & combined analysis","volume":"124","author":"C T Schmidt","year":"2023","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref1409","doi-asserted-by":"crossref","first-page":"752022","DOI":"10.3389\/fphar.2021.752022","article-title":"Neonatal Feeding Trajectories in Mothers With Bipolar Disorder Taking Lithium:\n                    Pharmacokinetic Data","volume":"12","author":"M L Imaz","year":"2021","journal-title":"Front Pharmacol"},{"key":"ref1411","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/cpt.770","article-title":"Treatment With Antipsychotics in Pregnancy: Changes in Drug Disposition","volume":"103","author":"A A Westin","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"ref1412","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta22230","article-title":"AntiEpileptic drug Monitoring in PREgnancy (EMPiRE): a double-blind randomised\n                    trial on effectiveness and acceptability of monitoring strategies","volume":"22","author":"S Thangaratinam","year":"2018","journal-title":"Health Technol Assess"},{"key":"ref1413","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1684\/epd.2019.1105","article-title":"Management of epilepsy in pregnancy: a report from the International League\n                    Against Epilepsy Task Force on Women and Pregnancy","volume":"21","author":"T Tomson","year":"2019","journal-title":"Epileptic Disord"},{"key":"ref1415","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1080\/17425255.2022.2106214","article-title":"Drug-drug interactions between psychotropic medications and oral\n                    contraceptives","volume":"18","author":"G Schoretsanitis","year":"2022","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref1416","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1177\/0269881116636107","article-title":"BAP Position Statement: Off-label prescribing of psychotropic medication to\n                    children and adolescents","volume":"30","author":"A N Sharma","year":"2016","journal-title":"J Psychopharmacol"},{"key":"ref1417","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1055\/a-1716-1856","article-title":"Serious Adverse Drug Reactions in Children and Adolescents Treated On- and\n                    Off-Label with Antidepressants and Antipsychotics in Clinical Practice","volume":"55","author":"K M Egberts","year":"2022","journal-title":"Pharmacopsychiatry"},{"key":"ref1418","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1111\/bcp.14958","article-title":"Current knowledge, challenges and innovations in developmental pharmacology: A\n                    combined conect4children Expert Group and European Society for Developmental,\n                    Perinatal and Paediatric Pharmacology White Paper","volume":"88","author":"A Smits","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"ref1419","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/FTD.0b013e31819f3328","article-title":"Pharmacokinetics and therapeutic drug monitoring of psychotropic drugs in\n                    pediatrics","volume":"31","author":"S Pichini","year":"2009","journal-title":"Ther Drug Monit"},{"key":"ref1420","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1080\/10837450902891527","article-title":"Pharmacokinetics in special populations","volume":"41","author":"I Poggesi","year":"2009","journal-title":"Drug Metab Rev"},{"key":"ref1421","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/ddrr.122","article-title":"Developmental pharmacology","volume":"16","author":"J N van den Anker","year":"2010","journal-title":"Dev Disabil Res Rev"},{"key":"ref1422","first-page":"21","article-title":"[Pharmacovigilance in child and adolescent psychiatry]","volume":"43","author":"K Egberts","year":"2015","journal-title":"Z Kinder Jugendpsychiatr Psychother"},{"key":"ref1423","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1080\/14740338.2016.1225721","article-title":"Therapeutic drug monitoring as a measure of proactive pharmacovigilance in child\n                    and adolescent psychiatry","volume":"15","author":"M Gerlach","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"ref1424","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1055\/s-0031-1271682","article-title":"Quetiapine in adolescents with non-affective psychotic disorders: an open-label\n                    trial","volume":"44","author":"L Holzer","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"ref1425","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1089\/cap.2014.0044","article-title":"Therapeutic drug levels of second generation antipsychotics in youth: a\n                    systematic review","volume":"25","author":"Z Whitney","year":"2015","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"ref1426","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1080\/14740338.2020.1770224","article-title":"Psychotropic drug concentrations and clinical outcomes in children and\n                    adolescents: a systematic review","volume":"19","author":"S M Kloosterboer","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"ref1427","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1080\/17425255.2023.2252340","article-title":"Clinical pharmacokinetics of antipsychotics in pediatric populations: a scoping\n                    review focusing on dosing regimen","volume":"19","author":"J Liang","year":"2023","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref1428","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/FTD.0b013e3181633429","article-title":"Large intraindividual variability of olanzapine serum concentrations in\n                    adolescent patients","volume":"30","author":"C J Bachmann","year":"2008","journal-title":"Ther Drug Monit"},{"key":"ref1429","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/FTD.0b013e318178e18d","article-title":"Large variability of aripiprazole and dehydroaripiprazole serum concentrations\n                    in adolescent patients with schizophrenia","volume":"30","author":"C J Bachmann","year":"2008","journal-title":"Ther Drug Monit"},{"key":"ref1430","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1751-7893.2012.00374.x","article-title":"Plasma clozapine and norclozapine in relation to prescribed dose and other\n                    factors in patients aged<18\u2009years: data from a therapeutic drug monitoring\n                    service, 1994-2010","volume":"7","author":"L Couchman","year":"2013","journal-title":"Early Interv Psychiatry"},{"key":"ref1431","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1055\/s-0031-1291294","article-title":"Therapeutic drug monitoring of children and adolescents treated with\n                    fluoxetine","volume":"45","author":"M Koelch","year":"2012","journal-title":"Pharmacopsychiatry"},{"key":"ref1432","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/01.ftd.0000249950.75462.7f","article-title":"Serum levels of olanzapine and its N-desmethyl and 2-hydroxymethyl metabolites\n                    in child and adolescent psychiatric disorders: effects of dose, diagnosis, age,\n                    sex, smoking, and comedication","volume":"28","author":"F M Theisen","year":"2006","journal-title":"Ther Drug Monit"},{"key":"ref1433","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1007\/s00702-020-02253-4","article-title":"Therapeutic drug monitoring of children and adolescents treated with\n                    aripiprazole: observational results from routine patient care","volume":"127","author":"K Egberts","year":"2020","journal-title":"J Neural Transm (Vienna)"},{"key":"ref1435","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1097\/01.chi.0000219832.23849.31","article-title":"Effectiveness, safety, and pharmacokinetics of quetiapine in aggressive children\n                    with conduct disorder","volume":"45","author":"R L Findling","year":"2006","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"ref1436","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/bcp.14465","article-title":"Risperidone plasma concentrations are associated with side effects and\n                    effectiveness in children and adolescents with autism spectrum disorder","volume":"87","author":"S M Kloosterboer","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"ref1437","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1089\/cap.2008.040","article-title":"Activation adverse events induced by the selective serotonin reuptake inhibitor\n                    fluvoxamine in children and adolescents","volume":"19","author":"S P Reinblatt","year":"2009","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"ref1438","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00004714-200302000-00012","article-title":"Clozapine pharmacokinetics in children and adolescents with childhood-onset\n                    schizophrenia","volume":"23","author":"J A Frazier","year":"2003","journal-title":"J Clin Psychopharmacol"},{"key":"ref1439","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1089\/104454602760219126","article-title":"Correlation of antipsychotic and prolactin concentrations in children and\n                    adolescents acutely treated with haloperidol, clozapine, or olanzapine","volume":"12","author":"C L Alfaro","year":"2002","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"ref1440","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00702-022-02485-6","article-title":"Therapeutic drug monitoring in children and adolescents with schizophrenia and\n                    other psychotic disorders using risperidone","volume":"129","author":"R Taurines","year":"2022","journal-title":"J Neural Transm (Vienna)"},{"key":"ref1441","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s00702-016-1573-y","article-title":"Relationship between clozapine dose, serum concentration, and clinical outcome\n                    in children and adolescents in clinical practice","volume":"123","author":"C Wohkittel","year":"2016","journal-title":"J Neural Transm (Vienna)"},{"key":"ref1442","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1097\/01.chi.0000143546.28821.11","article-title":"Multiple-dose pharmacokinetics of fluvoxamine in children and adolescents","volume":"43","author":"M Labellarte","year":"2004","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"ref1443","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00228-015-1982-0","article-title":"Therapeutic drug monitoring of second-generation antipsychotics in pediatric\n                    patients: an observational study in real-life settings","volume":"72","author":"M Pozzi","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"ref1444","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/FTD.0000000000000398","article-title":"Therapeutic Drug Monitoring in Children and Adolescents Under Pharmacotherapy\n                    With Olanzapine in Daily Clinical Practice","volume":"39","author":"S Fekete","year":"2017","journal-title":"Ther Drug Monit"},{"key":"ref1445","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1055\/s-0043-109695","article-title":"Relationship Between Daily Dose, Serum Concentration, and Clinical Response to\n                    Quetiapine in Children and Adolescents with Psychotic and Mood Disorders","volume":"50","author":"L Albantakis","year":"2017","journal-title":"Pharmacopsychiatry"},{"key":"ref1446","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1055\/s-2007-972573","article-title":"Therapeutic drug monitoring of quetiapine in adolescents with psychotic\n                    disorders","volume":"40","author":"M Gerlach","year":"2007","journal-title":"Pharmacopsychiatry"},{"key":"ref1447","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1055\/s-0029-1239540","article-title":"Serum concentrations, therapeutic response and side effects in children and\n                    adolescents with impulsive-aggressive symptoms during risperidone therapy","volume":"43","author":"K Klampfl","year":"2010","journal-title":"Pharmacopsychiatry"},{"key":"ref1448","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00228-020-03000-0","article-title":"Estimation of a preliminary therapeutic reference range for children and\n                    adolescents with tic disorders treated with tiapride","volume":"77","author":"S Fekete","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"key":"ref1449","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1007\/s40265-021-01618-7","article-title":"Clinical Value of Emerging Bioanalytical Methods for Drug Measurements: A\n                    Scoping Review of Their Applicability for Medication Adherence and Therapeutic\n                    Drug Monitoring","volume":"81","author":"T R Zijp","year":"2021","journal-title":"Drugs"},{"key":"ref1450","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/FTD.0000000000000831","article-title":"Relationship Between Amphetamine Concentrations in Saliva and Serum in Children\n                    and Adolescents With Attention-Deficit\/Hyperactivity Disorder","volume":"43","author":"C Wohkittel","year":"2021","journal-title":"Ther Drug Monit"},{"key":"ref1451","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/FTD.0000000000000520","article-title":"Interindividual and Intraindividual Variation of Methylphenidate Concentrations\n                    in Serum and Saliva of Patients With Attention-Deficit\/Hyperactivity\n                    Disorder","volume":"40","author":"J Preiskorn","year":"2018","journal-title":"Ther Drug Monit"},{"key":"ref1452","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1186\/s12888-022-04445-6","article-title":"The effect of therapeutic drug monitoring of risperidone and aripiprazole on\n                    weight gain in children and adolescents: the SPACe 2: STAR (trial) protocol of\n                    an international multicentre randomised controlled trial","volume":"22","author":"R A Hermans","year":"2022","journal-title":"BMC Psychiatry"},{"key":"ref1453","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1111\/bcp.15800","article-title":"Towards precision dosing of aripiprazole in children and adolescents with autism\n                    spectrum disorder: Linking blood levels to weight gain and effectiveness","volume":"89","author":"R A Hermans","year":"2023","journal-title":"British Journal of Clinical Pharmacology"},{"key":"ref1454","doi-asserted-by":"crossref","first-page":"397","DOI":"10.4088\/JCP.08r04171","article-title":"Increased antipsychotic sensitivity in elderly patients: evidence and\n                    mechanisms","volume":"70","author":"H Uchida","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"ref1455","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1177\/0091270005280297","article-title":"Aging and clinical pharmacology: implications for antidepressants","volume":"45","author":"F E Lotrich","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"ref1456","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1365-2125.2004.02096.x","article-title":"Drug metabolism and ageing","volume":"57","author":"M T Kinirons","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"ref1457","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.clpt.6100226","article-title":"The current state of knowledge on age, sex, and their interactions on clinical\n                    pharmacology","volume":"82","author":"J B Schwartz","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"ref1458","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13690-015-0068-x","article-title":"Burden of frailty in the elderly population: perspectives for a public health\n                    challenge","volume":"73","author":"F Buckinx","year":"2015","journal-title":"Arch Public Health"},{"key":"ref1459","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1479-8301.2012.00418.x","article-title":"Expert-based drug lists to measure anticholinergic burden: similar names,\n                    different results","volume":"13","author":"U Lertxundi","year":"2013","journal-title":"Psychogeriatrics"},{"key":"ref1460","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s40266-012-0044-x","article-title":"Association of anticholinergic burden with cognitive and functional status in a\n                    cohort of hospitalized elderly: comparison of the anticholinergic cognitive\n                    burden scale and anticholinergic risk scale: results from the REPOSI study","volume":"30","author":"L Pasina","year":"2013","journal-title":"Drugs Aging"},{"key":"ref1461","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/j.1532-5415.2008.01737.x","article-title":"Anticholinergic activity of 107 medications commonly used by older adults","volume":"56","author":"M L Chew","year":"2008","journal-title":"J Am Geriatr Soc"},{"key":"ref1463","first-page":"213","article-title":"Adverse drug events in older patients admitted as an emergency: the role of\n                    potentially inappropriate medication in elderly people (PRISCUS)","volume":"110","author":"H Dormann","year":"2013","journal-title":"Dtsch Arztebl Int"},{"key":"ref1464","first-page":"543","article-title":"Potentially inappropriate medications in the elderly: the PRISCUS list","volume":"107","author":"S Holt","year":"2010","journal-title":"Dtsch Arztebl Int"},{"key":"ref1465","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/pds.3429","article-title":"Prescribing potentially inappropriate medication (PIM) in Germany's elderly\n                    as indicated by the PRISCUS list. An analysis based on regional claims data","volume":"22","author":"I Schubert","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref1466","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/ageing\/afn197","article-title":"STOPP (Screening Tool of Older Persons' potentially inappropriate\n                    Prescriptions): application to acutely ill elderly patients and comparison with\n                    Beers' criteria","volume":"37","author":"P Gallagher","year":"2008","journal-title":"Age Ageing"},{"key":"ref1467","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1093\/ageing\/afm189","article-title":"Inappropriate prescribing in the older population: need for new criteria","volume":"37","author":"D O'Mahony","year":"2008","journal-title":"Age Ageing"},{"key":"ref1468","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/ageing\/afu145","article-title":"STOPP\/START criteria for potentially inappropriate prescribing in older people:\n                    version 2","volume":"44","author":"D O'Mahony","year":"2015","journal-title":"Age Ageing"},{"key":"ref1469","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1001\/archinternmed.2007.106","article-title":"The anticholinergic risk scale and anticholinergic adverse effects in older\n                    persons","volume":"168","author":"J L Rudolph","year":"2008","journal-title":"Arch Intern Med"},{"key":"ref1470","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s12603-012-0373-9","article-title":"Subthreshold depression in older subjects: an unmet therapeutic need","volume":"16","author":"A Cherubini","year":"2012","journal-title":"J Nutr Health Aging"},{"key":"ref1471","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/JCP.0b013e31817d79eb","article-title":"Assessment of the prescription of antidepressant drugs in elderly nursing home\n                    patients: a clinical and laboratory follow-up investigation","volume":"28","author":"M D Cherm\u00e1","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"ref1472","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2165\/11633520-000000000-00000","article-title":"Off-label prescribing in older patients","volume":"29","author":"S H Jackson","year":"2012","journal-title":"Drugs Aging"},{"key":"ref1473","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12028-012-9689-x","article-title":"Process improvement methods increase the efficiency, accuracy, and utility of a\n                    neurocritical care research repository","volume":"17","author":"S O'Connor","year":"2012","journal-title":"Neurocrit Care"},{"key":"ref1474","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0140-6736(07)61091-5","article-title":"Appropriate prescribing in elderly people: how well can it be measured and\n                    optimised?","volume":"370","author":"A Spinewine","year":"2007","journal-title":"Lancet"},{"key":"ref1475","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2165\/11632400-000000000-00000","article-title":"Evidence-based strategies for the optimization of pharmacotherapy in older\n                    people","volume":"29","author":"E Topinkov\u00e1","year":"2012","journal-title":"Drugs Aging"},{"key":"ref1476","first-page":"404","article-title":"When \"enough\" is not enough: new perspectives on optimal methadone\n                    maintenance dose","volume":"67","author":"S B Leavitt","year":"2000","journal-title":"Mt Sinai J Med"},{"key":"ref1478","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S2215-0366(17)30080-9","article-title":"Changes in substance use in patients receiving opioid substitution therapy and\n                    resulting clinical challenges: a 17-year treatment case register analysis","volume":"4","author":"M Herdener","year":"2017","journal-title":"Lancet Psychiatry"},{"key":"ref1479","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1097\/FTD.0000000000001116","article-title":"Levomethadone Therapeutic Drug Monitoring to Aid Opioid Withdrawal Therapy: A\n                    Short Communication","volume":"45","author":"P Pfeifer","year":"2023","journal-title":"Ther Drug Monit"},{"key":"ref1480","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S0140-6736(22)02403-5","article-title":"Contemporary medical, device, and surgical therapies for obesity in adults","volume":"401","author":"C M Perdomo","year":"2023","journal-title":"Lancet"},{"key":"ref1481","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S2468-1253(20)30302-2","article-title":"Adaptations in gastrointestinal physiology after sleeve gastrectomy and\n                    Roux-en-Y gastric bypass","volume":"6","author":"N Steenackers","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref1482","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1211\/jpp.61.05.0002","article-title":"Cytochrome P450-mediated metabolism in the human gut wall","volume":"61","author":"K Thelen","year":"2009","journal-title":"J Pharm Pharmacol"},{"key":"ref1483","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1467-789X.2009.00614.x","article-title":"A systematic review of drug absorption following bariatric surgery and its\n                    theoretical implications","volume":"11","author":"R Padwal","year":"2010","journal-title":"Obes Rev"},{"key":"ref1484","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1007\/s00228-021-03182-1","article-title":"Serum concentrations of antidepressants, antipsychotics, and antiepileptics over\n                    the bariatric surgery procedure","volume":"77","author":"S M Wallerstedt","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"key":"ref1485","first-page":"409","article-title":"Medication management and pharmacokinetic changes after bariatric surgery","volume":"66","author":"S Lorico","year":"2020","journal-title":"Can Fam Physician"},{"key":"ref1486","doi-asserted-by":"crossref","first-page":"e12988","DOI":"10.1111\/obr.12988","article-title":"Pharmacokinetic changes post-bariatric surgery: A scoping review","volume":"21","author":"L A McLachlan","year":"2020","journal-title":"Obes Rev"},{"key":"ref1487","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s11695-020-05048-4","article-title":"Bioavailability of Vortioxetine After a Roux-en-Y Gastric Bypass","volume":"31","author":"F Vandenberghe","year":"2021","journal-title":"Obes Surg"},{"key":"ref1488","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/FTD.0000000000000146","article-title":"Decreased Escitalopram Concentrations Post-Roux-en-Y Gastric Bypass Surgery","volume":"37","author":"M A Marzinke","year":"2015","journal-title":"Ther Drug Monit"},{"key":"ref1489","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1176\/appi.ajp.2011.11050719","article-title":"The effect of gastric bypass on the pharmacokinetics of serotonin reuptake\n                    inhibitors","volume":"169","author":"G G Hamad","year":"2012","journal-title":"Am J Psychiatry"},{"key":"ref1490","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/JCP.0b013e3182905ffb","article-title":"A comparison of duloxetine plasma levels in postbariatric surgery patients\n                    versus matched nonsurgical control subjects","volume":"33","author":"J L Roerig","year":"2013","journal-title":"J Clin Psychopharmacol"},{"key":"ref1491","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s13668-023-00498-5","article-title":"The Effects of Bariatric Surgery on Pharmacokinetics of Drugs: a Review of\n                    Current Evidence","volume":"12","author":"S K Konstantinidou","year":"2023","journal-title":"Curr Nutr Rep"},{"key":"ref1492","doi-asserted-by":"crossref","first-page":"4560","DOI":"10.1111\/bcp.14913","article-title":"Oral drug dosing following bariatric surgery: General concepts and specific\n                    dosing advice","volume":"87","author":"J S Kingma","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"ref1493","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.eurpsy.2005.07.006","article-title":"Randomised clinical trial comparing oral versus depot formulations of\n                    zuclopenthixol in patients with schizophrenia and previous violence","volume":"21","author":"C Arango","year":"2006","journal-title":"Eur Psychiatry"},{"key":"ref1494","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1055\/s-0028-1082072","article-title":"A double-blind placebo-controlled discontinuation study of zuclopenthixol for\n                    the treatment of aggressive disruptive behaviours in adults with mental\n                    retardation - secondary parameter analyses","volume":"41","author":"F H\u00e4ssler","year":"2008","journal-title":"Pharmacopsychiatry"},{"key":"ref1495","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0160-2527(00)00056-X","article-title":"Forensic psychiatric assessment and treatment in Germany. Legal framework,\n                    recent developments, and current practice","volume":"23","author":"R M\u00fcller-Isberner","year":"2000","journal-title":"Int J Law Psychiatry"},{"key":"ref1496","first-page":"52","article-title":"Forensische Aspekte des therapeutischen Drug-Monitorings (TDM) in der\n                    Psychiatrie","volume":"16","author":"H M\u00fcller","year":"2009","journal-title":"Psychopharmakotherapie"},{"key":"ref1497","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1586\/ern.10.180","article-title":"The pharmacological management of violence in schizophrenia: a structured\n                    review","volume":"11","author":"A Topiwala","year":"2011","journal-title":"Expert Rev Neurother"},{"key":"ref1498","first-page":"255","article-title":"[Psychotropic Drugs - Comparison of Application Practice in Forensic and General\n                    Psychiatry]","volume":"49","author":"S St\u00fcbner","year":"2022","journal-title":"Psychiatr Prax"},{"key":"ref1499","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3389\/fpsyt.2019.00963","article-title":"Pharmacological Treatment in Forensic Psychiatry-A Systematic Review","volume":"10","author":"K Howner","year":"2019","journal-title":"Front Psychiatry"},{"key":"ref1500","first-page":"182","article-title":"[Personalised medicine in forensic psychiatry: an example for other domains of\n                    psychiatry?]","volume":"60","author":"K R Goethals","year":"2018","journal-title":"Tijdschr Psychiatr"},{"key":"ref1501","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/FTD.0b013e31818622c4","article-title":"Prescribing patterns and the use of therapeutic drug monitoring of psychotropic\n                    medication in a psychiatric high-security unit","volume":"30","author":"I Castberg","year":"2008","journal-title":"Ther Drug Monit"},{"key":"ref1502","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3109\/15622975.2011.561872","article-title":"The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines\n                    for the biological treatment of substance use and related disorders. Part 2:\n                    Opioid dependence","volume":"12","author":"M Soyka","year":"2011","journal-title":"World J Biol Psychiatry"},{"key":"ref1503","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jmoldx.2016.01.003","article-title":"Preemptive Pharmacogenomic Testing for Precision Medicine: A Comprehensive\n                    Analysis of Five Actionable Pharmacogenomic Genes Using Next-Generation DNA\n                    Sequencing and a Customized CYP2D6 Genotyping Cascade","volume":"18","author":"Y Ji","year":"2016","journal-title":"J Mol Diagn"},{"key":"ref1504","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2165\/00003088-199937020-00004","article-title":"Therapeutic drug monitoring of antidepressants: cost implications and relevance\n                    to clinical practice","volume":"37","author":"M J Burke","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"ref1505","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1365-2710.1992.tb01318.x","article-title":"Serum drug level monitoring in affective disorders","volume":"17","author":"J Krska","year":"1992","journal-title":"J Clin Pharm Ther"},{"key":"ref1506","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1177\/0269881108089806","article-title":"Amisulpride doses and plasma levels in different age groups of patients with\n                    schizophrenia or schizoaffective disorder","volume":"23","author":"M J M\u00fcller","year":"2009","journal-title":"J Psychopharmacol"},{"key":"ref1507","doi-asserted-by":"crossref","first-page":"568","DOI":"10.4088\/JCP.12r08167","article-title":"Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia:\n                    synthesizing results across different research designs","volume":"74","author":"N Y Kirson","year":"2013","journal-title":"J Clin Psychiatry"},{"key":"ref1508","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/schbul\/sbs150","article-title":"Long-acting injectable vs oral antipsychotics for relapse prevention in\n                    schizophrenia: a meta-analysis of randomized trials","volume":"40","author":"T Kishimoto","year":"2014","journal-title":"Schizophr Bull"},{"key":"ref1509","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1684\/epd.2016.0880","article-title":"Dosing strategies for antiepileptic drugs: from a standard dose for all to\n                    individualised treatment by implementation of therapeutic drug monitoring","volume":"18","author":"C J Landmark","year":"2016","journal-title":"Epileptic Disord"},{"key":"ref1510","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s40263-021-00862-5","article-title":"Amantadine Revisited: A Contender for Initial Treatment in Parkinson's\n                    Disease?","volume":"35","author":"S Marmol","year":"2021","journal-title":"CNS Drugs"},{"key":"ref1511","doi-asserted-by":"crossref","first-page":"1036068","DOI":"10.3389\/fneur.2022.1036068","article-title":"The pharmacokinetics of continuous subcutaneous levodopa\/carbidopa infusion:\n                    Findings from the ND0612 clinical development program","volume":"13","author":"P A LeWitt","year":"2022","journal-title":"Front Neurol"},{"key":"ref1512","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/WNF.0000000000000354","article-title":"Pharmacodynamics, Efficacy, and Safety of IPX203 in Parkinson Disease Patients\n                    With Motor Fluctuations","volume":"42","author":"N B Modi","year":"2019","journal-title":"Clin Neuropharmacol"},{"key":"ref1513","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.3233\/JPD-212813","article-title":"Foslevodopa\/Foscarbidopa Is Well Tolerated and Maintains Stable Levodopa and\n                    Carbidopa Exposure Following Subcutaneous Infusion","volume":"11","author":"M Rosebraugh","year":"2021","journal-title":"J Parkinsons Dis"},{"key":"ref1514","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/bs.irn.2017.05.015","article-title":"Personalized Medicine and Nonmotor Symptoms in Parkinson's Disease","volume":"134","author":"N Titova","year":"2017","journal-title":"Int Rev Neurobiol"},{"key":"ref1515","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/mds.27027","article-title":"Personalized medicine in Parkinson's disease: Time to be precise","volume":"32","author":"N Titova","year":"2017","journal-title":"Mov Disord"},{"key":"ref1516","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2165\/00003088-199630010-00004","article-title":"Pharmacokinetic-pharmacodynamic relationships for benzodiazepines","volume":"30","author":"B E Laurijssens","year":"1996","journal-title":"Clin Pharmacokinet"},{"key":"ref1517","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1515\/cclm-2018-0482","article-title":"Evidence for the positive impact of ISO 9001 and ISO 15189 quality systems on\n                    laboratory performance - evaluation of immunohaematology external quality\n                    assessment results during 19 years in Austria","volume":"56","author":"C Buchta","year":"2018","journal-title":"Clin Chem Lab Med"},{"key":"ref1519","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.clinbiochem.2008.09.011","article-title":"ISO 15189 accreditation: Requirements for quality and competence of medical\n                    laboratories, experience of a laboratory I","volume":"42","author":"O Guzel","year":"2009","journal-title":"Clin Biochem"},{"key":"ref1521","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3343\/alm.2017.37.5.365","article-title":"International Organization for Standardization (ISO) 15189","volume":"37","author":"F Schneider","year":"2017","journal-title":"Ann Lab Med"},{"key":"ref1524","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1515\/cclm-2017-1179","article-title":"External quality assessment programs in the context of ISO 15189\n                    accreditation","volume":"56","author":"L Sciacovelli","year":"2018","journal-title":"Clin Chem Lab Med"},{"key":"ref1526","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13317-020-00134-0","article-title":"Quality and best practice in medical laboratories: specific requests for\n                    autoimmunity testing","volume":"11","author":"U Sack","year":"2020","journal-title":"Auto Immun Highlights"},{"key":"ref1527","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/00007691-199005000-00007","article-title":"Compliance with criteria necessary for effective drug concentration\n                    monitoring","volume":"12","author":"G A Pearce","year":"1990","journal-title":"Ther Drug Monit"},{"key":"ref1528","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/00007691-198007000-00002","article-title":"The importance of request and report forms in the interpretation of therapeutic\n                    drug monitoring data","volume":"2","author":"J R Svirbely","year":"1980","journal-title":"Ther Drug Monit"},{"key":"ref1529","volume-title":"ECDEO Assessment Manual for Psychopharmacology","author":"W Guy","year":"1976"},{"key":"ref1530","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","article-title":"The UKU side effect rating scale. A new comprehensive rating scale for\n                    psychotropic drugs and a cross-sectional study of side effects in\n                    neuroleptic-treated patients","volume":"334","author":"O Lingjaerde","year":"1987","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"ref1531","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2146\/ajhp090661","article-title":"Effects of therapeutic drug monitoring criteria in a computerized\n                    prescriber-order-entry system on the appropriateness of vancomycin level\n                    orders","volume":"68","author":"K A Traugott","year":"2011","journal-title":"Am J Health Syst Pharm"},{"key":"ref1532","first-page":"13","volume-title":"Sampling Times for Oral and Long-Acting Injectable Agents, in The Clinical Use\n                    of Antipsychotic Plasma Levels: Stahl's Handbooks, J.M. Meyer and S.M.\n                    Stahl, Editors","year":"2021"},{"key":"ref1533","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/17425255.2023.2220962","article-title":"Personalized switching from oral to long-acting injectable second-generation\n                    antipsychotics in schizophrenia treatment using pharmacokinetic\n                    considerations","volume":"19","author":"G Schoretsanitis","year":"2023","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref1534","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1080\/10408363.2018.1499708","article-title":"Sample management for clinical biochemistry assays: Are serum and plasma\n                    interchangeable specimens?","volume":"55","author":"G Lima-Oliveira","year":"2018","journal-title":"Crit Rev Clin Lab Sci"},{"key":"ref1535","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/BF01956868","article-title":"Plasma or serum in therapeutic drug monitoring and clinical toxicology","volume":"10","author":"D R Uges","year":"1988","journal-title":"Pharm Weekbl Sci"},{"key":"ref1536","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.cca.2018.10.043","article-title":"The right blood collection tube for therapeutic drug monitoring and toxicology\n                    screening procedures: Standard tubes, gel or mechanical separator?","volume":"488","author":"A Schrapp","year":"2019","journal-title":"Clin Chim Acta"},{"key":"ref1538","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1046\/j.1365-2125.2003.01821.x","article-title":"Comparability of whole-blood and plasma clozapine and norclozapine\n                    concentrations","volume":"56","author":"R J Flanagan","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"ref1539","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jpba.2018.12.040","article-title":"LC-MS application for therapeutic drug monitoring in alternative matrices","volume":"166","author":"V Avataneo","year":"2019","journal-title":"J Pharm Biomed Anal"},{"key":"ref1541","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1021\/acs.chemrestox.9b00301","article-title":"Extraction Procedures for Hair Forensic Toxicological Analysis: A\n                    Mini-Review","volume":"32","author":"C Ferreira","year":"2019","journal-title":"Chem Res Toxicol"},{"key":"ref1542","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/00007691-200404000-00020","article-title":"Detection times of drugs of abuse in blood, urine, and oral fluid","volume":"26","author":"A G Verstraete","year":"2004","journal-title":"Ther Drug Monit"},{"key":"ref1543","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s13318-020-00661-1","article-title":"Feasibility of Using Oral Fluid for Therapeutic Drug Monitoring of Antiepileptic\n                    Drugs","volume":"46","author":"M Patrick","year":"2021","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"ref1544","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/FTD.0000000000000520","article-title":"Interindividual and Intraindividual Variation of Methylphenidate Concentrations\n                    in Serum and Saliva of Patients With Attention-Deficit\/Hyperactivity\n                    Disorder","volume":"40","author":"J Preiskorn","year":"2018","journal-title":"Therapeutic Drug Monitoring"},{"key":"ref1545","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/FTD.0000000000000831","article-title":"Relationship Between Amphetamine Concentrations in Saliva and Serum in Children\n                    and Adolescents With Attention-Deficit\/Hyperactivity Disorder","volume":"43","author":"C Wohkittel","year":"2021","journal-title":"Therapeutic Drug Monitoring"},{"key":"ref1546","first-page":"136","article-title":"On the Relationship between Free Plasma and Saliva Amitriptyline and\n                    Nortriptyline","volume":"17","author":"P Baumann","year":"1982","journal-title":"Int Pharmacopsychiatry"},{"key":"ref1547","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/00007691-200408000-00019","article-title":"Assessment of storage and transport stability of new antidepressant and\n                    antipsychotic drugs for a nationwide TDM service","volume":"26","author":"S Heller","year":"2004","journal-title":"Ther Drug Monit"},{"key":"ref1548","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1373\/clinchem.2007.088344","article-title":"Errors in a stat laboratory: types and frequencies 10 years later","volume":"53","author":"P Carraro","year":"2007","journal-title":"Clin Chem"},{"key":"ref1549","first-page":"020705","article-title":"European survey on preanalytical sample handling - Part 2: Practices of European\n                    laboratories on monitoring and processing haemolytic, icteric and lipemic\n                    samples. On behalf of the European Federation of Clinical Chemistry and\n                    Laboratory Medicine (EFLM) Working Group for the Preanalytical Phase\n                    (WG-PRE)","volume":"29","author":"J Cadamuro","year":"2019","journal-title":"Biochem Med (Zagreb)"},{"key":"ref1550","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3109\/10408363.2011.600228","article-title":"Hemolyzed specimens: a major challenge for emergency departments and clinical\n                    laboratories","volume":"48","author":"G Lippi","year":"2011","journal-title":"Crit Rev Clin Lab Sci"},{"key":"ref1551","doi-asserted-by":"crossref","first-page":"248","DOI":"10.11613\/BM.2014.027","article-title":"Pre-analytical errors management in the clinical laboratory: a five-year\n                    study","volume":"24","author":"A Gimenez-Marin","year":"2014","journal-title":"Biochem Med (Zagreb)"},{"key":"ref1552","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1176\/ajp.2007.164.1.172","article-title":"Quetiapine cross reactivity with urine methadone immunoassays","volume":"164","author":"C G Widschwendter","year":"2007","journal-title":"Am J Psychiatry"},{"key":"ref1553","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1515\/cclm-2014-1149","article-title":"D. Brugnoni, and S. Mattioli, How to define a significant deviation from the\n                    expected internal quality control result","volume":"53","author":"F Ceriotti","year":"2015","journal-title":"Clin Chem Lab Med"},{"key":"ref1554","doi-asserted-by":"crossref","first-page":"113102","DOI":"10.1016\/j.jpba.2020.113102","article-title":"Opportunities and obstacles for microsampling techniques in bioanalysis: Special\n                    focus on DBS and VAMS","volume":"182","author":"V Londhe","year":"2020","journal-title":"J Pharm Biomed Anal"},{"key":"ref1555","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/mas.21441","article-title":"The use of mass spectrometry to analyze dried blood spots","volume":"35","author":"M Wagner","year":"2016","journal-title":"Mass Spectrom Rev"},{"key":"ref1556","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/FTD.0000000000000643","article-title":"Official International Association for Therapeutic Drug Monitoring and Clinical\n                    Toxicology Guideline: Development and Validation of Dried Blood Spot-Based\n                    Methods for Therapeutic Drug Monitoring","volume":"41","author":"S Capiau","year":"2019","journal-title":"Ther Drug Monit"},{"key":"ref1557","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.euroneuro.2017.01.009","article-title":"Dried Blood Spot sampling in psychiatry: Perspectives for improving therapeutic\n                    drug monitoring","volume":"27","author":"L C Martial","year":"2017","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref1558","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1515\/cclm-2019-0784","article-title":"Therapeutic drug monitoring of anti-epileptic drugs - a clinical verification of\n                    volumetric absorptive micro sampling","volume":"58","author":"T Canisius","year":"2020","journal-title":"Clin Chem Lab Med"},{"key":"ref1559","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/bcpt.13269","article-title":"Development and clinical applications of the dried blood spot method for\n                    therapeutic drug monitoring of anti-epileptic drugs","volume":"125","author":"K L Min","year":"2019","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref1560","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.clinbiochem.2020.03.004","article-title":"After another decade: LC-MS\/MS became routine in clinical diagnostics","volume":"82","author":"C Seger","year":"2020","journal-title":"Clin Biochem"},{"key":"ref1562","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1080\/17512433.2018.1549489","article-title":"A systematic review and combined analysis of therapeutic drug monitoring studies\n                    for long-acting paliperidone","volume":"11","author":"G Schoretsanitis","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref1564","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1017\/S1092852917000840","article-title":"Converting oral to long-acting injectable antipsychotics: a guide for the\n                    perplexed","volume":"22","author":"J M Meyer","year":"2017","journal-title":"CNS Spectr"},{"key":"ref1566","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1016\/j.pnpbp.2008.07.009","article-title":"Association of dopamine and opioid receptor genetic polymorphisms with response\n                    to methadone maintenance treatment","volume":"32","author":"S Crettol","year":"2008","journal-title":"Progress in Neuro-Psychopharmacology and Biological\n                    Psychiatry"},{"key":"ref1567","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/clpt.2013.221","article-title":"Pharmacogenomics in psychiatry: from therapeutic drug monitoring to genomic\n                    medicine","volume":"95","author":"S Crettol","year":"2014","journal-title":"Clinical pharmacology and therapeutics"},{"key":"ref1568","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1146\/annurev.med.56.082103.104724","article-title":"Pharmacogenomics and individualized drug therapy","volume":"57","author":"M Eichelbaum","year":"2006","journal-title":"Annu Rev Med"},{"key":"ref1569","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/01.jcp.0000088909.24613.92","article-title":"Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine\n                    pharmacokinetics","volume":"23","author":"J Kirchheiner","year":"2003","journal-title":"J Clin Psychopharmacol"},{"key":"ref1570","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.bbagen.2006.09.019","article-title":"Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing\n                    enzymes","volume":"1770","author":"J Kirchheiner","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"ref1571","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1177\/0091270006293754","article-title":"Therapeutic drug monitoring of antidepressants and cytochrome p450 genotyping in\n                    general practice","volume":"46","author":"J E Kootstra-Ros","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"ref1572","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0009-8981(01)00713-6","article-title":"Pharmacogenetic screening and therapeutic drugs","volume":"315","author":"W Steimer","year":"2002","journal-title":"Clin Chim Acta"},{"key":"ref1573","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1055\/s-0034-1383565","article-title":"Prediction of antidepressant response to venlafaxine by a combination of early\n                    response assessment and therapeutic drug monitoring","volume":"47","author":"T J Stamm","year":"2014","journal-title":"Pharmacopsychiatry"},{"key":"ref1574","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1186\/s12888-023-04756-2","article-title":"Effect of pharmacogenomics testing guiding on clinical outcomes in major\n                    depressive disorder: a systematic review and meta-analysis of RCT","volume":"23","author":"X Wang","year":"2023","journal-title":"BMC Psychiatry"},{"key":"ref1575","doi-asserted-by":"crossref","first-page":"104965","DOI":"10.1016\/j.neubiorev.2022.104965","article-title":"Effectiveness of pharmacogenomic tests including CYP2D6 and CYP2C19 genomic\n                    variants for guiding the treatment of depressive disorders: Systematic review\n                    and meta-analysis of randomised controlled trials","volume":"144","author":"D Arnone","year":"2023","journal-title":"Neurosci Biobehav Rev"},{"key":"ref1576","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/cpt.2748","article-title":"Pharmacogenomic testing and depressive symptom remission: a systematic review\n                    and meta-analysis of prospective, controlled clinical trials","volume":"112","author":"L C Brown","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"ref1577","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41380-021-01340-6","article-title":"Gene-drug pairings for antidepressants and antipsychotics: level of evidence and\n                    clinical application","volume":"27","author":"L E Murphy","year":"2022","journal-title":"Mol Psychiatry"},{"key":"ref1578","first-page":"52","article-title":"Forensic aspects of therapeutic drug-monitoring in psychiatry","volume":"16","author":"H Mueller","year":"2009","journal-title":"Psychopharmakotherapie"},{"issue":"44","key":"ref1579","doi-asserted-by":"publisher","first-page":"E1499","DOI":"10.1503\/cmaj.221785","article-title":"Cost-effectiveness of pharmacogenomic-guided treatment for major depression","volume":"195","author":"S Ghanbarian","year":"2023","journal-title":"CMAJ"},{"key":"ref1580","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/01.jcp.0000246211.95905.8c","article-title":"Optimizing early prediction for antipsychotic response in schizophrenia","volume":"26","author":"Y-C Chang","year":"2006","journal-title":"Journal of clinical psychopharmacology"},{"key":"ref1581","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1176\/appi.ajp.160.11.2063","article-title":"Early prediction of antipsychotic response in schizophrenia","volume":"160","author":"C U Correll","year":"2003","journal-title":"Am J Psychiatry"},{"key":"ref1582","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jad.2010.10.026","article-title":"Clinical value of early partial symptomatic improvement in the prediction of\n                    response and remission during short-term treatment trials in 3,369 subjects with\n                    bipolar I or II depression","volume":"130","author":"D E Kemp","year":"2011","journal-title":"J Affect Disord"},{"key":"ref1583","doi-asserted-by":"crossref","first-page":"352","DOI":"10.4088\/JCP.v68n0301","article-title":"Early prediction of antipsychotic nonresponse among patients with\n                    schizophrenia","volume":"68","author":"S Leucht","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"ref1584","doi-asserted-by":"crossref","first-page":"344","DOI":"10.4088\/JCP.07m03780","article-title":"Early improvement in the first 2 weeks as a predictor of treatment outcome in\n                    patients with major depressive disorder: A meta-analysis including 6,562\n                    patients","volume":"70","author":"A Szegedi","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"ref1585","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0165-0327(85)90071-0","article-title":"Cost-benefit analysis of prospective pharmacokinetic dosing of nortriptyline in\n                    depressed inpatients","volume":"8","author":"S A Simmons","year":"1985","journal-title":"J Affect Disord"},{"key":"ref1586","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1034\/j.1600-0447.2000.101005354.x","article-title":"Therapeutic drug monitoring of selective serotonin reuptake inhibitors\n                    influences clinical dosing strategies and reduces drug costs in depressed\n                    elderly patients","volume":"101","author":"J Lundmark","year":"2000","journal-title":"Acta Psychiatr Scand"},{"key":"ref1587","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1007\/s00115-024-01636-2","article-title":"TDM von Antidepressiva verk\u00fcrzt Klinikaufenthalt","volume":"95","author":"M Scherf-Clavel","year":"2024","journal-title":"Der Nervenarzt"},{"key":"ref1588","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00228-019-02766-2","article-title":"Nortriptyline serum concentration as a predictor for cardiac risk in\n                    amitriptyline-treated patients","volume":"76","author":"M Scherf-Clavel","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"ref1589","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3109\/13651501.2014.1000928","article-title":"\u201cLong-acting\u201d olanzapine in maintenance therapy of schizophrenia: A study with\n                    plasma levels","volume":"19","author":"M C Mauri","year":"2015","journal-title":"Int J Psychiatry Clin Pract"},{"key":"ref1590","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1055\/a-1963-7631","article-title":"Serious Adverse Drug Reactions to Antipsychotics in Minors with Multiple\n                    Disabilities: Preventability and Potential Cost Savings by Therapeutic Drug\n                    Monitoring","volume":"56","author":"S Fekete","year":"2023","journal-title":"Pharmacopsychiatry"},{"key":"ref1591","first-page":"362p","volume-title":"Der Blutspiegel: Kinetik der Konzentrationsabl\u00e4ufe in der\n                    Kreislauffl\u00fcssigkeit","author":"F H Dost","year":"1953"},{"key":"ref1592","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/s41398-025-03582-2","article-title":"The sense and nonsense of antipsychotic combinations: A model for dopamine\n                    D(2\/3) receptor occupancy","volume":"15","author":"M Spangemacher","year":"2025","journal-title":"Transl Psychiatry"},{"key":"ref1593","first-page":"243","article-title":"Optimal management of Alzheimer's disease patients: Clinical guidelines and\n                    family advice","volume":"6","author":"J Haberstroh","year":"2010","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref1594","first-page":"13","article-title":"Age-related decline in blood-brain barrier function is more pronounced in males\n                    than females in parietal and temporal regions","author":"X Shao","year":"2024","journal-title":"Elife"},{"key":"ref1595","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/brain\/awr298","article-title":"Blood\u2013brain barrier P-glycoprotein function in Alzheimer's disease","volume":"135","author":"DM E van Assema","year":"2011","journal-title":"Brain"},{"key":"ref1596","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00228-018-2419-3","article-title":"Determination of plasma concentration reference ranges for oral aripiprazole,\n                    olanzapine, and quetiapine","volume":"74","author":"J Korell","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"issue":"06","key":"ref1597","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1111\/epi.18330","article-title":"Evaluation of antiseizure medication concentration ranges in blood samples using\n                    an automated big data approach","volume":"66","author":"M Nersesjan","year":"2025","journal-title":"Epilepsia"}],"container-title":["Pharmacopsychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2860-7861.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T04:47:30Z","timestamp":1785214050000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2860-7861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":1551,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2026,7,27]]},"published-print":{"date-parts":[[2026,7]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2860-7861","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0176-3679","1439-0795"],"issn-type":[{"value":"0176-3679","type":"print"},{"value":"1439-0795","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}